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Abstract 
HPV16 is a double stranded DNA virus which has a close association with cervical 
cancer development.  HPV16 expresses two oncoproteins E6 and E7, which when 
overexpressed transform the virus-infected epithelial cells.  E6 and E7-encoding 
RNAs have been shown to be alternatively spliced to give at least four mRNA 
isoforms (E6 full length, E6*I, E6*II, E6*X) however it is not known what functions 
any putative alternative oncoproteins or indeed, RNA isoforms may have.  
Alternative splicing is regulated by host cell factors, namely SR proteins and 
hnRNP proteins.  SR proteins are the positive splicing regulators in the cell and 
generally promote splicing of both cellular and viral RNAs.  It is not known which 
RNA splicing factors are required for E6/E7 RNA processing during infection and 
transformation.  HPV16 viral RNAs are extensively alternatively spliced therefore 
identification of the host factors involved in the processing of viral RNAs could 
have therapeutic benefits because completion of the virus life cycle requires 
alternative splicing and if this could be prevented by targeting of the splicing 
factors involved, then the virus infection could be prevented.  Similarly if 
splicing is altered upon transformation of the cervical epithelial cells, then 
prevention of this alteration in splicing could perhaps inhibit virus-induced 
transformation of the cervical epithelial cells.  Recently it has been shown that 
overexpression of SR proteins can lead to cellular transformation and certain SR 
proteins have already been reported to be upregulated in some cancers.  
Therefore the focus of this PhD was to investigate the expression of the 
alternative E6/E7 RNA isoforms and identify the protein (s) responsible for their 
processing. 
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The first aim was to investigate the expression of the E6/E7 RNA isoforms in 
virus-infected cells and during cervical epithelial cell transformation and to try 
to assign any function to the individual isoforms.  E6 and E7 are encoded by the 
viral early genes but are expressed in both undifferentiated and differentiated 
virus infected cells.  Therefore I investigated whether the expression of the 
isoforms was altered during differentiation.  RT-PCR experiments were carried 
out using RNA extracted from undifferentiated and differentiated W12E cells 
(HPV16-infected cervical epithelial cells).  Results indicated that E6/E7 splicing 
is not altered upon epithelial differentiation however E6 and E7 mRNA 
abundance increased upon differentiation.  Furthermore, experiments carried 
out in W12G cells, where HPV16 genomes are integrated into the host genome 
and no viral life cycle is taking place, suggested that the increase in E6 and E7 
RNA expression was not due to cell differentiation, but due to a virus-induced 
increase in expression.  Further RT-PCR experiments in HPV16 transformed cells 
lines demonstrated that E6/E7 RNA isoform expression is altered as cervical 
epithelial cells become tumourigenic.  Small E6 isoforms, E6*II and E6*X are 
upregulated in virus transformed cells suggesting a tumour promoting function 
for the isoforms.  To test this, E6/E7 isoform-expressing constructs were created 
and transiently transfected into HPV-negative C33a cervical cancer cells and the 
proliferation rate and ability to form colonies in soft agar investigated.  
Compared to the longer E6/E7 isoforms the two smallest isoforms promoted 
cellular proliferation as the cell growth rate increased.  However anchorage 
independent growth assays were inconclusive suggesting there may be a 
combinatorial effect of the E6/E7 isoforms on transformation of the cells. 
My next aim was to investigate the expression of SR proteins during 
transformation of HPV16-infected epithelial cells.  Western blot and 
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immunohistochemical analysis showed that SR proteins SRSF1-3 were specifically 
upregulated upon cervical epithelial transformation.  For SRSF2 and 3, this was 
not due to gene amplification as qPCR analysis of gene copy number showed no 
significant difference in CT values between the W12 cell lines suggesting that 
upregulation of SRSF2 and 3 may be at a transcriptional level.  However there 
was a significant difference in SRSF1 gene copy number that may account for its 
upregulation.     
My final aim was to identify the SR protein (s) responsible for the alteration in 
E6/E7 isoform expression in HPV16-transformed cells.  This was achieved by 
siRNA depletion of the overexpressed SR proteins and RT-PCR of E6/E7 RNA.  
Surprisingly, none of the SR protein knockdowns resulted in any detectable 
alteration of RNA isoforms. However, SRSF2 knockdown specifically resulted in a 
significant reduction in all E6/E7 encoding RNAs.  Moreover, after SRSF2 
knockdown, p53 levels were increased suggesting an impairment of E6 protein 
function.  The reduction in E6/E7 RNA was not due to a decrease in transcription 
as demonstrated by transcription assays utilising an HPV16 LCR luciferase 
reporter.  Interestingly, E6/E7 RNA stability assays showed that RNA half life is 
reduced when SRSF2 is knocked down.  SRSF1 and 2 have previously been shown 
to be oncogenic in breast and ovarian cancers respectively. So the effects of 
SRSF2 knockdown on cell growth rate, colony formation, apoptosis entry and cell 
cycle were analysed in transformed cervical epithelial cells.  The results from 
these experiments indicated that overexpression of SRSF2 in cervical epithelial 
cells is tumour promoting.  My data clearly indicates that SRSF2 should be 
considered to be a proto-oncogene. 
6 
 
Table of contents 
Acknowledgements......................................................................... 2 
Abstract...................................................................................... 3 
Abbreviations .............................................................................. 12 
Introduction ................................................................................ 15 
1 Papillomaviruses ..................................................................... 15 
1.1 Classification .................................................................... 15 
1.2 Pathogenicity.................................................................... 18 
1.3 Vaccine........................................................................... 19 
1.4 HPV Life Cycle and Epithelial Differentiation .............................. 21 
1.4.1 Normal Epithelial Cell Cycle............................................. 22 
1.4.2 PV Infected Epithelial Cell Cycle........................................ 24 
1.5 Gene Expression ................................................................ 27 
1.5.1 Early Genes................................................................. 29 
1.5.2 Late Genes ................................................................. 32 
1.5.3 E6 ............................................................................ 33 
1.5.3.1 Avoidance of apoptosis.............................................. 35 
1.5.3.2 PDZ domain-containing proteins................................... 38 
1.5.3.3 Transcriptional Regulators.......................................... 41 
1.5.3.4 Immune Recognition Regulation ................................... 41 
1.5.3.5 Epithelial Organisation and Differentiation...................... 43 
1.5.3.6 Genome Stability..................................................... 43 
1.5.4 E7 ............................................................................ 46 
1.6 Transformation.................................................................. 50 
1.7 Cell Culture Model System .................................................... 51 
2 RNA Processing ....................................................................... 56 
2.1 Capping........................................................................... 56 
2.2 Alternative and Constitutive Splicing........................................ 57 
2.2.1 SR Proteins ................................................................. 62 
2.3 Polyadenylation and Cleavage ................................................ 65 
2.4 Export ............................................................................ 66 
2.5 SR Proteins and Cancer ........................................................ 68 
3 Aims.................................................................................... 70 
2 Materials and Methods............................................................... 73 
2.1.1 Enzymes .................................................................... 73 
2.1.2 Primers...................................................................... 73 
2.1.3 siRNAs ....................................................................... 73 
2.1.4 Plasmids/Vector ........................................................... 73 
2.1.5 Antibodies .................................................................. 78 
2.1.6 Bacterial Culture .......................................................... 79 
2.1.7 Cell Lines ................................................................... 79 
2.1.8 Common Reagents, chemicals and solutions .......................... 80 
2.2 Methods .......................................................................... 81 
2.2.1 DNA manipulation and cloning .......................................... 81 
2.2.1.1 Bacterial transformation............................................ 81 
2.2.1.2 Liquid Cultures ....................................................... 81 
2.2.1.3 Plasmid DNA extraction ............................................. 82 
2.2.1.4 Restriction enzyme digestion ...................................... 83 
2.2.1.5 Alkaline Phosphatase Treatment .................................. 83 
2.2.1.6 Phenol:Chloroform extraction and ethanol precipitation...... 84 
2.2.1.7 DNA ligation .......................................................... 85 
2.2.1.8 Agarose gel electrophoresis ........................................ 85 
7 
 
2.2.1.9 Acrylamide gel electrophoresis .................................... 86 
2.2.1.10 Nucleic acid quantification......................................... 87 
2.2.2 Tissue Culture ............................................................. 87 
2.2.2.1 Cell line growth and passaging..................................... 87 
2.2.2.2 Cell stocks ............................................................ 88 
2.2.2.3 Transfection using Lipofectamine ................................. 89 
2.2.2.4 Extraction of total cellular protein ............................... 91 
2.2.2.5 Extraction of total cellular RNA ................................... 92 
2.2.2.6 Extraction of total cellular DNA ................................... 92 
2.2.2.7 Growth curve analysis............................................... 93 
2.2.2.8 Colony formation assay ............................................. 93 
2.2.2.9 Inverse invasion assay ............................................... 94 
2.2.2.10 Cell cycle analysis ................................................... 95 
2.2.2.11 Transcription assay .................................................. 96 
2.2.3 Protein Analysis............................................................ 97 
2.2.3.1 Protein Quantification .............................................. 97 
2.2.3.2 SDS-PAGE.............................................................. 97 
2.2.3.3 Western Blotting ..................................................... 97 
2.2.3.4 TUNEL staining ....................................................... 98 
2.2.3.5 Annexin V staining ................................................... 99 
2.2.3.6 Senescence associated β-galactosidase staining ...............100 
2.2.4 RNA Analysis ..............................................................100 
2.2.4.1 RT-PCR................................................................100 
2.2.4.2 qRT-PCR ..............................................................103 
2.2.4.3 DNA sequencing .....................................................105 
3 Results 1..............................................................................107 
3.1 Introduction ....................................................................107 
3.1.1 Alternative splicing of E6 during epithelial differentiation ........116 
3.1.2 Alternative splicing of E6 during cervical tumour progression ....126 
3.1.3 SR proteins levels are altered upon transformation ................134 
3.1.4 SR protein overexpression may not be due to chromosomal 
duplication ...........................................................................142 
3.1.5 HPV11 E2 also up-regulates SRSF3 expression .......................145 
3.1.6 Small E6 isoforms promote cell growth ...............................148 
3.2 Discussion .......................................................................153 
4 Results 2..............................................................................159 
4.1 Introduction ....................................................................159 
4.1.1 SRSF2 controls HPV16 E6/E7 RNA expression in transformed cervical 
epithelial cells.......................................................................163 
4.1.2 SRSF3 not SRSF1 or SRSF2 is required for E6/E7 RNA expression 
during the virus life cycle..........................................................174 
4.1.3 SRSF2 knockdown in transformed cells functionally impairs E6 
protein 177 
4.1.4 SRSF2 contributes to the transformed phenotype of the cells ....182 
4.1.4.1 SRSF2 knockdown decreases cellular growth rate, alters cell 
morphology and interferes with the cell cycle ..............................182 
4.1.4.2 SRSF2 knockdown results in apoptosis ...........................190 
4.1.4.3 SRF2 knockdown inhibits anchorage independent growth ....199 
4.1.5 The mechanism of action of SRSF2 on E6/E7 expression: SRSF2 does 
not trans-activate the P97 promoter..............................................204 
4.1.6 The mechanism of action of SRSF2 on E6/E7 expression: SRSF2 
stabilises E6/E7 RNAs...............................................................209 
4.2 Discussion .......................................................................213 
8 
 
5 Discussion ............................................................................220 
5.1 General Perspectives..........................................................220 
5.2 Future Directions ..............................................................228 
5.3 Conclusions .....................................................................232 
6 References ...........................................................................233 
7 Appendix 1 ...........................................................................245 
8 Appendix 2 ...........................................................................246 
 
9 
 
List of figures 
 
Figure 1.1  Phylogenetic tree of Papillomavirus genus    17 
Figure 1.2  Schematic diagram of an uninfected cervical epithelium 23 
Figure 1.3  Schematic diagram of an HPV-infected epithelium  25 
Figure 1.4  Schematic diagram of linear HPV16 genome   28 
Figure 1.5  Crystal structure of the HPV16 E6 protein   34 
Figure 1.6  Crystal structure of the HPV45 E7 protein   45 
Figure 1.7  Flow chart of W12 cell lines     55 
Figure 1.8  Diagram showing some examples of alternative splicing 59 
Figure 1.9  Schematic diagram of the splicing process   60 
Figure 1.10  Schematic diagram of the 9 classical SR proteins  63 
Figure 1.11  Schematic diagram of RNA polyadenylation   67 
Figure 3.1  Diagram of HPV16 E6 isoforms     109 
Figure 3.2 E6 isoform expression is not altered upon epithelial differentiation 
           119 
Figure 3.3  E6 isoform expression is altered upon epithelial transformation 
           128 
Figure 3.4  E6 isoforms are also expressed in other transformed epithelial cell 
lines         133 
Figure 3.5 Specific SR proteins are upregulated upon cervical epithelial 
transformation       136 
Figure 3.6 Specific SR proteins are upregulated in cervical lesions  141 
Figure 3.7 SRSF1 DNA is amplified during cervical epithelial cell 
transformation but SRSF2 and SRSF3 DNA is not  144 
Figure 3.8 SRSF3 is upregulated by high and low risk papillomaviruses 147 
10 
 
Figure 3.9 Transient transfection of E6*II and E6*X isoforms promote cell 
growth        149 
Figure 3.10 Colony formation assay after transient transfection of E6 isoforms  
          152 
Figure 4.1 Computer prediction of SR protein binding sites in the HPV16 E6/E7 
open reading frame       164 
Figure 4.2 E6 RNA expression is reduced upon SRSF2 knockdown in W12GPXY 
cells         167 
Figure 4.3 E6 RNA expression is also reduced upon SRSF2 knockdown in CaSki 
cells         172 
Figure 4.4 E6 RNA expression is reduced upon SRSF3 knockdown in W12E cells 
          175 
Figure 4.5 SRSF2 knockdown results in increased p53 levels  179 
Figure 4.6 SRSF2 knockdown results in decreased pRb levels  181 
Figure 4.7  SRSF2 knockdown results in decreased cell growth rate in W12GPXY 
cells         183 
Figure 4.8 SRSF2 knockdown alters the morphology of the transfected cells 
         186 
Figure 4.9 SRSF2 knockdown affects the cell cycle    188 
Figure 4.10 Cells treated with siSRSF2 do no stain positive for TUNEL 192 
Figure 4.11 Cells treated with siSRSF2 stain positive for annexin V 196 
Figure 4.12 Cells treated with siSRSF2 have a reduced ability to form colonies 
in soft agar        201 
Figure 4.13 SRSF2 knockdown does not reduce transcription from the P97 
promoter        205 
Figure 4.14 SRSF2 knockdown alters the stability of the E6 isoform RNAs 
         211 
11 
 
Figure 4.15  Amino acid sequences of the E6 isoforms and small schematic 
diagrams of the possible proteins     215 
  
List of tables 
 
Table 1 Table listing the E6 interaction partners with their binding domains 
and consequences of the interaction listed   36 
Table 2 Sequences of all primers used in this thesis and their applications 
           76 
Table 3 Sequences and catalogue numbers of all siRNAs used throughout 
this project        77 
Table 4 A table listing all antibodies, their source and dilution used in this 
thesis         78 
Table 5 A table listing the transfection efficiencies obtained when 
transfecting the various cell lines with siGlo or GFP-plasmid in 293-
T cells used throughout the duration of this thesis  91  
Table 6 Efficiencies of the E6 isoform probe and primer sets  124 
  
12 
 
Abbreviations 
APS  Ammonium persulphate 
bp  base pair 
BPV  bovine papillomavirus 
CIN  cervical intraepithelial neoplasia 
CMV  cytomegalovirus 
CPSF  cleavage and polyadenylation specificity factor 
Cst-F  cleavage stimulatory factor 
CTD   carboxy terminal domain 
DAPI  4’, 6’-diamino-2-phenylindole hydrochloride 
DCS  donor calf serum 
DEPC  diethyl pyrocarbonate 
DMEM  Dulbecco’s modified eagle medium 
DMSO  dimethyl sulphoxide 
DNA  deoxyribonucleic acid 
ECL  enhanced chemiluminesence 
EDTA  ethylenediaminetre-acetic acid 
EGF  epidermal growth factor 
ESE  exonic splicing enhancer 
ESS  exonic splicing suppressor 
FCS  foetal calf serum 
GFP  green fluorescent protein 
13 
 
HEPES  N-2-hydroxyethyl piperazine-N’-2-ethane sulphonic acid 
hnRNP  heterogeneous nuclear ribonucleoprotein 
HPV  human papillomavirus 
IDC  indole derivative compound 
LCR  long control region 
mRNA  messenger RNA 
ORF  open reading frame 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PBS-T  PBS-Tween 
PCR  polymerase chain reaction 
PV  papillomavirus 
RT-PCR reverse transcriptase PCR 
qRT-PCR quantitative RT-PCR 
RNA  ribonucleic acid 
rpm  revolutions per minute 
RT  reverse transcriptase 
SDS  sodium dodecyl sulphate 
snRNP  small nuclear ribonucleoprotein 
SR  serine and arginine rich 
SV40  simian virus 40 
TBE  Tris-borate EDTA buffer 
TE  Tris-EDTA buffer 
14 
 
µ  micro 
U  units 
U2AF  U2 auxiliary factor 
UTR  untranslated region 
v/v  volume per volume 
w/v  weight per volume 
 
  
 
15 
Introduction 
1 Papillomaviruses 
1.1 Classification 
Papillomaviruses (PVs) are small double stranded DNA viruses with genomes of 
around 8kb in size.  PVs infect mucosal and cutaneous epithelial cells and cause 
benign lesions such as warts and veruccas.  Human papillomaviruses (HPVs) have 
also been linked to some malignancies including cervical and head and neck 
cancers. Papillomaviruses are classified according to homology between their L1 
gene sequences, as the L1 gene has been found to be the most conserved region 
of the genome (de Villiers et al., 2004).  A new virus is identified if the L1 region 
is more than ten percent different from the most similar viral sequence.  If the 
coding sequence is between two and ten percent different, the unidentified 
virus is considered to be a new subtype of the most similar virus and if the 
difference observed is less than two percent the new virus is considered a 
variant (Bernard, 2005).  Papillomaviruses can infect a very wide range of host 
species including birds, reptiles and mammals including humans, cattle and 
rabbits.   
There have been over 120 human types identified which can be divided up into 
groups of virus types called genera (de Villiers et al., 2004).  PVs can be divided 
into sixteen genera of viruses identified by Greek letters e.g. alpha-
papillomaviruses (Bernard, 2005).  Genera are composed of viruses that are 
involved in similar types of lesions e.g. alpha papillomaviruses all cause mucosal 
or genital lesions and are clinically the most important PV genus (de Villiers et 
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al., 2004).  Each genus can then be further divided up into species of PV, where 
closely related viruses can be grouped together, as very often closely related 
viruses have similar pathological features (Bernard, 2005).  The largest genus by 
far is the alpha-papillomavirus genus which contains 15 species of PV and 60 
different types.  Alpha papillomaviruses that contain the most common human 
infective viruses can then be further divided into two groups termed “high-risk” 
and “low-risk” viruses depending on their ability to lead to malignancies.  
HPV16, HPV18 and others that cause cervical cancer are members of the “high-
risk” alpha-PV genus.   
The second largest genus is the beta-PV genus, containing 5 species with 25 
different types.    Beta-PVs are cutaneous-specific viruses and are therefore not 
associated with cervical cancer.  Beta-papillomaviruses are found mainly in 
normal skin.  They can however be found associated with skin tumours 
particularly in immunosuppressed or immunocompromised people (Harwood et 
al., 2000).  Some beta-PVs are associated with Epidermodysplasia Verruciformis 
(EV), a rare autosomal recessive genetic condition that results in flat 
papillomavirus associated lesions on sun-exposed skin of young people and can 
lead to squamous cell carcinoma (SCC) (Sterling, 2005).  HPV5 and HPV8 are 
commonly found in EV related SCCs and are examples of beta-PV genus members 
(Sterling, 2005).  Gamma-PV, Mu-PV and Nu-PV genera also contain HPVs, 
however these viruses are less well defined than the alpha and beta-PVs.  The 
remaining 11 genera contain PVs from various mammals, birds and reptiles.  The 
papillomavirus phylogenetic tree is shown in Figure 1.1. 
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Figure 1.1 Phylogenetic tree of the papillomavirus genus.  Adapted from (de 
Villiers et al., 2004).  The most common anogenital infective HPVs, HPV16, 
HPV18, HPV31, HPV11 and HPV6 are indicated by red circles. 
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1.2 Pathogenicity 
HPVs target the epithelial tissue at three main sites, the anogenital tract, the 
respiratory tract and the skin.  After initial infection, the virus genome moves to 
the cell nucleus where it forms an episome and is stably maintained at around 50 
– 100 copies per cell (Stubenrauch & Laimins, 1999).  This state is considered to 
be a persistent infection.  During the productive infection where viral DNA is 
episomally maintained, infectious virions are produced.  This productive 
infection usually results in the formation of benign, warty lesions.  These benign 
lesions normally regress spontaneously without treatment, due to the presence 
of circulating CD4+ and CD8+ T lymphocytes (Stanley, 2001).  Antibodies to the L1 
capsid protein can be found in people with previous HPV infections these 
antibodies are found to provide long term protection and are the basis for the 
recently licensed HPV vaccine (Stanley, 2001).  However, during infection with 
some HPVs the circular genome can break and integrate into the host cell 
chromosome due to DNA damage.  DNA damage probably occurs after encounters 
with carcinogens in the case of mucosal epithelia and UV in the case of 
cutaneous epithelia.   HPVs with the capacity to integrate are termed high-risk 
HPVs.  This integration of the viral genome can result in malignancy.  High-risk 
HPVs are viruses that when they infect epithelial cells have the capacity to 
integrate their genome into the host chromosome and therefore result in 
uncontrolled cell proliferation, leading to tumour formation.  There is increasing 
evidence that integration does not always need to occur to lead to malignancy 
(Gray et al., 2010).  Low-risk HPVs do not have this capacity and therefore 
infection with low-risk viruses rarely leads to cancer development.  HPV16 and 
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18 are the most well known examples of high-risk viruses and HPV2 and 6 are 
examples of low-risk HPVs.  Beta-PVs are not normally further divided into low 
or high risk PVs, however some can cause cancer without genome integration.  
This happens by different mechanisms than alpha-PVs, which will not be 
discussed here.    
 
1.3 Vaccine 
There has long been a great interest in developing a vaccination to protect 
against HPV infection.  Original studies identified the protective ability of virus 
like particles (VLP) which are composed of L1 and L2 proteins, but without any 
viral DNA, making them non-infective.  L1 and L2 are highly immunogenic 
proteins which the virus only expresses away from the immune surveillance 
processes which do not occur in the granular layer of the epithelium.  The first 
demonstration of the protection provided by these VLPs was done using cotton-
tail rabbit papillomavirus, where rabbits vaccinated with L1 alone or L1-L2 VLPs 
developed fewer papillomas than control animals (Breitburd et al., 1995).  The 
first study using mucosal infective papillomaviruses were carried out using BPV4 
VLPs in cattle where again, the vaccinated animals developed fewer papillomas 
than control animals (Kirnbauer et al., 1996).  Recently there has been a vaccine 
licensed for use to prevent HPV infection.  The vaccine licensed in the UK is 
called Cervarix and contains HPV16 and HPV18 VLPs which elicit an immune 
response against L1 only.   
While this is obviously a huge leap in prevention of HPV16 and 18 infections and 
cervical cancers there is still a long way to go before HPV infections are 
Chapter 1  20 
 
eliminated.  While the vaccine has been approved for use, there is no data on 
the effectiveness of the vaccine in long term protection from infection.  While 
the UK immunises with a bivalent vaccine there is also a quadravalent vaccine 
licensed which protects not only against HPV16 and 18 infections but also HPV6 
and 11.  The choice of bivalent vaccine in the UK is largely an economic decision 
which may in hindsight prove to be a mistake.  The UK is only vaccinating girls, 
which seems strange as boys can not only become infected with the viruses but 
penile, anal and increasingly oral carcinomas have been linked to high-risk HPV 
infection.  Finally as the vaccine elicits an immune response against the L1 
protein, only the initial infection is prevented and the vaccine will have no 
effect for those people already infected with HPV.   There are some concerns 
that while vaccination against the most common high-risk viruses may eliminate 
these viruses, there are other HPVs that infect the anogenital epithelium and 
have the potential to lead to malignancies and that these viruses may fill the 
niche left by elimination of HPV16 and 18.  HPV16 and HPV18 are the most 
common causes of cervical cancers and if they are eliminated other high-risk 
viruses such as HPV31, 51 or 55 may take over and cause cancers. It may be that 
HPV16 and 18 are the most common cause of cervical cancer because they are 
the fittest viruses and can out-compete the other high-risk viruses where there is 
an infection with multiple virus types. With HPV16 and 18 eliminated the other 
high risk viruses may cause many more cervical cancers than they currently do.  
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1.4 HPV Life Cycle and Epithelial Differentiation 
PVs must infect the basal epithelial layer in order to initiate infection (Doorbar, 
2005).  This requires the epithelium to become damaged resulting in a disruption 
of the epithelial barrier allowing the virus access to the lower basal layer.  It has 
been suggested that infection of stem cells within the epithelium may be 
required for lesion persistence (Schmitt et al., 1996).  Recently it has been 
demonstrated, using a rabbit oral papillomavirus (ROPV) infection as a model 
system for low risk HPV infection, that low levels of viral DNA and RNA can be 
detected in previously infected basal stem cells up to one year after the initial 
infection has regressed, however no late protein expression was detected 
indicating that no productive infection was taking place (Maglennon et al., 
2011).  Viral DNA and RNA could not be detected in the surrounding normal 
epithelium indicating the virus may set up latency in particular basal stem cells 
(Maglennon et al., 2011).  This pool of latent ROPV DNA could be evidence of 
persistence and perhaps the virus could then be stimulated to reactivate by 
external factors (Maglennon et al., 2011). Stem cells can be found within hair 
follicles and replicate in the interfollicular epithelium, therefore for cutaneous 
specific PVs e.g. HPV5, this may be an important location of infection  (Boxman 
et al., 2001, Doorbar, 2005).  Similarly, Schmitt et al. (1996) demonstrated that 
Cotton-tail Rabbit Papillomavirus (CRPV) infect and persist in epidermal skin 
cells with stem cell like properties within the hair follicle. There is still some 
controversy about the viral entry receptor and this will be discussed later.  After 
initial receptor binding the virus is then thought to enter the cell via a clathrin-
mediated endocytosis process (Selinka et al., 2002).  As the basal cells start to 
differentiate and move up through the skin layers, the PV life cycle begins. 
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1.4.1 Normal Epithelial Cell Cycle 
In normal epithelial tissues the basal cell layer is the only layer where DNA 
synthesis occurs.  In this layer proliferation associated keratins such as K5 and 
K14 are expressed.  After cell division one daughter cell remains in the basal 
layer while the other leaves the basal layer and enters the spinous layer.  In this 
layer, the transit amplifying cells exit the cell cycle and begin to differentiate, 
and while in the spinous layer and the cells begin to accumulate keratins 
(Stubenrauch & Laimins, 1999).   This layer is mitotically inactive and the major 
role of the spinous layer cells is to produce more keratins (Fuchs, 1990). As the 
cells differentiate the keratin expression profile is altered.  Proliferation 
associated keratins are switched off and differentiation associated keratins such 
as K10 and K1 are expressed. Finally, as the cells move up through the spinous 
layer and enter the granular layer they begin to produce envelope proteins such 
as Involucrin and Filaggrin (Fuchs, 1990). After reaching the granular layer the 
cells stop producing keratins.  Once the cornified layer is reached the cells then 
loose the cell nucleus, essentially becoming dead keratin-containing cells 
(Stubenrauch & Laimins, 1999).  These cells are then sloughed off naturally 
allowing a continuous cycle of replacement from the basal layer.  The whole 
epithelium differentiation program takes around 14 days to complete.  The 
structure of the normal epithelium is shown in Figure 1.2. 
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Figure 1.2 Schematic diagram of an uninfected cervical epithelium.  Actively 
dividing cells are located in the stratum basale.  As transit amplifying cells move 
up through the epithelium into the stratum spinosum they stop dividing and 
undergo differentiation.  Terminally differentiated cells are located in the 
stratum granulosum and are naturally sloughed off. “K”, Keratin. 
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1.4.2 PV Infected Epithelial Cell Cycle 
After infection of basal epithelial cells the PV genome is deposited in the 
nucleus and maintained as viral episomes.   Maintenance of the viral episome 
requires the early viral proteins E1 and E2.   E1 is the protein responsible for 
initiating the viral DNA replication and E2 is involved with regulating the 
transcription of viral RNAs among other functions (Phelps & Howley, 1987).  E2 is 
also the viral protein which can bind to mitotic chromosomes via a tethering 
protein, therefore allowing the distribution of the viral genomes along with the 
normal separation of chromosomes between dividing cells (You et al., 2004, 
Parish et al., 2006a, Donaldson et al., 2007).  During the initial stages of 
infection only the viral early genes are expressed.  The other viral early genes E6 
and E7 are responsible for driving cellular proliferation and avoiding apoptosis 
(Dyson et al., 1989, Crook et al., 1991).  As the infected cell moves up through 
the cell layers there is some evidence that it may become locked in the G2 stage 
of the cell cycle by action of E1^E4  (Davy et al., 2002, Davy et al., 2005), 
preventing differentiation and allowing amplification of viral DNA to continue 
before packaging of the genomes into the newly synthesised viral capsids occurs 
(Doorbar, 2005).  However there is also evidence that mitosis occurs within 
lesions, and in fact this is one major clinical sign of a PV induced lesion.  
Therefore this is still a grey area of papillomavirus research. Blockage of cell 
cycle exit, by E1^E4, may allow cellular replicative enzymes to remain active 
and allow viral replication (Doorbar, 2005).  During the amplification stage of 
the PV life cycle other promoters that are late in infection (Milligan et al., 
2007), found throughout the viral genome, may become active, increasing the 
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Figure 1.3 Schematic diagram of an HPV-infected cervical epithelium.  HPVs 
enter the basal layer through wounds in the epithelium and the virus infects 
actively dividing cells in the stratum basale.  Only viral early proteins E6 and E7 
(red) and E1 and E2 are expressed in the basal layer.  As the cells move up 
through the epithelium into the stratum spinosum they are stimulated by the 
virus to continue dividing where no division should be taking place resulting in 
the characteristic “wart”.  Differentiation is postponed in this layer to allow the 
virus to amplify its genetic material.  All early genes (red and blue) are 
expressed in this layer.  Virus late structural proteins (yellow) are only expressed 
in terminally differentiated cells in the stratum granulosum and the cells are 
naturally sloughed off, releasing the newly formed virus particles.  “K”, Keratin. 
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 levels of transcription of E4 and E5 (Middleton et al., 2003, Doorbar, 2005) and 
eventually the other late genes, L1 and L2 which encode for the viral structural 
proteins (Doorbar & Gallimore, 1987).   E5 is responsible for blocking the 
immune system activation in response to HPV infection by preventing the MHC 
class I and II molecules from presenting to the immune system (Zhang et al., 
2003, Ashrafi et al., 2005).  The late PV proteins are only expressed once the 
infected cell reaches the granular layer because these proteins are 
immunogenic, and form the basis of the HPV vaccine; therefore they must be 
hidden from the immunosurveillence processes in the epithelium.  L1 proteins 
can induce a neutralising T cell response which is why they are hidden from the 
immune system (reviewed by (Stanley, 2008).  The newly formed viral particles 
are released as the cells reach the stratum corneum and are naturally sloughed 
off.  The release of the viral particles by sloughing of the epithelial cells 
provides protection for the virus from the environment.  The epithelium acts as 
a barrier to infection and protects from the external environment.  Infection of 
the epithelium by HPV interferes with these epithelial functions as the tightly 
regulated epithelial structure is disrupted by wart formation.  The structure of 
the papillomavirus infected epithelium is shown in Figure 1.3. 
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1.5 Gene Expression 
HPV gene expression is tightly regulated and linked to epithelial differentiation.  
The expression of viral genes can be divided into two stages, early gene 
expression and late gene expression.  Early genes are gene that are expressed as 
soon as the virus enters the basal epithelial cells and establishes its genome as 
an episome.  Late proteins are expressed only as the infected cell becomes 
differentiated as these proteins are often highly immunogenic and can only be 
expressed away from the immune surveillance.  The viral genes are named 
according to where in the viral life cycle they are expressed.  There are eight 
viral genes, E1, E2, E4, E5, E6, E7, L1 and L2 where E stands for early and L 
stands for late genes.  HPV16 has two main viral promoters; P97 which is 
activated early in infection and from which the majority of the early genes are 
expressed and P670 which is activated upon differentiation and from which late 
genes are expressed.  HPV16 also has three polyadenylation sites, one just after 
the E5 ORF at nucleotide 4215 which is used during early gene expression and 
two just after the L1 ORF at nucleotide 7321 and are used during late gene 
expression.  There are also other promoters that can be found throughout the 
viral genome (Milligan et al., 2007).  The linear HPV16 genome is shown in Figure 
1.4. 
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Figure 1.4 Schematic diagram of the linear HPV16 genome.  The major early 
(P97) and late promoter (P670) are indicated by arrows along with other 
promoters identified by Milligan et al. (2007).  The early and the two late 
polyadenylation sites are indicated by vertical bars.  The position of each of the 
viral genes and the Long Control Region (LCR) is drawn in relation to the virus 
genome. 
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1.5.1 Early Genes 
There are six early genes that function to maintain the viral genome and 
promote cellular proliferation and viral DNA replication.  Traditionally, the first 
genes to be expressed after virus infection are thought to be E6 and E7 which 
together function to promote cell growth and inhibit apoptosis.  These genes will 
be discussed in more detail later.  However, in 2002 a report was published 
showing that for HPV31b at least, E1 and E2 are the first viral genes to be 
expressed (Ozbun, 2002).  E1 and E2 transcripts could be detected four hours 
after initial HPV31b infection of the keratinocytes and the other viral transcripts 
could not be detected until eight hours after initial infection (Ozbun, 2002).  It 
was also suggested that the E1 and E2 transcripts originated from a different 
promoter than the major early promoter (Ozbun, 2002).  Both of these scenarios 
are possible as the expression of E1 and E2 first would then control the 
expression of the other viral genes.  However expression of E6 and E7 first is 
possible if expression of these genes can be activated by host transcription 
factors.   
E1 is the viral helicase and binds to the origin of replication to promote viral 
DNA replication (Hughes & Romanos, 1993).  E1 unwinds the viral DNA allowing 
the entry of the DNA replication machinery.  E1 also actively recruits 
Topoisomerase I, DNA polymerase α and replication protein A (RPA) ready for 
DNA replication (Park et al., 1994, Loo & Melendy, 2004, Clower et al., 2006).  
E1 binding to the long control region is a weak interaction therefore E2 acts to 
aid the binding (Frattini & Laimins, 1994).   
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E2 is the viral replication and transcription factor and binds to the viral long 
control region regulating viral RNA transcription.  It is conventionally thought 
that E2 controls the levels of E6 and E7 during the viral life cycle by binding to 
the four E2 binding sites on the HPV16 LCR and repressing E6/E7 expression and  
repression is lost when the viral genome integrates leading to the overexpression 
of E6 and E7 (Choo et al., 1987).  However there may be other mechanisms 
controlling the overexpression of E6 and E7 for example involvement of host 
transcription factors.  E2 has also been shown to bind to mitotic chromosomes 
through an interaction with a cellular protein and therefore allows the equal 
division of viral episomes between daughter cells during mitosis.  For HPV16 the 
cellular partner is thought to be TopBP1 (Donaldson et al., 2007) and Brd4 is 
thought to be the cellular partner in BPV infections (You et al., 2004).  BPV has 
also been shown to bind ChIR1 and tether to mitotic chromosomes (Parish et al., 
2006a).  Not all alpha-papillomaviruses interact with Brd4 and are still found 
tethered to mitotic chromosomes, therefore perhaps different viruses use 
different tethering proteins (McPhillips et al., 2006). E2 has also shown to bind 
to numerous nuclear proteins including p53, p300/CBP and SR proteins (Lee et 
al., 2000a, Parish et al., 2006b, Mole et al., 2009b).  E2 has been shown to 
transcriptionally upregulate certain splicing regulatory SR proteins by binding to 
the promoters and activating transcription (Mole et al., 2009a, Mole et al., 
2009b).  E2 regulation has been shown for SRSF1, SRSF2 and SRSF3 (Mole et al., 
2009a, Mole et al., 2009b).  The upregulation of these splicing factors is an 
extremely important process as the viral life cycle depends on extensive splicing 
of viral RNAs therefore these splicing regulators are required for the processing 
of the viral RNAs, this will be discussed in more detail later.   
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E5 is expressed late in infection and is considered to be the major viral 
oncoprotein in Bovine papillomavirus infections.  BPV E5 is required for 
transformation of BPV infected fibroblasts; however this is not the case for high 
risk HPV E5 (Yang et al., 1985) and in fact β-HPVs do not encode E5 at all. The 
main function attributed to HPV E5 is the down regulation of MHC class I and II 
thereby inhibiting any immune response to viral infection (Zhang et al., 2003, 
Ashrafi et al., 2005).  E5 has been shown to bind to MHC Class I and sequester 
the protein in the Golgi apparatus therefore preventing the MHC molecule from 
presenting viral peptides to the immune system for action (Ashrafi et al., 2005).  
E5 also interferes with the turnover of the Epidermal growth factor receptor 
(EGFR) leading to an increased number of receptors trafficked to the cell surface 
(Straight et al., 1993).  The cells then have an exaggerated response to EGF and 
cellular proliferation is increased (Pim et al., 1992).  E5 can bind to the 16kDa 
subunit of the vacular ATPase, which in turn alters the pH of the endosome 
(Rodriguez et al., 2000).  The change in pH leads to altered trafficking of the 
endosomes.  Therefore the expression of E5 late in infection will increase the 
proliferation of the normally replication inactive differentiating cells. 
The final gene to be expressed is E4.  Although E4 is technically termed an early 
gene it is in fact expressed later in infection as the cells differentiate.  E4 does 
not have a start codon so the protein is expressed from a spliced isoform RNA 
encoding the first five amino acids of the E1 open reading frame to give a hybrid 
E1^E4 protein.  E1^E4 binds to cytokeratins in the cytoplasm of the cell altering 
the cell structure and collapsing the whole keratin network, making viral escape 
easier by disrupting the integrity of the membrane (Wang et al., 2004).  E1^E4 
can also induce a G2 arrest in infected cells allowing the viral DNA to continue to 
be replicated without the cell undergoing mitosis (Davy et al., 2002).  E1^E4 
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binds cyclin B1 /cdk1 complex in the cytoplasm and prevents the complex from 
progressing the cell into mitosis (Davy et al., 2005).  However this control must 
be overcome as the clinical definition of a wart is the presence of mitotic cells 
outwith the normal basal layer. 
 
1.5.2 Late Genes 
PVs express two late genes, L1 and L2.  These proteins are the viral structural 
proteins and together they form the viral capsid.  L1 is the major capsid protein 
and L2 the minor.  They are only expressed in the granular layer of the 
epithelium to avoid triggering an immune response.  Papillomaviruses have 
capsids composed of 72 capsomeres containing 360 copies of the L1 protein and 
around 12 copies of the L2 protein resulting in a 30:1 ratio of L1:L2 proteins per 
capsid (Greenstone et al., 1998).  L1 is thought to be the major receptor binding 
protein.  In 2009 an interesting report was published which may go some way to 
making sense of the cellular binding receptor controversy.  Kines et al. (2009) 
showed that L1 bound to heparan sulphate proteoglycans on the basement 
membrane, which had been exposed after wounding the epithelium (Kines et al., 
2009).  Here the virus remained bound for an extended period of time.  It was 
suggested that binding to the basement membrane initially allowed the virus to 
specifically infect proliferating cells, as cells that migrate to fill the wound site 
will divide to fill the layers of the epithelium (Kines et al., 2009).  If the virus 
bound initially to epithelial cells out with the basement membrane, they would 
not be dividing and therefore the viral replication strategy would fail.  This is in 
contrast to other reports that suggest PVs persistently infect epithelial stem 
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cells.  A possible explanation for this discrepancy could be that the virus infects 
dividing cells and then changes the phenotype of the cell to be stem cell like in 
order for viral persistence.  While bound to the basement membrane, the virus 
undergoes a conformational change resulting in L2 being cleaved and a 
neutralising epitope is exposed (Kines et al., 2009).  It is thought that this 
conformational change exposes the cellular binding epitope of L1 and allows the 
virus to attach to the wound-invading basal cells (Kines et al., 2009).  The 
conformational cleavage is thought to be carried out by furin which is secreted 
from the wounded epithelium or PC5/6 which is associated with the heparan 
sulphate proteoglycans (Kines et al., 2009).  The authors suggested that it is the 
difference between the extracellular matrix of cultured cells and the basement 
membrane of the epithelium that may explain some of the different reports in 
receptor binding experiments (Kines et al., 2009). 
 
1.5.3 E6 
E6 and E7 cooperate in lesions and cancers to promote cell growth and avoid 
cellular apoptosis.  For this reason these two proteins may be considered to be 
the viral oncoproteins for high risk papillomaviruses.  E6 has three main methods 
of binding to protein partners; E6 contains two zinc finger motifs and a PDZ 
binding domain.  The zinc finger domains are responsible for binding to E6’s 
associated cellular binding partner E6AP.  This interaction of E6 with E6AP can 
then go on to lead to numerous other protein interactions.  E6AP is a cellular 
ubiquitin ligase that binds to E6 and therefore controls its function (Huibregtse 
et al., 1991, Scheffner et al., 1993).  E6 has multiple cellular targets which it  
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Figure 1.5 Crystal structure of the HPV16 E6 protein.  The E6 protein contains 
two zinc finger domains and a PDZ-binding domain located at the extreme C-
terminus of the protein.  The N-terminal portion of the protein is shown in blue 
and the C-terminal portion in yellow adapted from (Nomine et al., 2006).  The 
amino acids present in all isoforms are highlighted in the red box and the 
approximate position of the splice junction indicated by a red arrow on the 
crystal structure. 
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interacts with in order to alter the cell to allow for efficient viral infection and 
replication.  The crystal structure of HPV16 E6 is shown in Figure 1.5.  The E6 
interacting partners are outlined in Table 1. 
 
1.5.3.1 Avoidance of apoptosis 
Perhaps the most infamous target for high risk E6 is p53 (Crook et al., 1991).  
p53 is a cellular tumour suppressor protein which acts to monitor the cell cycle 
and arrest the cell if there is any damage to the DNA before signalling for the 
cell to enter apoptosis by increasing the expression of the Bcl-2 family of 
apoptosis regulators (Schuler & Green, 2005).  One of the functions of high risk 
E7 proteins is to degrade the retinoblastoma protein (p105) and other pocket 
proteins (p130 and p107) thereby driving the cell into S phase by relieving 
repression of the E2F transcription factor (Dyson et al., 1989).  Under normal 
circumstances uncontrolled proliferation would result in the activation of p53 
and apoptosis would occur.  However E6 acts to circumvent this signal for 
apoptosis by degrading p53.  This allows the infected cell to continue to 
proliferate and divide where it should not, thereby allowing viral replication to 
continue.  E6 interacts with E6AP and alters its affinity for p53 (Hengstermann et 
al., 2001).  p53 becomes extensively ubiquitinated and therefore degraded by 
the proteasome (Scheffner et al., 1993). Amino acid residue 47 has been shown 
to be partly responsible for directing the degradation of p53 as mutations in this 
amino acid lose the ability to degrade p53 (Nomine et al., 2006).  However, all 
of the mutations studied by Nomine et al., (2006) retained the ability to bind 
E6AP suggesting there are other factors that are recruited to ubiquitinate p53  
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Binding Domain Protein Function 
Via E6AP p53 Apoptosis avoidance 
 Bak Apoptosis avoidance 
 c-Myc Apoptosis avoidance 
 Tuberin Proliferation 
 hMCM7 Genome Instability 
PDZ hDlg Loss of cell-cell communication 
 hScrib Loss of cell-cell communication 
 MAGI 1-3 Loss of cell-cell communication 
Direct binding via LXXLL motif IRF-3 Immune System Activation 
 E6AP Ubiquitination 
 Paxillin Epithelial organisation 
Unknown binding domain Procaspase-8 Apoptosis Avoidance 
 
Table 1: Table listing the E6 interaction partners with their binding domains and 
the consequences of the interaction listed.
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and that mutation of amino acid 47 is interfereing with the recruitment of 
additional ubiquitin ligases. 
High risk E6 also targets Bak for degradation.  E6/E6AP can bind to and signal 
Bak for proteasomal degradation (Thomas & Banks, 1998).  Bak is a member of 
the Bcl-2 group of apoptotic proteins, which is very similar to Bax, another 
proapoptotic member of the Bcl-2 family (reviewed in (Ola et al., 2011) .  Bak 
and Bax have been shown to have very similar proapoptotic functions and there 
may in fact be some redundancy between their apoptotic functions.  Bak, unlike 
Bax, has been found to be most active in the upper epidermal layers of the skin, 
the same location that HPV replication occurs (Krajewski et al., 1996, Thomas & 
Banks, 1998).  It is thought that under normal conditions within the cell, E6AP 
regulates the levels of Bak, however the presence of HPV18 E6 has been shown 
to decrease Bak levels through proteasomal degradation (Thomas & Banks, 
1998).  This degradation of Bak prevents the protein being able to permeabilise 
the mitochondrial and ER membranes, therefore also avoiding the activation of 
the caspase cascade and preventing the cell from entering apoptosis (Adams & 
Cory, 2007).  E6/E6AP has not been shown to target Bax in the same manner as 
it targets Bak, however this may be because p53 has been shown to regulate Bax 
within the cell (Moll et al., 2005).  The degradation of Bak interferes with the 
cells ability to enter apoptosis through activation of the intrinsic apoptosis 
pathway (Adams & Cory, 2007).   c-Myc is another pro-apoptotic protein that is 
targeted for degradation by E6/E6AP (Gross-Mesilaty et al., 1998).  c-Myc is a 
cellular protein that has two seemingly conflicting functions.  c-Myc controls 
both cellular proliferation and is also involved in the apoptotic pathway 
(reviewed in (Soucek & Evan, 2010).  Under normal circumstances low level 
expression of c-Myc within quiescent cells drives the cells into S-phase and 
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inhibition induces a growth arrest, therefore controlling cellular proliferation 
(Pucci et al., 2000).  However overexpression of c-Myc drives the cell into 
apoptosis (Pucci et al., 2000).  E6/E6AP binds to c-Myc and results in its 
degradation (Gross-Mesilaty et al., 1998).  The degradation of c-Myc may seem 
strange due to the proliferation properties of c-Myc; however this degradation is 
probably to alleviate the proapoptotic functions of c-Myc, as E6 also results in 
the degradation of other apoptotic proteins.  
 
1.5.3.2 PDZ domain-containing proteins 
In order to be able to transform the infected cells, HPV must be able to disrupt 
normal inter- and intra- cellular communication pathways.  E6 contains a PDZ 
binding domain at the extreme C-terminus of the protein; in fact the last four 
amino acids of high risk E6 proteins comprise a PDZ binding domain:  X-(S/T)-X-
(V/I/L).  HPV16 E6 ends with E-T-Q-L and HPV18 ends with E-T-Q-V.  Proteins 
with this motif at their C terminus can bind to partner proteins containing PDZ 
structural domains which are around 90 amino acids in length (Cho et al., 1992).  
Low risk papillomavirus E6 proteins do not end with a PDZ binding domain which 
has led to the hypothesis that the E6-PDZ domain interactions are important for 
transformation of cells infected with high risk HPV (Kiyono et al., 1997).  E6 
interacts with all of the following proteins, which are involved in the 
maintenance of tight junctions between cells, via an interaction with their PDZ 
domains. PDZ domains are found mainly in signalling molecules with roles in cell 
polarity and differentiation. These so-called scaffold proteins have been 
proposed to mediate assembly of protein complexes at key cellular sites and to 
integrate cell signalling. hScrib, hDlg and  MAGI 1-3 are all members of this 
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group of proteins.  Interestingly, E6 proteins from different high risk viruses have 
differing specificities for degradation of different PDZ proteins.  For example 
HPV16 E6 directs the degradation of hScrib preferentially over hDlg whereas 
HPV18 E6 does the opposite (Thomas et al., 2005).   
hScrib is the human homologue of the Drosophila Scribble protein which 
normally regulates the growth of the cells and can also act as a tumour 
suppressor (Dow et al., 2003).  hScrib is normally located at tight junctions 
between cells.  E6/E6AP binds to hScrib and facilitates its degradation therefore 
reducing the control over cellular growth and also results in the cell loosing 
contact with the extracellular matrix and therefore allowing cellular 
transformation and tumour invasion to occur (Nakagawa & Huibregtse, 2000).   
hDlg is the human homologue of the Dlg tumour suppressor in Drosophila.  Like 
hScrib it is involved in epithelial tight junctions and is also involved in cellular 
adhesion, cellular proliferation and cellular polarity (Woods & Bryant, 1991, 
Woods et al., 1996).  hDlg also acts as a scaffold protein allowing a platform for 
protein interactions (Humbert et al., 2003). Again E6 binds to hDlg and results in 
the ubiquitin-mediated degradation of hDlg (Gardiol et al., 1999).  This results in 
a loss of cellular adhesion, proliferation and polarity leading to tumourigenesis.  
The staining pattern of hDlg in transformed cells is very different to that of non-
transformed cells.  In normal epithelial cells hDlg is found predominately at tight 
junction plaques between neighbouring cells, however in transformed cells hDlg 
staining is predominately cytoplasmic suggesting a loss of cell-cell 
communication between neighbouring transformed cells.  As E6 has been shown 
to bind to PDZ domain containing proteins it is thought that E6 is the protein 
which is involved in the redistribution of hDlg during transformation. 
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MAGI-1-3 are also involved in the regulation of tight junctions (Laura et al., 
2002).  Interaction with these proteins will disrupt adhesion to the extracellular 
matrix.  MAGI proteins are degraded by ubiquitin-mediated proteasomal 
degradation directed by E6 (Glaunsinger et al., 2000, Thomas et al., 2002).  
MUPP1 is another E6 protein partner, which controls cellular proliferation and is 
also involved in control of cell junctions and cell polarity (Lee et al., 2000b).  
Therefore when E6 binds to MUPP1 cell growth becomes uncontrolled and the 
cells loose structural integrity.   
All of the previously mentioned functions for E6 degradation of PDZ domain 
containing proteins have been highlighted to explain transformation of the HPV 
infected cells.  While these functions are active when E6 becomes overexpressed 
(e.g. when the HPV genome becomes integrated and the cells are transformed), 
a recent study has also shown that PDZ domain-containing proteins can bind to 
and stabilise low levels of E6 expressed during an infection aiding in maintaining 
the viral episomes.  Nicolaides et al (2011) showed that the PDZ binding domain 
of E6 is required for E6 stability (Nicolaides et al., 2011).  hScrib, and other PDZ 
domain containing proteins, can bind to and stabilise HPV16 E6 levels in 
transfected epithelial cells and this stabilisation is dependent on the PDZ domain 
of the hScrib and the PDZ binding domain of E6 (Nicolaides et al., 2011).  The 
stabilisation of E6 led to enhanced episome maintenance as a mutated 
interaction between hScrib and E6 resulted in frequent loss or integration of the 
HPV genomes (Nicolaides et al., 2011).  Therefore this PDZ domain interaction 
for E6 is important for viral infection as well as for transformation. 
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1.5.3.3 Transcriptional Regulators 
E6 can not only inhibit apoptosis and disrupt communications between 
neighbouring cells; E6 can also disrupt transcription of various genes through 
binding to transcriptional regulators.  Perhaps the most well known 
transcriptional regulator targeted by E6 is p300/CBP (Zimmermann et al., 1999).  
p300/CBP is a transcriptional co-activator of p53, therefore not only does E6 act 
to degrade p53 directly, it also inhibits p53 action by preventing p300/CBP 
activation.  The inability of p300/CBP to bind and activate p53 will reduce p53’s 
ability to activate the DNA damage response (Kessis et al., 1993).  E6 binds to 
p300/CBP via its second zinc finger domain (Zimmermann et al., 1999).  
Similarly, E6 also promotes the degradation of Tuberin which relieves the control 
over pro-proliferation genes normally exerted by Tuberin (Lu et al., 2004).  
Tuberin along with its binding partner Hamartin normally inhibits S6 kinase and 
thereby prevents the activation of eIF4E-binding protein 1 (4EBP1) (Lu et al., 
2004).  The inactivation of 4EBP1 suppresses protein translation which negatively 
controls cellular proliferation.  E6 induced degradation of Tuberin prevents it 
from binding Hamartin and therefore indirectly activates protein translation and 
cellular proliferation. 
 
1.5.3.4 Immune Recognition Regulation 
All viruses must by nature avoid the immune response.  HPV can establish a 
persistent infection therefore it must have evolved ways of avoiding recognition 
by the immune system.  HPV16 E6 has been shown to bind to Interferon 
Regulatory Factor-3 (IRF-3) and prevents its transcriptional activity (Ronco et 
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al., 1998) .  IRF-3 has two modes of antiviral activity, it can either directly 
activate Bax leading to apoptosis or it can transcriptionally activate antiviral 
genes as part of a virus activated transcription factor complex (Wathelet et al., 
1998).  Interference with this antiviral pathway is common to many viruses 
including RNA and DNA viruses (Chattopadhyay et al., 2011).  Under normal 
circumstances after detection of a viral infection the cell will undergo apoptosis, 
IRF-3 normally acts to control apoptosis progression.  IRF-3 as part of the larger 
transcription factor complex can transactivate the IFN-β promoter, which 
therefore means that by disturbing IRF-3 functions, HPV16 can avoid the 
activation of the antiviral response.  Ronco et al (1998) showed that IRF-3 can 
transactivate the promoter of a reporter construct and co-transfecting HPV16 E6 
prevented this transactivation while cotransfection of HPV6 E6 did not.  This 
suggests that high risk viruses have evolved to inhibit the antiviral immune 
response. 
Not only does HPV16 E6 prevent IRF-3 activity but it also prevents expression of 
TLR9.  Toll Like Receptors are cellular receptors that recognise specific 
molecular patterns and alters the immune system to an infected cell.  TLR9 is 
activated in response to foreign double stranded DNA.  HPV16 E6 and E7 can 
down regulate expression of TLR9 mRNA therefore allowing the virus to escape 
immune recognition (Hasan et al., 2007).  HPV16 oncoproteins were shown to be 
much more efficient at reducing TLR9 mRNAs than those from HPV18 or HPV6 
(Hasan et al., 2007) which could be one of the reasons why HPV16 is much more 
efficient at establishing a persistent infection and is more frequently associated 
with cervical cancers. 
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1.5.3.5 Epithelial Organisation and Differentiation 
HPV16 E6 has been shown to bind to paxillin and disrupt the actin fibres that 
form the cytoskeleton (Tong & Howley, 1997).  Paxillin plays an important role 
in the structural organisation of the cell.  When epithelial cells were transfected 
with BPV1 E6 the actin filaments were severely disrupted (Tong & Howley, 
1997).  HPV16 E6 has also been shown to bind to ERC-55 or E6-BP which is a 
calcium binding protein (Chen et al., 1995).  The interaction with E6-BP is likely 
to disrupt the normal calcium signalling in the cell thereby postponing epithelial 
differentiation and promoting mitosis (Chen et al., 1995). 
 
1.5.3.6 Genome Stability 
An important feature of transformed cells is as they become more transformed 
their genomes become more unstable, allowing mutations to build up and 
contributing to the transformed phenotype of the cells.  HPV16 E6 has been 
shown to bind to the pRb binding domain of hMCM7 (human minichromosome 
maintenance seven protein) (Kukimoto et al., 1998).  Normally hMCM7 and other 
members of the hMCM family bind to chromatin before S phase entry and are 
displaced during DNA replication (Fujita et al., 1996).  If hMCM7 does not 
reattach to the chromatin then only one round of DNA replication can take 
place.  pRb normally binds to the C-terminus of the hMCM7 protein, which 
inhibits DNA replication in Xenopus (Sterner et al., 1998).  Therefore Kukimoto 
et al (1998) suggested E6 binding to hMCM7 prevents pRb binding and thus 
relieves repression of DNA replication.  This deregulated DNA replication may 
allow genetic mutations to arise and build up, leading to genomic instability.  
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Not only does HPV16 E6 allow mutations to build up it also acts to prevent repair 
of single strand DNA breaks.  HPV16 E6, HPV8 E6 and HPV1 E6 can all bind to and 
inhibit XRCC1 thereby preventing repair of single strand breaks in the host 
genome allowing mutations to arise and not be repaired (Iftner et al., 2002).  
These authors suggested a possible benefit to the virus in that XRCC1 normally 
interacts with DNA polymerase β and by interacting with XRCC1, E6 is releasing 
DNA polymerase β and promoting DNA replication (Iftner et al., 2002).  This 
hypothesis makes sense as above all viruses want to replicate and produce 
progeny viruses.  There is no benefit to the virus in causing cancers.  Similarly 
HPV16 E6 has been shown to induce the proteasomal degradation of O(6)- 
methylguanine DNA methyltransferase preventing the DNA repair functions 
normally exerted by this molecule (Srivenugopal & Ali-Osman, 2002). 
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Figure 1.6 Crystal structure of the HPV45 E7 protein.  The E7 protein contains 
a zinc finger domain and three CR domains.  The Conserved Region domains are 
named due to their homology to Adenovirus E1A pRb binding domains.  The E7 
proein is shown as a dimmer with zinc atoms indicated in red and yellow.  
Different dimmers are shown in green and blue (Ohlenschlager et al., 2006).  
The highly structured C-terminus of E7 is present in the E6*X isoform. 
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1.5.4 E7 
The E7 protein is made up of three conserved regions; Conserved Region (CR) 1, 
2 and 3. The crystal structure of HPV16 E7 is shown in Figure 1.6.  HPV45 E7 is 
composed of 3 beta sheets and 2 alpha helices.  E7 has homology with SV40 
Large T antigen and adenovirus E1A protein (Dyson et al., 1989).  The conserved 
regions are named due to their high homology with adenovirus E1A which also 
binds to and degrades pRb.    The most well known interaction of E7 is with the 
retinoblastoma family of proteins including the pocket proteins pRb (p105), p107 
and p130 (Dyson et al., 1989).  The N-terminus of E7 is unstructed and flexible 
meaning the CR2 domain responsible for pRb binding is highly accessible 
(Ohlenschlager et al., 2006). E7 binds to pRb inducing its degradation (Boyer et 
al., 1996).  This degradation releases pRb’s association with E2F (Chellappan et 
al., 1992).  E2F is a transcriptional activator which is involved in regulation of 
transcription of genes encoding proteins essential for the progression of the cell 
cycle (reviewed by (Sun et al., 2007).  The release of E2F from pRb allows E2F to 
bind to and activate the promoter regions of many S phase and cellular growth-
related genes including cyclin A and cyclin E which are both required to allow 
the cell to enter S phase (Melillo et al., 1994, Sun et al., 2007).  Under normal 
circumstances if the cell has encountered damage or circumstances that are not 
permissive for replication, pRb binds to E2F and prevents it binding to and 
activating promoters of S phase genes.  However, E7 degradation of pRb results 
in the release of E2F and therefore the expression of S phase entry genes 
resulting in the replication of cellular and viral DNA.   
Not only is cyclin A and cyclin E expression increased due to E2F activation, 
HPV16 E7 has also been shown to directly bind to these cyclins independent of 
Chapter 1  47 
 
pRb binding.  HPV16 E7 has also been reported to bind and inhibit p21 and p27 
cyclin inhibitory functions (Zerfass-Thome et al., 1996, Funk et al., 1997, Jones 
et al., 1997).  p16 and p21 are associated with cell cycle exit in keratinocytes 
leading to differentiation.  Therefore the inhibition of these proteins is 
important for viral DNA replication in cells which would normally be replication 
inactive.  Furthermore E7 binds E2F6 and prevents its normally repressive 
functions on E2F activated S-phase genes (McLaughlin-Drubin et al., 2008).  E2F6 
is a member of the polycomb repressor complex that normally associates with 
chromatin and prevents transcription (McLaughlin-Drubin et al., 2008).  It was 
suggested by the authors that this repression of E2F6 activity resulted in an 
extended S-phase allowing viral DNA synthesis to continue (McLaughlin-Drubin et 
al., 2008). 
E7 also interacts with other transcription factors including p300/CBP, PCAF and 
Mi2β.  p300/CBP are transcriptional co-activators and are involved in many 
pathways in the cell, including DNA repair, cell proliferation and apoptosis (for 
review see Goodman and Smolik., 2000).  p300/CBP can activate transcription of 
proteins which control the cell cycle making them important tumour suppressor 
proteins (for review see Goodman & Smolik., 2000).  Bernat et al. (2003) showed 
that E7 interacts directly with p300 and results in a decrease in its 
transcriptional activity (Bernat et al., 2003).   
E7 has also been shown to interact with p600 a retinoblastoma associated 
protein through the N-terminal domain of E7 (Huh et al., 2005).  This interaction 
has been shown to be independent of pRb (Huh et al., 2005).  The interaction of 
E7 with p600 is thought to be important for the transforming activities of HPV16 
E7 (Huh et al., 2005).  Reduction of p600 in transformed cells results in a 
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reduction in anchorage-independent growth whether the cells are HPV-positive 
or not (Huh et al., 2005).  It has also been shown that p600 is an important 
regulator of anoikis.  Anoikis is a form of apoptosis which is initiated when cells 
are stimulated to grow without contact with a matrix (for review see Chiarugi & 
Giannoni., 2008).  For example in differentiating epithelia, cells should not 
undergo cell division when they are no longer attached to the basement 
membrane.  Anoikis is the form of apoptosis which prevents this form of cell 
division from occurring.  In papillomavirus infections, where there is division 
outside of the basal layer, this control pathway must be overcome.  Therefore 
E7 binding to p600 is an important step to allow viral DNA synthesis during 
infection and also once the cells have become transformed and are growing in an 
uncontrolled manner. 
E7, along with E6, contributes to chromosomal instability by binding to γ-tubulin 
and altering the recruitment of γ-tubulin to centrosomes (Nguyen et al., 2007).  
Interfering with centrosomes indirectly affects the ability of the chromosomes to 
segregate properly and divide evenly between daughter cells during mitosis.  
During a normal mitosis, the cell has exactly two centrosomes; however one of 
the hallmarks of HPV infection is the presence of multipolar centrosomes 
(Duensing & Munger, 2003, Duensing et al., 2008).  The main action of E7 is 
through uncoupling the synthesis of new centrosomes from the cell cycle by 
degrading pRb/p107/p130 and interfering with cdk2 activity (Dyson et al., 1989, 
Nguyen & Munger, 2008).  However Nguyuen et al. (2007) showed that E7 can 
also bind to γ-tubulin and retard its association with centrosomes, thus 
interfering with the formation of new centrosomes (Nguyen et al., 2007).  The 
build up of genetic instability in HPV-infected cells is also likely added to by the 
interaction of E7 with Nuclear Mitotic Apparatus Protein 1 (NuMA) and dynein 
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(Nguyen & Munger, 2009).  NuMA and dynein are both found at spindle points 
during mitosis and when E7 is expressed in the cell, these proteins are 
delocalised resulting in errors during mitosis (Nguyen & Munger, 2009).  NuMA is 
targeted to the spindle poles by dynein and acts to stabilise the fibres (Nguyen & 
Munger, 2009).  NuMA and dynein importantly have also been shown to be 
involved with cell polarity organisation (Nguyen & Munger, 2009).  NuMA has 
been shown to localise at the apical membrane of dividing basal cells, 
identifying the cell which is to go on to further divide from the cell which has 
committed to differentiation.  Dynein has also been reported to have similar 
functions (Nguyen & Munger, 2009).  Nguyen and Münger. (2009) reported that 
E7 interacts with NuMA and interferes with the protein’s ability to bind to 
protein partners, including dynein, thereby inhibiting the formation of the 
spindle poles.  However, as this is a dynamic process some active NuMA and 
dynein would eventually reach the spindle pole, thereby delaying mitosis and 
allowing the build up of mitotic abnormalities (Nguyen & Munger, 2009).   
Genomic instability is a consequence of transformation by high risk viruses.  The 
uncontrolled proliferation induced by HPV16 E7 and the lack of an apoptotic 
pathway as a result of E6 activity allows the build up of genetic mutations and 
E7’s interference with mitosis only adds to this.  However this is unlikely to be 
the sole reason for E7 interaction with NuMA as low risk E7 proteins also bind 
NuMA (Nguyen & Munger, 2009).  Nguyen and Münger. (2009) also suggested that 
this interaction could be required for viral life cycle in that disruption of NuMA 
will also interfere with the identification of cell polarity, therefore it may allow 
viral DNA replication in cells which have moved into the suprabasal layer and 
should be entering differentiation (Nguyen & Munger, 2009). 
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1.6 Transformation 
E6 and E7 are two of the earliest genes expressed after viral infection and the 
RNAs encoding them are expressed throughout the epidermal layers of the skin.  
E6 and E7 are the two major oncogenes of the high risk HPVs, which along with 
E5 account for the oncogenicity of these viruses.   There is convincing evidence 
of the role of E5 in the transformation process during a BPV viral infection, 
however the role of alpha virus E5 during the transformation process is not quite 
so convincing.  In fact, after genome integration, E5 is no longer expressed.  So 
E5 is probably not present in many cervical cancers.  E6 and E7 both have many 
cellular interacting partners that are regulated in order to allow increased 
cellular proliferation and cause cell transformation.  In a normal infection, E6 
and E7 are expressed at low levels acting to allow viral replication in response to 
epithelial differentiation.  During cell transformation, the genome breaks into a 
linear form and becomes integrated into the host cell chromosome and the 
repression of the levels of E6/E7 expression is disrupted resulting in E6 and E7 
being overexpressed (Choo et al., 1987).  This disruption is due to the break in 
the circular genome usually occurring around the E1 and E2 region of the 
genome (Choo et al., 1987).   
E2 in combination with its other functions, discussed above, represses the 
expression of E6 and E7 in a normal infection (Bernard et al., 1989, Tan et al., 
1992, Tan et al., 1994).  Disruption in the E2 gene leads to deregulated 
expression of E6 and E7.  While E6 and E7 expression at low levels is necessary 
for the productive viral life cycle, high levels of expression lead to chromosome 
abnormalities and genomic instability which then aids in the transformation of 
the infected cells.  The proliferative effects of E7 lead to uncontrolled DNA 
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replication allowing mutations to build up in the cellular DNA.  Likewise E7’s 
ability to interfere with mitotic spindle and centrosome assembly adds to the 
genomic instability (Nguyen & Munger, 2009).  E6’s ability to block apoptotic 
pathways allows the cells to continue with their cell cycle even though there 
have been mistakes made thereby building upon E7’s effects (Crook et al., 1991, 
Thomas & Banks, 1998).  E6 and E7 expression is sufficient to immortalise cells 
but other changes in the cell are required to malignantly transform the cell. 
 
1.7 Cell Culture Model System 
Due to the complexities of the HPV viral life cycle and its tight link with 
epithelial differentiation the virus is difficult to study in the laboratory 
environment.  Until fairly recently the only methods of studying HPV gene action 
were by either transiently or stably expressing virus proteins in transformed 
cells.  While this is good enough for binding studies, protein/protein interactions 
and for functional studies on the individually expressed proteins it does not 
allow any functional information from the natural system where multiple viral 
proteins are expressed at any one time in a background of changing cellular 
protein expression.  In order to get an idea of the functions of the viral proteins 
at various stages in the virus life cycle, a system that allows for differentiation 
of infected epithelial cells is required.   
There are three cell culture systems that are used when studying the 
papillomavirus life cycle; namely organotypic raft culture systems; HPV stably 
transformed NIKS cells and W12 cells.  Raft cultures are systems that provide 
cells with a 3D support system allowing the cells to fully differentiate in culture.  
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The epidermal cells are grown on a matrix of collagen on top of a wire grid at 
the liquid air interface, where any nutrients must diffuse to the upper layers via 
a concentration gradient similar to the in vivo system.   The rafts are grown for 
around two weeks to allow the cells to differentiate.  If the epithelial cells 
contain HPV genomes they can produce infectious virus.  Raft cultures are 
excellent systems for studying the complete virus life cycle or late viral proteins 
that require differentiation for production.  However, they are relatively time 
consuming and cumbersome to handle in the laboratory.  While these systems 
are the best for inducing complete differentiation and efficient virus production, 
other less cumbersome systems are often routinely used where almost complete 
differentiation of the cells and less efficient virus production is acceptable.  
One such system for studying the virus life cycle is the NIKS system.  NIKS stands 
for Normal Immortal KeratinocyteS and were originally isolated by Professor 
Allen-Hoffmann in 1999 from the BC-1-Ep strain of human neonatal foreskin 
keratinocytes (Allen-Hoffmann et al., 2000).  The NIKS cells spontaneously arose 
after passaging normal foreskin keratinocytes until senescence (Allen-Hoffmann 
et al., 2000).  The cells that survived this crisis were termed NIKS.  NIKS cells 
retain the ability to differentiate in culture similar to the parental cells (Allen-
Hoffmann et al., 2000).  They also have wild type p53 levels and do not undergo 
anchorage independent growth (Allen-Hoffmann et al., 2000).  The major 
identifiable difference between the NIKS and the parental cells is the 
appearance of an extra copy of the long arm of chromosome 8 in the NIKS cells 
(Allen-Hoffmann et al., 2000).  Significantly the c-Myc gene is located on 
chromosome 8, however steady state levels of c-Myc RNA in NIKS are not 
increased compared to the parental cells (Allen-Hoffmann et al., 2000).  
Importantly, an extra copy of chromosome 8 is often associated with increased 
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growth in human cells as an extra chromosome 8 is often found in cancers 
including breast and prostate cancers (Allen-Hoffmann et al., 2000).  These NIKS 
cells were then stably transfected with HPV16 genomes taken from the W12 cell 
line (see below) and a GFP expression plasmid conferring G418 resistance (Flores 
et al., 1999).  These cells were shown to fully differentiate in raft culture and 
therefore could complete a productive viral infection (Flores et al., 1999).  The 
NIKS cells could not only support the HPV16 viral life cycle but also other HPV 
types such as HPV31b (Flores et al., 1999).  The ability of these cells to support 
a productive virus infection has made them ideal for studying papillomavirus life 
cycles.  Importantly Flores et al were able to detect virus like particles in the 
nucleus of the transfected NIKS in raft culture suggesting the virus can indeed 
undergo a productive virus life cycle (Flores et al., 1999).  The only caveat for 
using these cells in my view is that the genomes have been transfected and NIKS 
have not been infected “naturally”, however these cells can be passaged so will 
be continuously available whereas stocks of other naturally occurring cell lines, 
such as the W12 line, will eventually run out.   
In our laboratory we use the W12 model system.  W12 cells are cervical 
epithelial cells that were originally isolated from a low grade cervical lesion by 
Professor Margaret Stanley in 1989.  W12E (clone 20863) cells contain around 100 
episomal copies of the HPV16 genome and can differentiate in monolayer and 
raft culture allowing completion of a productive viral infection (Stanley et al., 
1989, Jeon et al., 1995).  As these cells were isolated from a low grade lesion, 
the HPV16 genomes are naturally occurring virus genomes and the cells have 
been immortalised by the virus itself making the system arguably much more like 
the natural infectious situation.  The W12 system was evolved to produce a 
second cell line which contains integrated HPV16 genomes, called W12G cells 
Chapter 1  54 
 
(clone 20861) (Jeon et al., 1995).  W12E and W12G cells can both differentiate 
in culture and are not transformed.  They require murine J2 3T3 feeder layer 
cells and mitogens including EGF, Cholera toxin and hydrocortisone for growth.  
In our laboratory two more cells lines were sequentially derived from W12G 
cells.  W12GPX were derived by growing W12G cells without feeder layer cells. 
Following crisis and cell death, a new cell line, W12GPX was established that 
was able to grow in the absence of feeder cells. W12GPXY cells were then 
derived from W12GPX cells by growing them in the absence of mitogens in the 
medium (Aasen et al., 2003).  W12GPX and W12GPXY cells display a transformed 
phenotype and are invasive in raft cultures. Moreover, when injected into nude 
mice, W12GPXY cells formed large squamous cell carcinomas (Aasen et al., 
2003).  W12GPX and W12GPXY cells have lost the ability to differentiate as when 
grown in organotypic raft culture there was no differentiation (Aasen et al., 
2003).  Finally, while W12GPX cells grow in monolayer culture in large colonies 
similar to untransformed epithelial cells, W12GPXY cells grow in small colonies.  
The W12 model system comprising these four cell lines allows the study of both 
the productive viral life cycle and the HPV16-induced transformation of the 
cervical epithelial cells.  Like other well known cervical cancer cell lines 
W12GPX and W12GPXY cells only express the HPV16 E6 and E7 proteins, however 
the benefit of using the W12 cell lines is that we have a series of cell lines 
derived from a common ancestor cell with varying phenotypes relating to 
increased transformation with W12G cells being non-transformed and the 
W12GPXY cells are fully transformed with the W12GPX cells in an intermediate 
state of transformation.  A flow chart showing the derivation of the W12 cell 
lines is shown in Figure 1.7.  
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Figure 1.7 Flow chart of W12 cell line.  W12E cells containing episomal copies 
of the HPV16 genome and W12G cells containing integrated copies of the HPV16 
genome were isolated from a low grade CIN 1 lesion: both are immortalised but 
not transformed.  W12E cells allow the study of the virus life cycle.  W12GPX 
and W12GPXY cells were further derived from W12G cells and are transformed 
cervical epithelial cells.  W12G, W12GPX and W12GPXY cells allow the study of 
HPV16 induced cellular transformation. 
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2 RNA Processing 
RNA expression is a tightly regulated process that involves a number of steps and 
levels of control.  There are a number of stages of processing before RNAs are 
considered to be mature and functionally active.  RNAs must be transcribed, 
capped, spliced and polyadenylated before they can be exported from the 
nucleus and translated.  Each stage is tightly regulated with a number of 
proteins involved at every step.  It should also be said that these steps do not 
occur independently, capping, splicing and polyadenylation occur co-
transcriptionally.  RNA processing is one of the most important processes in the 
cell. Alterations in RNA processing can have wide ranging results as simply 
skipping an exon or including an intron in an mRNA can change the function of 
the resulting protein. 
 
2.1 Capping 
After transcription the first processing stage of the newly transcribed RNA is 
capping.  The newly formed RNA will exit the RNA polymerase with a pppA 5’ 
end (Moore & Proudfoot, 2009).  Three enzymatic reactions then occur to 
convert the triphosphate 5’ end structure (pppA) to 7 methyl Guanosine cap 
(7meGpppA) (reviewed by (Zorio & Bentley, 2004).   Once recruited to the 
promoter region, the polymerase C-terminal domain (CTD) becomes active by 
phosphorylation of the serine 5, and this phosphorylation recruits the capping 
enzymes to the 5’ end of the RNA (Hocine et al., 2010).  Once capped the 
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phosphorylation status of the C-terminus of the polymerase changes and the 
serine 2 becomes phosphorylated which signals that transcription elongation is to 
take place (Hocine et al., 2010).  As the newly formed RNA emerges from the 
RNA polymerase one of the triphosphates is removed by RNA terminal 
phosphatase allowing guanyl transferase to add a GTP to the chain (Hocine et 
al., 2010).  Methyl transferase then methylates the guanine (Hocine et al., 
2010).  The cap structure provides stability to the freshly synthesised RNA 
preventing the degradation by exonucleases in the nucleus (Shimotohno et al., 
1977).  The cap also aids in the export of the RNA from the nucleus to the 
cytoplasm for translation by recognising the nuclear export complex (Hamm & 
Mattaj, 1990).  Once added the cap is bound by the cap binding complex which 
remains bound until it is replaced by translation initiation factors.  The cap is 
recognised by the translation initiation factor complex (eIF4F), comprising of 
eIF4E which recognises the cap structure, the RNA helicase eIF4A and eIF4G 
which forms a scaffold, thereby enhancing the translation of the RNA (Pierrat et 
al., 2007).  Finally, it is also thought that the cap binding complex aids 
polyadenylation as the newly transcribed RNA forms a loop and the cap binding 
complex is found bound to poly(A) binding protein (PABP) that attaches to the 
polyadenylated tail of the mRNA (Cooke & Alwine, 1996).   
 
2.2 Alternative and Constitutive Splicing 
Splicing is the process of the removal of introns and joining of exons from 
premature mRNAs to form mature mRNAs.  It is a very complex process with a 
number of steps and multiple proteins involved.  There are two types of splicing: 
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constitutive and alternative splicing.  Constitutive splicing is where particular 
introns are removed every time the RNA is expressed.  Alternative splicing is 
where the removal of introns or exons can be different depending on conditions 
or signals within the cell.  Alternative splicing increases the number of 
functionally different proteins that can be expressed from single RNAs.  A 
diagram of constitutive and alternative splicing is shown in Figure 1.8.  There 
are different types of alternative splicing, for example there is intron retention 
where the normally non-coding intron is retained within the RNA or alternative 
exon splicing is where in one RNA one exon is retained and another spliced out 
whereas in another RNA the retained exon from the first RNA is removed and the 
exon that was removed in the first RNA is retained.  Around 94% of all human 
RNAs are alternatively spliced (Ward & Cooper, 2010).   
The process of splicing is shown in Figure 1.9.  The first step in the splicing 
process is recognition of the 5’ splice site by U2 auxiliary factor U2AF (Graveley, 
2000).  U2AF binds to the pyrimidine tract and the 3’ splice site and SF1/mBBP 
then locates and binds to the branch point sequence (reviewed by (Graveley, 
2000).  U1 small nuclear ribonucleoprotein (snRNP) then binds U2AF (reviewed 
by (Graveley, 2000).  This is termed the E or early complex. U2 snRNP binds to 
the branch point sequence converting the E complex to the A complex 
(Graveley, 2000).  B complex is then formed by U4/U6 and U5 snRNPs binding to 
the complex (reviewed by (Graveley, 2000).  The complex is rearranged to form 
the C complex when U6 displaces U1 and interacts 
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Figure 1.8 Diagram showing some examples of alternative splicing.  Splicing 
can be divided into two types, Constitutive and Alternative splicing.  
Constitutive splicing is when introns are removed and exons are joined together 
every time the mRNA is expressed.  Alternative splicing arises when under some 
conditions an intron can be retained in the resulting mRNA (Intron retention) or 
exons can be removed (exon exclusion) or exons can be included or removed 
depending on cellular signals (alternative exon). 
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Figure 1.9 Schematic diagram of the splicing process.  E) shows the E complex 
formation with the U1 snRNP (red) bound to the 5’ splice site and U2AF (orange) 
bound to the 3’ splice site and the SF1 (pink) bound to the branchpoint. A) The A 
complex then forms with U2 snRNP (purple) replacing the SF1 at the 
branchpoint.  B) The B complex arises when the U6/U4 U5 complex binds to the 
RNA.  C) The C complex where the actual splicing reaction occurs.  The 5’ splice 
site bound by U6 attacks the branchpoint forming a “lariat” structure.  The 3’ 
end of the first exon then cleaves the 5’ end of the second exon and joins 
together.  The lariat structure containing the intron is removed and degraded.  
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 with U2 snRNP that is already bound to the RNA and form a loop which is now 
the active spliceosome and U5 snRNP stabilises the loop (Graveley, 2000).  The C 
complex is the active splicing complex.  The branch point A residue can form an 
unusual phosphodiester bond with the G residue of the 5’ splice site forming a 
loop or “lariat” structure (Hocine et al., 2010).  The 3’ end of the cleaved exon 
1 then cleaves the 5’ splice site of the second exon and can join together to 
form a mature mRNA (Hocine et al., 2010).  The intron is removed still in the 
lariat structure bound by snRNPs ready for degradation (Hocine et al., 2010).  
The whole process is controlled by serine/arginine rich (SR) and heterogeneous 
nuclear ribonucleoproteins (hnRNP) proteins.  SR proteins act to enhance splicing 
by binding to sequences within the open reading frame called exonic splicing 
enhancers and intronic splicing enhancers and recruiting members of the 
spliceosome (Wu & Maniatis, 1993, Staknis & Reed, 1994, Shen et al., 2004, Cho 
et al., 2011).  hnRNP A/B proteins bind to the exonic splicing suppressors or 
intronic splicing suppressors and act to inhibit splicing.  SR and hnRNP proteins 
have antagonistic functions and the levels of the proteins and where on the pre-
mRNA they bind determine which splice sites are selected.  SR and hnRNP 
proteins binding to the mRNA act to define the exons and signal to the 
spliceosome where the splicing reaction is to take place. 
Viruses by nature carry very little nucleic acid and many viruses have evolved to 
make use of the cellular splicing machinery in order to encode for multiple 
proteins from small amounts of genetic material.  HPV is one such virus.  Human 
papillomaviruses have a complex life cycle that involves a tight regulation of 
expression of the viral genes.  Although papillomaviruses have eight genes they 
encode a large number of alternatively spliced RNAs which maximises their 
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coding capacity.  For example, HPV16 encodes at least 13 late RNAs through 
extensive alternative splicing (Milligan et al., 2007). 
 
2.2.1 SR Proteins 
Serine/ Arginine rich (SR) proteins are the cellular splicing factors that are 
responsible for the identification of splice sites and recruitment of the 
components of the spliceosome (Wu & Maniatis, 1993, Staknis & Reed, 1994, 
Shen et al., 2004, Cho et al., 2011).  For this reason they are considered positive 
splicing regulators.  There are nine classical SR proteins that have a high degree 
of homology meaning there is some functional redundancy between the family 
members and are shown in Figure 1.10 (Shepard & Hertel, 2009).  The family 
members have recently been renamed to have a standard nomenclature (Manley 
& Krainer, 2010). They are named SR proteins because they have a large 
serine/arginine rich domain.  Each protein has at least one RNA recognition 
domain (RRM) as well as a serine/arginine rich domain.  The RRM is involved in 
recognising and binding to specific splicing enhancer sequences in the target 
RNA (Long & Caceres, 2009).  The RS domain is subject to phosphorylation and is 
involved in other protein-protein and protein-RNA interactions (Long & Caceres, 
2009).  Not only are SR proteins involved in splicing they are also involved in 
other RNA processing events in cells, such as mRNA export from the nucleus to 
the cytoplasm, mRNA stability and nonsense mediated decay (Huang & Steitz, 
2001, Lemaire et al., 2002, Zhang & Krainer, 2004). 
A lot of work has been carried out into understanding the functions of SR 
proteins as they seem to be involved in multiple stages of RNA processing.  It is  
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Figure 1.10 Schematic diagram of the 9 classical SR proteins.  The protein 
structural domains of the 9 classical SR proteins are outlined in the diagram.  
Every SR protein contains at least one RNA Recognition Motif (RRM) and an RS 
domain (serine/arginine rich domain).  Zn denotes a zinc motif and the RRMH 
domain denotes an RRM homology domain. 
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still unclear whether one SR protein family member is responsible for all of the 
SR mediated processing steps for a single RNA or whether multiple SR protein 
family members interact on an individual RNA.  As SR proteins recognise specific 
sequences on the RNA at first it would seem likely that only one SR protein type 
is involved, however, due to the high redundancy in SR protein functions and a 
lack of true consensus binding sequences, it seems more likely that multiple SR 
proteins have the capability to be involved in the processing of individual RNAs.  
This would also explain why depletion of a single SR is not fatal to a normal cell 
if the SR proteins were in fact able to replace one another. 
As previously mentioned SR proteins are involved in a number of RNA processing 
events as well as splicing.  Certain SR proteins have been shown to shuttle 
continuously between the nucleus and the cytoplasm, e.g. SRSF3 and SRSF7, 
while other SR proteins, mainly SRSF2, have been shown to be nucleus confined 
(Caceres et al., 1998).  This shuttling suggests that SR proteins may in fact be 
involved in transporting mRNAs from the nucleus to the cytoplasm for translation 
(Sanford et al., 2004, Michlewski et al., 2008). SRSF3 and SRSF7 were found to 
require a 22 nucleotide sequence on cargo RNAs and were found to work 
synergistically to export mRNA from the nucleus to the cytoplasm (Huang & 
Steitz, 2001).  This ability of the SR proteins to bind and aid export of mRNAs 
may be of vital importance to those mRNAs that do not contain introns and 
therefore do not need to be spliced (Huang & Steitz, 2001).  Dephosphorylation 
of the SR proteins was shown to be important for SRSF7 export functions in the 
nucleus and phosphorylation had to occur before the protein could re-enter the 
nucleus (Huang et al., 2004).  In addition to this role in mRNA export SRSF1 has 
been shown to be associated with 80S ribosome after sucrose gradient 
fractionation suggesting a direct role in translation initiation (Sanford et al., 
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2004).  This translation enhancing role was demonstrated for both intron 
containing and intron lacking mRNAs, indicating that the translational effect is 
completely independent from the splicing activity of the SR protein (Sanford et 
al., 2004).  SR proteins, e.g. SRSF2, have also been demonstrated to be involved 
in transcriptional elongation of certain mRNAs (Lin et al., 2008). Depletion of 
SRSF2 resulted in reduced levels of freshly formed polyadenylated mRNA due to 
a decrease in phosphorylation of RNA Polymerase II Serine 2 and therefore the 
stalling of transcription on actively transcribing genes (Lin et al., 2008).  SR 
proteins also have a role in mRNA stability as some SR proteins can target mRNAs 
containing premature stop codons to the nonsense mediated decay pathway for 
degradation (Zhang & Krainer, 2004).  In addition SRSF1 has been demonstrated 
to control the stability of the chicken PKCI-1-r mRNA (Lemaire et al., 2002).  
Binding of SRSF1 to a purine-rich sequence within the UTR of the PKCI-1-r mRNA, 
results in reduced stability of the RNA and its subsequent degradation (Lemaire 
et al., 2002).  Thus SR proteins have multiple roles in RNA processing and can 
affect almost all stages from transcription to translation. 
 
2.3 Polyadenylation and Cleavage 
Once the mRNA has been transcribed and spliced the 3’ end of the message must 
be polyadenylated.  Polyadenylation again helps with the stability of the mRNAs.  
In eukaryotic RNAs the poly (A) tail can be between 200 and 300 nucleotides in 
length (Sheets & Wickens, 1989).  Once transcribed the poly (A) signal (AAUAAA) 
on the RNA is then recognised and the RNA cleaved 10-30 nucleotides 
downstream of the signal allowing the RNA to dissociate with the polymerase, 
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and adenine residues added to the tail.  Cleavage and polyadenylation involve a 
number of factors including cleavage/polyadenylation specificity factor (CPSF), 
cleavage stimulation factor (CstF), cleavage factors I and II (CF), poly (A) 
polymerase (PAP), symplekin and poly (A) binding protein nuclear 1 (PABN1) (for 
review see Zhang et al., 2010).  CPSF recognises the RNA exiting the polymerase 
and recruits PAP to bind the RNA.  CstF recognises the GU rich region of the RNA 
downstream from the poly (A) signal and PABN1 can bind to the poly (A) tail 
stimulating PAP to continue to add adenines to the 3’ end of the RNA (Kuhn et 
al., 2009).  The number of A residues added to the tail is variable and although 
at first may seem random, there is some level of control over this as there are 
de-adenylation enzymes which act to regulate the number of A residues on a 
particular RNA.  A diagram of polyadenylation is shown in Figure 1.11. 
 
2.4 Export 
The final highly regulated step in the nuclear RNA processing pathway is mRNA 
export.  Most mammalian mRNAs use TAP/p15 as their export adaptor (Cullen, 
2003) although there are other export proteins.  TAP and its cofactor p15 form 
heterodimers, which enhances the shuttling and nuclear pore binding 
capabilities of TAP (Wiegand et al., 2002).  These export adaptors do not 
specifically recognise the RNA itself but proteins bound to the RNA, such as 
ALY/REF which is loaded onto the RNA during splicing (Zhou et al., 2000).  
ALY/REF has recently been shown to be recruited to the 5’ end of the spliced 
mRNA in a cap- and splicing dependent process (Cheng et al., 2006).  ALY/REF 
interacts directly with the cap-binding complex which the authors suggested  
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Figure 1.11 Schematic diagram of RNA polyadenylation.  Cleavage stimulatory 
factor (CstF) (orange) binds to the GU rich region and cleavage/polyadenylation 
specificity factor (CPSF) (blue) binds to the polyadenylation signal of the 
extending RNA molecule and allows dissociation of the RNA from the 
polymerase.  CPSF then recruits poly (A) polymerase (PAP) (red). Poly (A) binding 
nuclear protein 1 (PABN1) (purple) binds to the poly (A) tail and stimulates PAP 
to continue adding Adenine residues to the tail. 
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could explain why mRNA complexes are exported in a 5’ to 3’ direction (Cheng 
et al., 2006).  ALY/REF is also a shuttling protein which enhances the shuttling 
of mRNAs from the nucleus to the cytoplasm (Zhou et al., 2000).  SR proteins can 
also act to recruit the export adaptor TAP after losing some phosphorylation 
after splicing has occurred (Huang et al., 2003). Finally, it has also been shown 
that UAP56, which is involved in spliceosome assembly, recruits ALY/REF to the 
mRNA during splicing (Luo et al., 2001).  All of these steps explain how spliced 
mRNAs can be exported out of the nucleus; however how the small numbers of 
unspliced or intronless mRNAs are exported from the nucleus remains unclear.  
When TAP/p15 is bound the mRNA is recruited to the nuclear pore complex, 
where TAP can bind the pore and is exported out of the nucleus into the 
cytoplasm (Cullen, 2003).  Nuclear pore complexes (NPCs) mediate all 
communication between the cytoplasm and nucleus.   
 
2.5 SR Proteins and Cancer 
The prototypical SR protein SRSF1 (SF2/ASF) has recently been identified as 
being an oncoprotein (Karni et al., 2007).  SRSF1 was shown to be upregulated in 
breast cancers due to chromosomal amplification of the SRSF1 gene found on 
chromosome 17q23 (Karni et al., 2007).  Karni et al. (2007) showed that 
overexpressing SRSF1, but not SRSF2, in mouse fibroblast 3T3 cells was sufficient 
to transform the cells allowing anchorage independent growth in soft agar (Karni 
et al., 2007).  When these SRSF1 overexpressing cells were injected into nude 
mice they formed large tumours, while cells overexpressing other SR proteins, 
SRSF2 and SRSF6, resulted in fewer and smaller colonies (Karni et al., 2007).  
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SRSF1 overexpression enhanced cellular proliferation and protected the cells 
from apoptosis.   The expression of a number of proto-oncogenes and tumour 
suppressors was found to be altered upon overexpression of SRSF1 (Karni et al., 
2007).  SRSF1 overexpression resulted in the expression of a tumourigenic 
isoform of S6K1 (Karni et al., 2007).  S6K1 is involved in the mTOR pathway and 
is involved in regulation of cell growth and apoptosis.  When overexpressed, 
SRSF1 and SRSF2 resulted in an increase in isoform-2 production and a decrease 
in isoform-1 expression (Karni et al., 2007).  Normally isoform-1 is the 
predominant isoform in the cell.  Overexpression of SRSF6 did not alter the 
expression pattern of the S6K1 isoforms (Karni et al., 2007).  When the isoforms 
were studied in order to test if they had any oncogenic functions, by 
overexpressing mouse isoforms in NIH 3T3 cells, overexpression of S6K1 isoform-
2 resulted in colony formation in soft agar, whereas overexpression of isoform-1 
did not allow for colony formation (Karni et al., 2007).  However the colonies 
formed by overexpression of isoform-2 were not as numerous as the colonies 
formed by overexpressing SRSF1 alone, therefore other SRSF1 targets must be 
involved in the transformation process (Karni et al., 2007).   Karni et al. (2007) 
showed that reducing the overexpression of SRSF1 back to relatively normal 
levels was enough to reverse the transformed state of the cells (Karni et al., 
2007).  They therefore concluded that SRSF1 could in fact be considered to be a 
proto-oncogene.  However due to the high degree of homology between 
different SR proteins it is likely that SRSF1 is not unique amongst the SR proteins 
as possibly being oncogenic, SRSF2 and SRSR6 were also found to have some 
similar effects as SRSF1 during the study (Karni et al., 2007).  Similar studies 
have been carried out on SRSF3 showing similar results.  He et al. (2011) showed 
that by knocking down SRSF3 in ovarian cancer cells they could reduce cell 
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growth, inhibit anchorage independent growth and induce apoptosis in these 
transformed cells (He et al., 2011).  
 
3 Aims 
There are still some outstanding questions that have yet to be answered with 
regards to the current knowledge about HPV16 E6/E7 oncoprotein mRNA 
splicing.  My hypothesis is that alternative splicing of HPV16 E6/E7 mRNAs is 
likely to be altered in response to epithelial differentiation status or 
transformation state of the HPV16-positive transformed cells.  It is also likely 
that these isoforms carry out different viral functions, whether at the protein 
level or the RNA level.  As host factors are required for cellular and viral 
processing it is probable that one or more of the splicing regulatory proteins that 
have been previously shown to be oncogenic in cancers and upregulated upon 
HPV16 virus infection is responsible for any changes in virus mRNA expression 
detected. 
The first aim of this PhD was to investigate the alternative splicing patterns of 
HPV16 E6/E7 RNAs in the virus life cycle and during tumourigenesis. As shown 
previously, four isoforms of E6/E7 RNAs can be expressed (Tang et al., 2006).  
RT-PCR studies were performed in order to determine whether splicing of E6/E7 
is altered upon differentiation of HPV16 infected epithelial cells or during HPV16 
induced transformation of the epithelial cells using the W12 model of cervical 
tumour progression.    
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The functions of these E6/E7 mRNA isoforms were investigated in order to 
determine whether the alterations detected during the transformation or 
differentiation of the epithelial cells was related to any function.  Mammalian 
expression constructs were generated expressing each of the individual E6/E7 
isoforms.  Functions of the different isoforms were assessed by expressing 
individual isoforms and carrying out growth curve studies and colony formation 
assays. 
As alternative splicing is regulated by host cell splicing regulatory proteins the 
second aim for this PhD was to determine SR protein levels in transformed and 
virally infected cervical epithelial cells.  Therefore the expression levels of a 
subset of SR proteins were investigated during W12 model cell line 
transformation and patient tissue.  The levels of SR proteins in W12 model 
cervical epithelial cell lines were determined by western blotting and in patient 
tissues by immunohistochemistry.   
To reveal any function for specific SR proteins in the HPV16-positive transformed 
cell lines, cells were siRNA treated in order to determine the SR proteins 
responsible for E6/E7 RNA processing.  Thus RT-PCR experiments were 
performed and the SR protein responsible for E6/E7 mRNA processing during 
cervical epithelial cell transformation and HPV16 life cycle identified.  
Furthermore, HPV16 LCR transcription assays and RNA stability assays were 
preformed to define the level of control the SR protein exerts over E6/E7 mRNA 
processing.   
Finally, as previous publications have shown that overexpression of some SR 
proteins have the ability to transform cells the final aim for this PhD is to 
determine affects of SR protein knockdown on transformed cervical epithelial 
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cells (Karni et al., 2007, He et al., 2011).  Growth curve experiments, colony 
formation assays and Annexin V apoptosis assays were all performed. 
73 
2 Materials and Methods 
 
2.1.1 Enzymes 
All enzymes were purchased from Invitrogen (Life Technologies) unless otherwise 
stated. 
2.1.2 Primers 
All primers used in this thesis were purchased from Integrated DNA Technologies 
with the exception of the E6/E7 PCR primers and GAPDH primers which were 
purchased from Sigma-Genosys.  Probe and primer sets were purchased from 
Eurogentec Ltd and predesigned and validated gene expression assays were 
purchased from Applied Biosystems. 
2.1.3 siRNAs 
All siRNAs used in this thesis were purchased from Dharmacon RNAi Technologies 
with the exception of the SRSF1 siRNA which was purchased from Sigma.  All SR 
protein siRNAs are commercially available.  SRSF1 and siGlo siRNAs were single 
molecule siRNAs and SRSF2 and SRSF3 were SMARTpool siRNAs. 
2.1.4 Plasmids/Vector 
pGEM®-T Easy (Promega): Taq DNA polymerase-amplified PCR products were 
cloned into this vector.  The vector is supplied pre-cut with EcoRV and has 3’ 
thymidine residues added to either end of the vector.  The thymidine residues 
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complement the adenine residues added to the ends of amplified PCR products 
by Taq DNA polymerase.  The inserted product is cloned into the β-galactosidase 
gene which inactivates the enzyme, allowing detection of bacterial clones 
containing the ligated product by blue/white selection on Xgal/IPTG agar plates. 
pEGFP-C1 (Clontech): A mammalian expression vector containing a CMV 
promoter and an SV40 polyadenylation site.  PCR products cloned into the 
multiple cloning site will have an N-terminal GFP tag. 
p3XFLAGCMV10 (Sigma): Mammalian expression vector containing a CMV 
promoter and an SV40 polyadenylation site.  Inserts inserted into the multiple 
cloning site will have three FLAG epitopes added to the N-terminus. 
p3XFLAGCMV10E6E7: Nucleotides 87 - 856 of HPV16 E6/E7 were cloned into the 
Hind III and Xba I sites of the p3XFLAGCMV10 vector. 
pEGFP-C1-E6*I:  Nucleotides 94-226^409-858 of HPV16 E6/E7 were cloned into 
the BglII and BamH1 sites of the pEGFP-C1 vector. 
pEGFP-C1-E6*II: Nucleotides 94-226^526-858 of HPV16 E6/E7 were cloned into 
the BglII and BamH1 sites of the pEGFP-C1 vector. 
pEGFP-C1-E6*X: Nucleotides 94-226^742-858 of HPV16 E6/E7 were cloned into 
the BglII and BamH1 sites of the pEGFP-C1 vector. 
pGL3Control (Promega): Mammalian expression vector which contains an SV40 
promoter and late polyadenylation site.  The vector contains firefly luciferase 
which can be used to monitor expression of cloned products. 
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pGL3Basic (Promega): Mammalian expression vector containing an SV40 late 
polyadenylation site but no promoter. 
pGL3HPV16LCR: Nucleotides 7101 – 137 of the HPV16 LCR were cloned into the 
pGL3-basic vector. 
E2 Trans: HPV16 E2 encoding mammalian expression construct was a gift of 
Prof. Peter Howley. 
GFPHPV6E2: GFP tagged HPV6 E2 mammalian expression construct was a gift of 
Dr Kevin Gaston. 
GFPHPV11E2: GFP tagged HPV11 E2 mammalian expression construct was a gift 
of Dr Kevin Gaston. 
GFPHPV16E2: GFP tagged HPV16 E2 mammalian expression construct was a gift 
of Dr Kevin Gaston. 
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Table 2: Sequences of all primers used in this thesis and their applications 
Primer Sequence  5’ to 3’ Use 
E6 PrimerA F GAGAACTGCAATGTTTCAGGACCC PCR 
E7 PrimerX R GAACAGATGGGGCACACAATTCC PCR 
GAPDH F TCCACCACCCTGTTGCTGTA PCR 
GAPDH R ACCACAGTCCATGCCATCAC PCR 
E6 PrimerABglII F AAAGGGAAAAGATCTGAGAACTGCAATGT
TTCAGGACCC 
Cloning 
E7 PrimerXBamH1 R GAACAGATGGGGCACACAATTCCATTGGA
TCCAAAGGGAAA 
Cloning 
T7 TAATACGACTCACTATAGG Sequencing 
SP6 GATTTAGGTGACACTATAG Sequencing 
pEGFP-C1 CATGGTCCTGCTGGAGTTCGTG Sequencing 
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Table 3: Sequences and catalogue numbers of all siRNAs used throughout this 
project. 
 
siRNA Sequence Final 
Concentration 
Company 
Catalogue Number 
HPV16 E6 AGU UAC CAC AGU UAU GCA C 40nM Custom 
siGlo RISC-
free 
control 
N/A 17nM Dharmacon  
D-001600-01-20 
SRSF1 CAU CUA CGU GGG UAA CUU A 20nM Sigma 
SASI_Hs02_0031326
0 
GCA CGA AGG UCC AAG UCC A 
CCA GUG UCC AAG AGG GAA U 
CUC CCG AUG UGG AGG GUA 
U 
SRSF2 
Smartpool 
GCG AGC UGC GGG UGC AAA 
U 
10nM Dharmacon   
M-019711-00-0005 
GAG UGG AAC UGU CGA AUG 
G 
GGA CUG UAA GGU UUA UGU 
A 
CGA AGU GUG UGG GUU GCU 
A 
SRSF3 
Smartpool 
CGA GAU GAU UAU CGU AGG A 
10nM Dharmacon 
 M-030081-00-0005 
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2.1.5 Antibodies 
The antibodies used in western blotting and flow cytometry experiments are 
listed in the table along with the dilution they were used at and their source. 
Antibody Species Dilution Source Catalogue 
Number 
GAPDH clone 6CS Mouse 1:1000 Biodesign 
International 
H86504M 
 
GFP 2555 Rabbit 1:500 Cell Signalling 2555S 
γ-tubulin GTU88 Mouse 1:2000 Abcam ab11316 
SRSF1 clone 96 Mouse 1:1000 Zymed 32-4500 
SRSF3 clone 7B4 Mouse 1:250 Zymed 33-4200 
SRSF7 clone 98 Mouse 1:10 Dr James 
Stevenin 
 
Phosphorylated 
SR Proteins 
Mab104 
Mouse neat ATTC 
hybridoma 
supernatant 
 
p53 clone DO-7 Mouse 1:500 BD Pharmingen 554294 
pRb clone 4H1 Mouse 1:2000 Cell Signalling 
Technology 
9309 
HPV16 E2 
TVG261 
Rabbit 1:5000 Prof Iain Morgan  
Table 4: A table listing all antibodies, their source and dilutions used in this 
thesis. 
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2.1.6 Bacterial Culture 
The DH5α strain of Escherichia coli was used to maintain all plasmid DNA. 
Cultures were grown in L-broth or on plates containing L-broth and 1.5% Bacto-
agar. 100µg/ml ampicillin or kanamycin was added as appropriate.   
 
2.1.7 Cell Lines 
J2 3T3:  A fibroblast cell line isolated from the J2 clone of random bred Swiss 
mouse. 
 W12E:  An epithelial cell line containing around 100 episomal copies of the 
HPV16 genome (Stanley et al., 1989, Jeon et al., 1995). 
W12G:  An epithelial cell line containing 30 integrated copies of the HPV16 
genome (Stanley et al., 1989, Jeon et al., 1995). 
W12GPX:  A transformed epithelial cell line containing integrated copies of the 
HPV16 genome.  The cell line is feeder layer independent but mitogen 
dependent.  W12GPX cells were derived from the W12G cell line (Aasen et al., 
2003). 
W12GPXY:  A transformed epithelial cell line containing integrated copies of the 
HPV16 genome.  The cell line is both feeder layer and mitogen independent.  
W12GPXY cells were derived from the W12GPX cell line (Aasen et al., 2003). 
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C33a:  A transformed epithelial cell line negative for HPV DNA and RNA.  Both 
p53 and pRb are present but are elevated in levels and of molecular mass 
respectively. 
CaSki:  A transformed epithelial cell line containing over 500 integrated HPV16 
genomes. 
SiHa:  A transformed epithelial cell line containing 1-2 integrated HPV16 
genomes. 
HEK 293-T:  Human embryonic kidney cell line stably transfected with the SV40 
large T antigen.   
 
2.1.8 Common Reagents, chemicals and solutions 
30% Acrylamide/bisacrylamide mix 29% (w/v) acrylamide, 1% (w/v) N,N’-
methylene bisacrylamide 
10X PBS 1.37M NaCl, 26mM KCl, 100mM Na2HPO4, 
18mM KH2PO4,  pH7.4 
1X PBS-Tween (PBS-T) 137mM NaCl, 2.6mM KCl, 10mM Na2HPO4, 
18mM KH2PO4, 0.1% (v/v) Tween 20 
10X TBE 0.89M Tris, 0.89M Boric Acid, 25mM EDTA 
TE buffer 10mM Tris-HCl, 1mM EDTA, pH 8.0 
Chapter 2  81 
 
DNA loading dye 50% glycerol, 1% SDS, 10mM Tris-HCl pH 
8.2, Bromophenol blue 
SDS protein loading buffer 125mM Tris pH 6.8, 4% SDS, 20% glycerol, 
Bromophenol blue, 5% β-
Mercaptoethanol  
 
2.2 Methods 
2.2.1 DNA manipulation and cloning 
2.2.1.1 Bacterial transformation 
Plasmid stocks and cloned vectors were maintained and amplified in DH5α E. coli 
(Invitrogen #18265-017).  10-50ng of plasmid or 5µl of ligated product was added 
to 50µl chemically competent cells and incubated on ice for 30 minutes.  The 
reactions were heat shocked at 42°C for 45 seconds followed by a 5 minute 
incubation on ice.  450µl L-Broth was added to the cells and incubated at 37°C 
for 1 hour with shaking at 225rpm.  200µl culture was plated onto an L-agar 
plate with appropriate antibiotics and incubated at 37°C overnight. 
 
2.2.1.2 Liquid Cultures 
Small-scale bacterial cultures were prepared by inoculating 5ml of L-broth 
containing 100µg/ml of the appropriate antibiotic with a single colony of 
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bacteria.  The cultures were incubated overnight at 37°C with shaking at 
225rpm.  In order to make a large culture 100ml L-broth containing antibiotics 
was inoculated with 100µl of a small culture. 
 
2.2.1.3 Plasmid DNA extraction 
Plasmid DNA was routinely extracted from small overnight bacterial cultures 
using the PureLink Quick Plasmid Miniprep kit (Invitrogen #K210010).  The 
extractions were carried out according to the manufacturer’s protocol.  Briefly, 
1.5ml of an overnight culture was pelleted by centrifuging at 13 200 rpm for 2 
minutes in an eppendorf 5415 R bench top centrifuge and the media removed.  
The pellet was resuspended in 250µl resuspension buffer containing RNase A.  
250µl lysis buffer, containing SDS to denature proteins, was added to the 
reaction and incubated at room temperature for 5 minutes before 850µl 
precipitation buffer was added.  The reaction was added to a spin column and 
spun at 13 200 rpm for 10 minutes to remove cellular debris.  The column was 
washed twice in 700µl wash buffer before the DNA was eluted in 75µl TE buffer 
into a new collection tube.   
For transient transfections large bacterial cultures were inoculated and the 
PureLink HiPure Plasmid DNA Purification Maxiprep kit (Invitrogen # K210004) 
was used as the Miniprep kit can leave residual bacterial endotoxins in the DNA 
prep.  The extractions were carried out according to the manufacturer’s 
protocol.  The initial steps are the same as described above only in larger 
volumes.  For this procedure all centrifugation steps were carried out using a 
Beckman Coulter Avanti J-E centrifuge (JA-14 rotor).  After eluting the DNA in 15 
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ml of elution buffer 10.5ml isopropanol was added to concentrate the DNA and 
remove salts.  5ml 70% ethanol was added to remove any remaining salts before 
the pellet was air dried and resuspended in 500µl TE buffer. 
 
2.2.1.4 Restriction enzyme digestion 
Plasmid or PCR-amplified DNA was digested using approximately 2U of restriction 
enzyme per µg of DNA.  The reaction was carried out in the appropriate 
restriction buffer for 1-3 hours at 37°C. 
 
2.2.1.5 Alkaline Phosphatase Treatment 
In order to remove phosphates from the cut ends of digested plasmids CIP 
treatment was performed.  This was especially important during cloning as BglII 
and BamHI were used to clone E6 isoforms.  BglII and BamHI-cut vectors can 
religate without the addition of an insert.  Purified cut plasmid was CIP digested 
in a volume of 50 µl.  5µl of 10X reaction buffer (New England Biolabs) and 1µl 
(10U) CIP enzyme (New England Biolabs) were added to 30µl (10-15µg) plasmid 
and the volume made up to 50µl.  The reaction was incubated at 37°C for 1 
hour. 
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2.2.1.6 Phenol:Chloroform extraction and ethanol precipitation 
In order to remove excess salts and impurities from extracted RNA or DNA, a 
phenol:chloroform extraction was performed.  An equal volume of 
phenol:chloroform was added to the nucleic acid and mixed thoroughly.  
Phenol:choloform was supplied at pH 4.3 for RNA extractions or pH 7.9 for DNA 
extractions.  The reactions were centrifuged at 13 200 rpm in a bench top 
eppendorf 5415 R centrifuge for 5 minutes at room temperature.  The upper 
aqueous phase was harvested to a clean eppendorf tube and one half volume of 
chloroform added and mixed thoroughly.  Again the samples were centrifuged at 
13200 rpm at room temperature for 2 minutes.  The upper aqueous phase was 
harvested to a clean eppendorf tube.  One tenth of the volume of 3M sodium 
acetate pH 5.2 was added followed by 2.5 volumes of 100% ethanol.  The 
reactions were mixed thoroughly and stored at -20°C overnight or on ice for 30 
minutes. 
To harvest the nucleic acid, the samples were centrifuged at 13200 rpm for 10 
minutes at room temperature in an RNase and DNase free 1.5 ml screw-capped 
eppendorf tube (Starstedt) and the supernatant removed.  5 volumes of 70% 
ethanol was added and centrifuged at 13200 rpm at room temperature for 10 
minutes.  The supernatant was removed and the nucleic acid pellet drained and 
dried followed by resuspension in either TE buffer (DNA) or DEPC treated water 
(RNA). 
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2.2.1.7 DNA ligation 
PCR products were cloned into pGEM-T Easy vector (Promega) following the 
manufacturer’s instructions.  Briefly, 1µl (50 ng/µl) of pre-cut vector was added 
to 5µl of 2X rapid ligation buffer.  Up to 3µl (~25ng) of purified PCR product was 
added followed by 1 µl (3U/µl) of T4 ligase.  The reactions were incubated at 
4°C overnight.   
Digested inserts were ligated into the appropriately digested vector using T4 
DNA ligase (10 000U/ml) (Invitrogen).  The reactions were generally carried out 
in a 10µl volume with 1X ligation buffer (Invitrogen) and incubated for at least 2-
3 hours at room temperature.  A ratio of 3:1 insert: vector was typically used. 
 
2.2.1.8 Agarose gel electrophoresis 
DNA of greater than 1Kb in size was resolved in 0.7-1% (w/v) agarose gels 
(Roche) in 1XTBE.  Agarose gels were electrophorised in 1XTBE buffer at 80V.  
DNA was stained in 0.5µg/ml ethidium bromide for 20 minutes before being 
visualised under UV.  In order to gauge the relative size of the DNA fragments 
1Kb DNA ladder (Invitrogen) was included in the gel. 
 
2.2.1.8.1 Agarose gel DNA extraction 
Extraction of DNA from agarose gels was carried out using the Qiagen Gel 
Extraction kit as described in the manufacturer’s instructions.  Briefly, the 
agarose slice containing the DNA was weighed and 5 volumes of buffer QG was 
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added and incubated at 50°C for up to 10 minutes or until the agarose had 
dissolved.  1 volume of isopropanol was added and transferred to a spin column.  
The samples were centrifuged at 13200rpm for 1 minute and the flow through 
discarded.  The column was washed in wash buffer twice before the DNA was 
eluted into 30µl EB buffer and stored at -20°C. 
 
2.2.1.9 Acrylamide gel electrophoresis 
For DNA fragments less than 1kb, DNA was resolved on a 6% acrylamide gel.  
Acrylamide gels were composed of 3 ml of 30% acrylamide/bisacrylamide mix 
(Biorad), 1.5ml 10X TBE, 10.5ml dH2O, 100µl of 10% APS and 12µl TEMED (Sigma).  
Gels were run in 1X TBE at 100V and the DNA stained in 0.5µg/ml ethidium 
bromide for 20 minutes before visualisation under UV using a Syngene Bio 
Imaging GeneFlash machine.  1Kb DNA ladder (Invitrogen) was included on the 
gel to calculate the size of the DNA fragment. 
 
2.2.1.9.1 Acrylamide gel DNA extraction 
To extract DNA from acrylamide gels, gel slices were incubated with 400µl 0.5M 
NaCl, 1mM EDTA overnight at 4°C.  The acrylamide was spun out by centrifuging 
at 13200 rpm for 2 minutes in an eppendorf 5415 R bench top centrifuge and the 
DNA was precipitated by addition of one tenth volume of 3M sodium acetate pH 
5.2 and 2.5 volumes 100% ethanol.  After incubation at -20°C overnight the DNA 
was harvested by centrifugation at 13200 rpm for 10 minutes at room 
temperature and the supernatant discarded.  70% ethanol was added and 
centrifuged at 13200 rpm for 10 minutes at room temperature and the 
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supernatant discarded.  The pellet was drained and dried before being 
resuspended in DEPC treated H2O or TE buffer. 
 
 
2.2.1.10 Nucleic acid quantification 
The concentration of all extracted nucleic acids was determined using an 
Eppendorf BioPhotometer spectrophotometer.  An A 260 reading of 1 is equivalent 
to 40µg/ml of RNA and 50µg/ml double stranded DNA. The purity of the nucleic 
acid was determined using the A260/A280 ratio.  A reading of around 1.8-2.0 was 
considered to be reasonably pure. 
 
2.2.2 Tissue Culture 
2.2.2.1 Cell line growth and passaging 
CaSki, SiHa, W12GPXY, C33a and 293-T cells were maintained in DMEM 
(Invitrogen) with the addition of 10% foetal bovine serum (Invitrogen).  Cultures 
were passaged 2-3 times per week with splitting generally 1:5, 1:10 or 1:20 
depending on the cell line.  To passage the cells, the medium was removed and 
the cells washed in 1X sterile PBS and trypsinised using 1X trypsin-EDTA 
(Invitrogen) and incubated at 37°C until the cells detached.  Cells were then 
resuspended into 10ml DMEM + 10% FBS and centrifuged at 1000 rpm for 5 
minutes in a Heraeus Multifuge 3 S-R centrifuge and TTH-750 rotor.  The pellet 
was resuspended in 10ml DMEM + 10% FBS and divided into 10cm plates at the 
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desired density.  J2 3T3 cells were maintained in DMEM + 10% donor calf serum 
(Invitrogen). 
W12E, W12G and W12GPX cells were maintained in DMEM + 10% FBS, 0.1nM 
Cholera Toxin and 0.4µg/ml Hyrocortisone.  W12E and W12G cells require to be 
plated out on a feeder layer of J2 3T3 cells.  In preparation for W12E or G cell 
growth, 3T3 cells were treated with 4µg/ml Mitomycin-C for 2-5 hours before 
harvesting the cells and counting.  3T3 cells were resuspended to 5x105 cells in 
4ml of culture media.  1x106 W12 cells were added to the 3T3 cells and the cells 
plated out into five 10cm tissue culture plates, meaning 1X106 3T3 cells and 
2X105 W12 cells were added to each plate.  After 24 hours, 0.5ng/ml epidermal 
growth factor was added to the cells.  Cells were grown for 5 days for 
undifferentiated cells or 10 days for differentiated cells.  While growing, the 
medium was changed and EGF added every two days to each plate until 
harvesting.  To harvest the W12 cells, the 3T3 cells were first trypsinised and 
discarded before the W12 cells were harvested. 
 
2.2.2.2 Cell stocks 
To make stocks of cells, cells were harvested and counted before being 
resuspended to 1X106 cells/ml in DMEM + 10% FBS + 10% Dimethylsulphoxide 
(DMSO) (Sigma).  Cells were transferred into screw cap 2ml cryo-vials and stored 
at -80°C overnight before being transferred into liquid nitrogen for long term 
storage. 
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2.2.2.3 Transfection using Lipofectamine  
2.2.2.3.1 Forward transfection using Lipofectamine RNAiMAX 
In general, unless otherwise stated siRNA transfections were carried out as a 
forward transfection.  24 hours before transfection, 2x105 of the appropriate 
cells were plated out in DMEM + 10% FBS without antibiotics.  Transfections were 
most commonly carried out in 6 well plates.  In a 1.5ml eppendorf, the required 
concentration of siRNA for a single well was diluted into 250µl Opti-mem serum 
free medium (Invitrogen) and in a separate 1.5ml eppendorf tube 5µl 
Lipofectamine RNAiMAX (Invitrogen) was diluted into 245µl Opti-mem medium.  
The complexes were combined and incubated for 20 minutes at room 
temperature before being added drop-wise to the cells.  siRNA transfections 
were commonly carried out for 48 hours however for some experiments an 
incubation period of 24-72 hours was required.  Transfection efficiency was 
monitored by the transfection of a fluorescently labelled control siRNA siGlo.  
siGlo is a fluorescently labelled siRNA which is excited at 557nm and is visible 
under the red channel.  Transfection efficiency was monitored by counting the 
number of fluorescent cells in a field of vision and estimating the percentage 
efficiency. 
 
2.2.2.3.2 Reverse transfection using Lipofectamine RNAiMAX 
For some experiments a reverse transfection was more appropriate.  The 
required concentrations of siRNA and 5µl Lipofectamine RNAiMAX were diluted 
into 500µl Opti-mem.  The reagents were incubated at room temperature for 20 
minutes before 2x105 cells were added and plated out into a 6 well plate.  2.5ml 
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of medium without antibiotics was then added and incubated at 37°C for 24-72 
hours.  If siRNA knockdown and plasmid transfection were required to be carried 
out simultaneously this protocol was also followed with the addition of the 
plasmid to the initial dilution step before the addition of the cells. 
 
 
2.2.2.3.3 Forward transfection using Lipofectamine 
 
Unless otherwise stated plasmid transfections were carried out as a forward 
transfection.  24 hours before transfection, 2x105 of the appropriate cells were 
plated out in DMEM + 10% FBS without antibiotics.  Transfections were most 
commonly carried out in 6 well plates.  In a 1.5ml eppendorf, the required 
concentration of plasmid was diluted into 100µl Opti-mem serum free medium 
(Invitrogen) and in a separate 1.5ml eppendorf tube 5µl Lipofectamine 
(Invitrogen) was diluted into 95µl Opti-mem medium.  The complexes were 
combined and incubated for 40 minutes at room temperature.  800µl of serum 
and antibiotic free medium was added to the lipofectamine complexes before 
being added drop-wise to the cells.  Before addition of the plasmid transfections 
the medium was removed from the cells and 800µl of serum and antibiotic free 
medium was added to the cells.  The transfections were incubated at 37°C for 5-
6 hours before the medium was replaced with DMEM + 10% FBS.  Plasmid 
transfections were commonly carried out for 48 hours.  Transfection efficiency 
was monitored by transfection with pMAXGFP (Lonza). 
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Table 5: A table listing the transfection efficiencies obtained when transfecting 
the various cell lines with siGlo or GFP-plasmid in 293-T cells used during the 
course of the project. 
2.2.2.4 Extraction of total cellular protein 
Cells were washed twice in ice cold PBS after the removal of the culture 
medium.  NP40 lysis buffer (0.5% NP40, 150mM NaCl, 50mM Tris HCl pH 8) with 
protease (Roche Diagnostics) and phosphatase (Roche Diagnostics) inhibitors (one 
tablet per 10ml of lysis buffer) was added to the cells and the cells scraped into 
the buffer on ice.  The lysed cells were transferred to a 1.5ml eppendorf tube 
and incubated on ice for 30 minutes with periodic vortexing.  The extracts were 
centrifuged at 13 200 rpm at 4°C for 10 minutes in an eppendorf 5415 R bench 
top centrifuge.  The supernatant was transferred to a new eppendorf tube and 
stored at -80°C. 
 
Cell type Transfection efficiency 
W12GPXY 80-90% 
CaSki 70-80% 
W12E/W12G 70-80% 
C33a 70-80% 
293-T 95-100% 
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2.2.2.5 Extraction of total cellular RNA 
After removal of the medium, the cells were washed in PBS and 1ml TRIzol 
(Invitrogen) added for every 1x106 cells.  The cells were scraped into TRIzol and 
transferred to a snap-cap Greiner RNase-free tube.  The cells were incubated at 
room temperature for up to 10 minutes or stored at -20°C.  One fifth volume of 
chloroform was added and mixed thoroughly and incubated at room temperature 
for 3 minutes.  The RNA was centrifuged at 10 000 rpm at 4°C for 15 minutes in 
the Beckman Coulter Avanti J-E centrifuge (JA-14 rotor).  The upper aqueous 
layer was carefully harvested into a new snap-capped tube.  A half volume of 
isopropanol was added and incubated at room temperature for 10 minutes 
before centrifugation at 10 000 rpm for 10 minutes at 4°C.  The supernatant was 
removed and the pellet washed in 70% ethanol.  Again the RNA was centrifuged 
at 10 000 rpm for 10 minutes at 4°C.  The ethanol was removed and the pellet 
drained and air dried before being resuspended in DEPC treated H2O.  RNA 
concentrations were determined as described in section 2.2.1.10. 
 
2.2.2.6 Extraction of total cellular DNA 
Cells were harvested by trypsinisation and counted.  The cells were washed 3 
times in ice cold PBS and centrifuged at 1000 rpm at room temperature for 5 
minutes in a Heraeus Multifuge 3 S-R centrifuge and TTH-750 rotor.  300µl of 
lysis buffer (100mM NaCl, 10mM Tris-HCl pH 8.0, 25mM EDTA, 0.5% SDS, 
0.1mg/ml Proteinase K) was added to 1-3 X107 cells.  The extractions were 
incubated at 55°C overnight to completely lyse the cells.  The DNA was then 
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phenol/chloroform extracted and ethanol precipitated as described in section 
2.2.1.6. 
 
2.2.2.7 Growth curve analysis 
Cells were reverse transfected as described in section 2.2.2.3.2 with the 
appropriate siRNA and plated into 6 well culture plates.  Cells were trypsinised 
and counted every 24 hours after plating for 72 hours and the total cell numbers 
calculated. 
 
2.2.2.8 Colony formation assay 
For colony survival assays, 1% agarose (Roche Diagnostics) in dH2O, 0.7% agarose 
(Roche diagnostics) in dH2O and 2X DMEM (Invitrogen) + 20% FBS (Invitrogen) 
were prepared.  Cells were plated out 24 hours prior to transfection. In order to 
prepare the base layer, 1.25ml 1% agarose and 2.5ml 2X DMEM + 20% FBS for 
each 60mm plate was combined and plated before being stored at 4°C overnight 
after setting.  Cells were plated out and a forward transfection carried out as 
described in sections 2.2.2.3.1 and 2.2.2.3.3.  The transfections were incubated 
at 37°C for 24 hours.  The top agarose layer was prepared by combining 1.25ml 
melted 0.7% agarose into 1.25ml 2X DMEM + 20% FBS for each 60mm plate.  The 
cells were harvested and counted and 1 X 105 cells for each 60mm plate was 
added to the top layer.  The top layer containing the transfected cells was 
plated out onto the base layer and incubated at 37°C for 12 – 14 days.  The top 
layer was removed and 0.005% crystal violet staining solution was added and 
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incubated for 1 hour at room temperature.  The stain was removed and the 
plates air dried before being photographed using a Sony DSC-P200 Digital 
camera. 
 
2.2.2.9 Inverse invasion assay 
To test the invasiveness of the cells, cells were plated out and transfected for 48 
hours as described in section 2.2.2.3.1.  Basement membrane matrix (VWR) was 
diluted 1:1.5 with ice cold serum-free DMEM and incubated on ice for 5 minutes.  
60µl of diluted matrigel was pipetted carefully into support transwells (Fisher) 
added to a 24 well plate.  The transwells containing the matrigel were incubated 
at 37°C for 1 hour to set.  The transfected cells were harvested by trypsinisation 
and counted and resuspended to a concentration of 2X105 cells/ml.  After 1 hour 
the 24 well plate was removed from the incubator and turned upside down.  The 
plate was carefully removed leaving the transwells standing upside down on the 
lid.  2x104 cells or 100µl of resuspended cells was added to the bottom of the 
transwells and the plate carefully added to the lid.  The 24 well plate was then 
incubated at 37°C for 2-3 hours upside down.  600µl of serum free medium was 
added to wells on a new 24 well plate.  For every transwell, three wells 
containing medium were prepared.  The new 24 well plate was incubated at 
37°C until ready to use.  After 2-3 hours the 24 well plate was turned the 
correct way up and the transwells washed twice in two of the wells containing 
the serum free medium.  The transwell was placed into the remaining well 
containing serum-free medium and 150µl of DMEM + 10% FBS was added to the 
centre of the well creating a concentration gradient of serum.  The transwells 
were incubated at 37°C for 3 days.  After 3 days cells were stained in 4µM 
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Calcein-A.  4mM Calcein-A was diluted 1:1000 into serum-free DMEM and HEPES 
(100:1 DMEM:HEPES).  500µl of diluted Calcein-A was added to a 24 well plate.  
The transwells were removed from the medium and placed into the 24 well plate 
containing staining solution. 500µl of diluted Calcein-A was added into the 
transwell and the plate incubated at 37°C for 1 hour.  The cells were then 
viewed under the fluorescence Leica DMIRE2 microscope.  Z stack images were 
taken every 10µM to determine invasion potential. 
 
2.2.2.10 Cell cycle analysis 
Cells were plated out at a density of 1X106 cells and were transfected as 
described in section 2.2.2.3.1.  After 48 hours the cells were harvested by 
removing the medium washing in PBS twice.  Cells were trypsinised and 
collected by centrifugation at 1000 rpm at 4°C for 10 minutes in a Heraeus 
Multifuge 3 S-R centrifuge and TTH-750 rotor.  The cell pellet was washed in PBS 
and centrifuged under the same conditions as above another two times.  The 
samples were then resuspended in 500µl of PBS and placed onto ice 
immediately.  The cells were fixed by the addition of 4.5 ml of ice cold 70% 
ethanol added drop wise over a vortex at low speed.  The cells were incubated 
on ice for 30 minutes, or if not required immediately, left at -20°C.  For DNA 
analysis, the cells were stained with Propidium Iodide.  The samples were 
centrifuged under the same conditions as before and the ethanol removed.  The 
pellet was again washed twice in PBS as before.  The cells were resuspended in 
500µl of PBS and 10µg/µl of Propidium Iodide and 10µg/µl Ribonuclease A added.  
The staining was carried out for at least 3 hours at 4°C.  The samples were 
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analysed using the EXPO32ADCXL4 Colour program on a Beckman Coulter Epics 
XL-MCL machine. 
 
2.2.2.11 Transcription assay 
293-T cells were transfected as described in section 2.2.2.3.3 and incubated at 
37°C for 48 hours.  Cells were washed twice in PBS before 300µl 1X Reporter 
Lysis Buffer (Promega) was added and incubated at room temperature for 15 
minutes.  Cells were scraped into the reporter lysis buffer and transferred to -
80°C overnight.  Following an overnight incubation, the samples were defrosted 
on ice and centrifuged at 13 200 rpm at 4°C for 30 minutes in an eppendorf 5415 
R bench top centrifuge before the supernatant was transferred to a new 
eppendorf tube.  80µl of extract was added per well of a white 96 well plate 
(Fisher Scientific catalogue number: MPA-560-030D).  Luciferase assay substrate 
(Promega) was dissolved into Luciferase assay buffer (Promega) and aliquoted 
and stored at -80°C.  1 ml of resuspended luciferase assay substrate was diluted 
into 3 ml dH2O and the plate read by a Thermolabsystems Luminoskan Ascent 
plate reader.  The plate reader adds 80µl diluted luciferase substrate to each 
well and measures the luciferase activity. 
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2.2.3 Protein Analysis 
2.2.3.1 Protein Quantification 
10µl of protein extract was added to 1ml diluted 1X Bradfords reagent (Biorad) 
in a plastic cuvette.  BSA (Sigma) standards (0.1mg/ml, 0.2mg/ml, 0.4mg/ml, 
1mg/ml and 2mg/ml) were also prepared and the absorbance at wavelength A595 
was measured.  The concentrations of the protein samples were determined 
after a standard curve of protein standards was produced and the equation of 
the straight line solved for each sample (y=mx+c). 
 
2.2.3.2 SDS-PAGE 
Equal concentrations of extracted proteins were added to 1X NuPAGE LDS 
protein loading dye (Invitrogen) and 1X NuPAGE sample reducing agent 
containing 500mM DTT (Invitrogen) before being boiled at 100°C for 5 minutes to 
denature any secondary structures that may be present in the protein sample.  
Samples were resolved on NuPAGE Novex 4-12% gradient Bis-Tris polyacrylamide 
gels (Invitrogen) in 1X MES running buffer (Invitrogen).  Electrophoresis was 
carried out at 200V. 
 
2.2.3.3 Western Blotting 
After electrophoresis, protein gels were transferred onto nitrocellulose 
membranes using the Invitrogen iBlot system.  The iBlot system is a dry blotting 
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method of protein transfer and takes 7 minutes to complete.  Membranes were 
blocked in 5% non-fat Marvel powdered milk in PBS-0.1% Tween20 for 1-2 hours 
at room temperature.  Membranes were washed briefly in PBS-T before being 
incubated at 4°C overnight with rotation with the desired primary antibody.  
The primary antibodies and their dilutions are listed in table 3.  The following 
day the membranes were washed in PBS-T (1X 15 minute wash followed by 3X 5 
minute washes) and incubated with the appropriate secondary antibody for 2 
hours at room temperature.  Secondary antibodies (GE Healthcare) were diluted 
1:2000 in 2.5% non-fat Marvel in PBS-T. All secondary antibodies were 
horseradish peroxidase tagged.  Membranes were washed in PBS-T (as above) 
before being detected by chemiluminesence by incubating with either ECL 
(Pierce) for 1 minute or with ECL (plus) (GE Healthcare) for 5 minute depending 
on the primary antibody.  Proteins were detected using Kodak 18X24 mm Medical 
X-Ray film and the Xograph Compact X4 film processor. 
 
2.2.3.4 TUNEL staining 
Cells were plated out in a 4 well chamber slide ready for forward siRNA 
transfection as described in section 2.2.2.3.1.  After 24-72 hours of transfection 
the medium was removed from cells and washed twice in 1ml PBS.  TUNEL 
staining was carried out using the DeadEnd Fluorometric TUNEL system 
(Promega).  The cells were then fixed with 1ml 4% formaldehyde for 25 minutes 
at 4°C.  The formaldehyde was removed and the cells washed twice in PBS for 5 
minutes at room temperature.  The PBS was removed and the cells 
permeabilised in 1ml 0.2% TRITON X-100 in PBS at room temperature for 5 
minutes.  The cells were then washed twice in 1ml PBS for 5 minutes.  A positive 
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control was set up by adding 100µl of RQ1 DNase-1 buffer (Promega) and 
incubating at room temperature for 5 minutes.  The buffer was replaced with 
another 100 µl DNase-1 buffer containing 10U/ml RQ1 DNase-1 and incubated at 
room temperature for 10 minutes.  The buffer was removed and the cells 
washed in deionised water 4 times.  100µl Equilibration buffer (Promega) was 
added and incubated at room temperature for 10 minutes.  The staining solution 
comprising of 45µl Equilibration buffer, 5µl Nucleotide Mix (50 µM fluorescein-
12-dUTP, 100 µM dATP, 10mM Tris-HCl (pH 7.6), 1mM EDTA)  and 1µl rTdT 
enzyme per well was prepared and 50µl of the staining solution was added to 
each well and incubated in humidified chamber at 37°C for 1 hour.  The reaction 
was stopped by filling the well with 2X SSC (Promega) and incubating at room 
temperature for 15 minutes.  The cells were washed three times in 1ml PBS at 
room temperature for 5 minutes.  The wells were air dried before 1 drop of 
Vectashield + DAPI was added and a glass coverslip placed on top.  The 
Vectashield was allowed to set before the slide was viewed under the Leica 
DMIRB fluorescent microscope or stored overnight at 4°C in the dark. 
 
2.2.3.5 Annexin V staining 
Cells were transfected as described in section 2.2.2.3.1 and harvested by 
trypsinisation.  Floating cells were also collected by centrifugation of the 
medium.  The cells were washed in ice cold PBS and centrifuged at 1000 rpm at 
room temperature for 5 minutes.  The cells were resuspended at a concentration 
of 1X106 cells/ml in annexin binding buffer (10mM HEPES, 140mM NaCl, 2.5mM 
CaCl2 pH 7.4).  To 100µl of resuspended cells, 5µl of annexin V conjugate 488nm 
(Invitrogen) and 1µg/ml propidium iodide was added.  The staining cells were 
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incubated at room temperature in the dark for 15 minutes before 400µl of 
annexin binding buffer was added and placed on ice.  Samples were analysed on 
a BD Biosciences FACScalibur machine. 
 
2.2.3.6 Senescence associated β-galactosidase staining 
The senescence β-gal staining kit (Cell Signalling Technology) was used to 
measure senescence in transfected cells.  Cells were transfected as described in 
section 2.2.2.3.1 and incubated for 24 – 72 hours.  The medium was removed 
from the cells and they were washed twice in 1ml PBS.  The cells were fixed in 
1ml 1X Fixative solution for 15 mins at room temperature.  Meanwhile staining 
solution composed of 930µl staining solution, 10µl staining supplement A, 10µl 
staining supplement B and 50µl X-Gal for each well was prepared.  The cells 
were washed twice in 2ml PBS before 1ml staining solution was added and 
incubated overnight at 37°C without 5% CO2.  The cells were visualised the next 
day under the Leica DMIL LED light microscope or the staining solution was 
removed and 1ml 70% glycerol was added and stored at 4°C. 
 
2.2.4 RNA Analysis 
2.2.4.1 RT-PCR 
2.2.4.1.1 mRNA extraction 
Following RNA extraction as described in section 2.2.2.5, mRNA was extracted 
from the total cellular RNA using the Qiagen Oligotex mRNA extraction kit as 
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described in the manufacturer’s instructions.  Briefly, 250µg of RNA in 250µl of 
DEPC-H2O was added to 250µl of Buffer OBB and 15µl of Oligotex solution and 
mixed.  The RNA was incubated at 70°C for 3 minutes to denature any secondary 
structure before incubating at 20°C for 10 minutes to allow the poly A tail of the 
mRNA to bind to the Oligotex particles.  The RNA was centrifuged at 16110 g for 
2 minutes in an eppendorf 5415 R bench top centrifuge and the supernatant 
removed.  The Oligotex pellet was resuspended in 400µl Buffer OW2 and 
transferred to a spin column.  The column was centrifuged at 16110 g for 1 
minute and the flow through discarded.  The column was transferred to a new 
1.5ml eppendorf tube and 400µl Buffer OW2 applied to the column.  The RNA 
was again centrifuged at 16110 g for 1 minute and the flow through discarded.  
The spin column was again transferred to a new 1.5ml eppendorf tube and 20µl 
of Buffer OEB preheated to 70°C was added and the mRNA resuspended.  The 
mRNA was centrifuged at 16110 g for 1 minute before a second 20µl of hot 
Buffer OEB was added to maximise the mRNA yield.  The mRNA was centrifuged 
again at 16110 g for 1 minute and the eluted mRNA stored at -20°C. 
 
2.2.4.1.2 DNase-1 treatment for RT-PCR 
After RNA extraction as described in section 2.2.2.5, any remaining DNA in the 
RNA extract was removed by DNase-1 digestion using the Promega RQ1 DNase-1 
kit as described in the manufacturer’s instructions.  1U of RQ1 was used per 1µg 
of RNA.  Reaction buffer to a final concentration of 1X was added to the reaction 
and the digestion carried out for 1 hour at 37°C.  1µl of DNase-1 stop solution 
was added per µg of RNA and incubated at 65°C for 10 minutes to stop the 
reaction.  The RNA was then phenol:chloroform extracted as described in section 
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2.2.1.6 to remove enzyme and excess salts from the sample that may inhibit 
downstream applications. 
 
2.2.4.1.3 Reverse Transcription 
After DNase-1 digestion, the RNA was reverse transcribed into cDNA using the 
Superscript III kit (Invitrogen) following the manufacturer’s instructions.  1µl of 
10mM dNTP mix and 1µl of Oligo dT20 (50µM) primer was added to 1µg of RNA 
and incubated at 65°C for 5 minutes to disrupt any secondary structures.  The 
reactions were placed on ice and 2µl 10X RT buffer (200mM Tris-HCl (pH 8.4), 
500mM KCl), 4µl 25mM MgCl2, 2µl 0.1M DTT, 1µl 40U/µl RNase OUT and 1µl 
(1U/µl) of either Superscript III or DEPC-treated H2O (for the RT- controls) were 
added.  The reactions were incubated at 50°C for 50 minutes before being 
incubated at 85°C for 5 minutes to stop the reaction.  The samples were placed 
on ice and 2U (1µl) RNase H was added and incubated at 37°C for 20 minutes to 
degrade the initial mRNA strands. 
 
2.2.4.1.4 PCR 
2µl of cDNA (~100µg) or 1µl (~0.5µg) of miniprep DNA was amplified in a PCR 
reaction using Taq DNA polymerase (Invitrogen).  Reactions were carried out in 
50µl volumes with 38.1µl DEPC treated H2O, 5µl 10X PCR Buffer (200mM Tris-HCl 
(pH 8.4), 500mM KCl), 1.5µl 50mM MgCl2, 1µl 10mM dNTPs, 1µl gene specific 
forward primer (10µM), 1µl gene specific reverse primer (10µM), 2µl cDNA and 
0.4µl 5U/µl Taq DNA polymerase.  The final concentration for the PCR reaction 
was 1X PCR Buffer, 200nM Primers, 200µM dNTPs, 1.5mM MgCl2 and 2U Taq DNA 
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polymerase.  PCRs were carried out on a Hybaid PCR Express machine with a 
general program consisting of: 
   95°C – 2 minutes 
   95°C – 30 seconds 
   55°C – 30 seconds 
   72°C – 1 minute 
   72°C – 5 minutes 
   55°C – 5 minutes 
   72°C – 10 minutes 
   4°C – hold 
 
PCR products were resolved on acrylamide gels as described in section 2.2.1.9.1. 
 
2.2.4.2 qRT-PCR 
2.2.4.2.1 DNase-1 Treatment for qPCR 
After RNA extraction as described in section 2.2.2.5, any remaining DNA in the 
RNA extract was removed by DNase-1 digestion using the Ambion TURBO DNase-1 
kit as described in the manufacturer’s instructions.  RNA was diluted to 50ng/µl 
in a 30µl volume.  3µl 10X reaction buffer and 1µl of 2U/µl TURBO DNase was 
added to the reaction and the digest carried out for 30 minutes at 37°C.  3.5µl 
of Inactivation Reagent was added and incubated at room temperature for 5 
minutes to stop the reaction.  The RNA was then centrifuged at 13 200 rpm for 
25-30 
cycles 
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1.5 minutes in an eppendorf 5415 R bench top centrifuge and the supernatant 
recovered to a fresh tube.  The centrifugation step was repeated and the 
recovered RNA stored at -20°C. 
 
2.2.4.2.2 Reverse transcription 
After DNase-1 digestion the RNA was reverse transcribed into cDNA using the 
Affinityscript qPCR cDNA synthesis kit (Stratagene) following the manufacturer’s 
instructions.  10µl of 2X Mastermix, 2µl of Oligo dT20 primer, 1µl random primers 
(0.1µg/µl) and either 1µl Affinityscript RT/RNase Block enzyme was added to 6µl 
of DNase-1 treated RNA and incubated with the following program on the Hybaid 
PCR Express machine: 
25°C – 5 minutes 
   42°C – 45 minutes 
   95°C – 5 minutes 
   4°C - hold 
 
2.2.4.2.3 qPCR 
After reverse transcription or DNA extraction, cDNA or DNA was amplified using 
an Applied Biosystems 7500 qPCR machine.  For some targets, for example many 
human genes, probe and primer sets are commercially available and have been 
optimised and shown to have close to 100% efficiency.  Therefore when possible 
these Taqman predesigned gene expression assays were ordered.  However for 
other targets, for example viral genes, there are no commercially available 
assays, therefore these assays had to be custom designed and synthesised. The 
Stratagene Brilliant qPCR mastermix was used for qPCR reactions. Reactions 
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were prepared as follows: 12.5µl of 2X Mastermix, 2.25µl of 10µM forward 
primer, 2.25µl of 10µM reverse primer, 0.5µl of 5µM probe, 0.5µl of 15µM 
reference dye, 5µl of DEPC-water and 2µl cDNA or 100ng DNA.  If a Taqman 
predesigned gene expression assay was being used then the reactions are 
prepared as follows: 12.5µl of 2X Mastermix, 1.25µl gene expression assay, 0.5µl 
of 15µM reference dye, 10.75µl of DEPC-water and 2µl (~15ng) cDNA or 100ng 
DNA.  The amplification protocol consisted of 50°C for 2 minutes, 95°C for 10 
minutes, 40 cycles at 95°C for 15 seconds followed by 60°C for 1 minute.  To 
calculate the relative efficiencies of probe and primer sets, cDNA or plasmid 
standard curves were generated and the efficiency calculated from the slope of 
the line using the formula Efficiency = 10(-1/slope)-1.  For probe and primer sets to 
be used in a relative quantification calculation the efficiencies must be within 
+/- 10% of each other.  The predesigned assays were all guaranteed to be 100% 
efficient therefore no standard curve was performed.  Relative quantification 
was not used with these assays.  The relative efficiencies for my custom E6 
isoform probe and primer sets were extremely varied out with +/- 10% of each 
other and could not be used for relative quantification.   
 
2.2.4.3 DNA sequencing 
Sequencing of PCR products or cloned vectors was carried out on an ABI PRISM 
3130XI Genetic Analyzer machine.  All sequencing reactions were carried out 
using the Applied Biosystems Big Dye Mix and 5X sequencing buffer.  The DNA to 
be sequenced was amplified as follows: 2 µl Big Dye Mix, 4 µl 5X Sequencing 
Buffer, 2 µl 10 µM sequencing primer, 6 µl ddH2O and 6 µl (~3µg) of DNA from a 
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standard miniprep.  The products were amplified using the PCR Express machine 
as follows  
    
95°C - 10 sec 
   50°C - 5 sec   
   60°C - 4 min 
4°C - hold 
 
Products were purified using the EdgeBio Spin column purification method.  The 
columns were centrifuged for 2 minutes at 3K in an eppendorf 5415 R bench top 
centrifuge to remove storage solution.  The collection tube was discarded and 
the spin column inserted into a fresh collection tube.  The PCR sequencing 
reaction was transferred onto the centre of the gel in the spin column and the 
column centrifuged for 2 minutes at 3K in an eppendorf 5415 R bench top 
centrifuge.  The DNA was dried under vacuum for 15-20 minutes and the pellet 
resuspended in 25 µl of Hi-Di Formamide (Applied Biosystems). 
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3.1 Introduction 
A large body of scientific evidence has led to the conclusion that E6 and E7 are 
the major oncoproteins of the high risk HPVs.  However, one problem with our 
current knowledge is that the high risk virus E6 and E7 mRNAs can be 
alternatively spliced yet it is not known which E6/E7 mRNA isoform(s) contribute 
to the transformed phenotype.  Interestingly, low risk virus E6/E7 mRNAs appear 
not to be alternatively spliced suggesting that high risk HPV oncogenes have 
evolved to encode alternative protein isoforms that contribute to the virus 
replication cycle in some way but also may be involved in cancer progression.  In 
particular, HPV16 E6 can be alternatively spliced with the production of at least 
four isoforms.  The first reports of E6 being alternatively spliced came in 1986 
when Smotkin and Wettstein identified two spliced isoforms of HPV16 E6 after 
RT-PCR analysis of RNA isolated from transformed cells and tumour biopsies 
(Smotkin & Wettstein, 1986).  In this study they identified the largest spliced 
product, now called E6*I as being the predominant isoform in transformed cells.   
It was suggested that this spliced product in fact allows for efficient translation 
of E7 protein.  The initiation codon for E7 is only two bases downstream from 
the termination codon of E6.  Therefore the hypothesis is that there is not 
enough RNA between the two open reading frames to allow for efficient 
translation re-initiation.  Splicing of the RNA and termination of the E6 isoform 
protein at an earlier stop codon allows more space between the E6 isoform 
termination codon and the E7 start codon. However, further studies have since 
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demonstrated that E7 is translated as efficiently from E6/E7 bicistronic mRNAs 
as from spliced E6 mRNAs (Stacey et al., 1995).  Furthermore, the assumption 
from these earlier studies was that, as E6*I is the predominant isoform in 
cervical tumour cells, the isoform may have tumour promoting functions.  
However, a number of studies over many years have suggested that this is 
unlikely to be true. As will be discussed, E6*I appears to have opposing functions 
to E6 with regards to a number of cellular interacting partners. 
 
In 2006, Tang et al. reported the possibility of four mRNA splice isoforms being 
produced from the open reading frames encoding E6 and E7 (Figure 3.1) (Tang et 
al., 2006).  One splice donor site was located in the E6 open reading frame with 
two splice acceptor sites in the E6 open reading frame and one in the E7 open 
reading frame (Tang et al., 2006).  The two splice acceptor sites in the E6 coding 
region were those already identified in previous studies: E6*I and E6*II.  A third 
acceptor site was identified in the E7 region and the putative isoform was 
named E6*X.  There have been comparatively few reported functions for E6*I 
compared to the number of reports of full length E6 functions and no reported 
functions for E6*II and E6*X.   
 
The first report of any function for HPV16 E6*I came from Shirasawa et al. in 
1994 where they showed that while E6 has a repressive effect on the P97 major 
early promoter, low levels of E6*I could in fact trans-activate the promoter, 
indicating that E6*I may have completely separate functions to E6 (Shirasawa et 
al., 1994).  The next report of E6*I function came from studying the effects of E6 
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Figure 3.1 Diagram of HPV16 E6 isoforms. Schematic diagram of the E6/E7 
isoforms with the splice donor (SD) and acceptor (SA) sites labelled and the 
nucleotide numbers given.   
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 and E6*I on p53.  As already stated, E6 targets p53 for proteasomal degradation 
to inhibit growth arrest and apoptosis in HPV-infected cells.  Shalley et al. 
(1996) and Pim et al. (1997) studied HPV16 E6 and HPV18 E6 respectively and 
found that the spliced E6 product acts to protect p53 from the degradation 
induced by full length E6 proteins (Shally et al., 1996, Pim et al., 1997).  Pim et 
al. (2007) also demonstrated that expression of E6*I in CaSki cervical cancer cells 
decreased the levels of cellular proliferation similar to expression of p53 in CaSki 
cells (Pim et al., 1997).  This finding suggests that E6*I, at least for HPV18, is in 
fact acting to suppress the transformed phenotype of the cells. 
 
E6 has been shown to have anti-apoptotic effects, therefore many of the studies 
into E6*I function have analysed levels of apoptosis.  E6*I was shown to have an 
opposing effect from E6 full length on procaspase 8.  Filippova et al. (2007) 
reported that the full length E6 protein could bind to procaspase 8 and 
accelerate its degradation thus preventing U2OS cells from entering apoptosis 
(Filippova et al., 2007).  In contrast, although the smaller E6*I isoform could still 
bind procaspase 8, it stabilised it thus making the cells susceptible to apoptosis 
(Filippova et al., 2007).  The authors explained this seemly paradoxical 
interaction of the two E6 isoforms with procaspase 8 by suggesting that the ratio 
of the two isoforms may be the important factor in determining procaspase 8 
levels and therefore the cells’ potential to enter apoptosis (Filippova et al., 
2007).  Furthermore, the procaspase 8 binding domains of E6 and E6*I have been 
identified and are not the same, perhaps explaining why two similar proteins can 
have such diverse effects (Filippova et al., 2007).  This suggests that there could 
be a very delicate balance of E6 expression in HPV-infected cells.  Similar results 
Chapter 3  111 
 
have been demonstrated for FADD and TNF R1 where both the full length E6 and 
E6*I have opposing effects on stabilising or destabilising the molecules upon 
protein-protein interaction (Filippova et al., 2002, Filippova et al., 2004, 
Filippova et al., 2009).  The targeting of these apoptosis effector molecules 
shows that E6 very tightly regulates the extrinsic apoptosis pathways.  In these 
studies E6 and E6*I were shown to be able to form complexes which may also be 
important in controlling E6 action (Filippova et al., 2009).  The levels of E6 in 
the cell were also reported to be important as low levels of E6 and E6*I make 
cells resistant to TNF induced apoptosis (Filippova et al., 2009).  E6-mediated 
control over apoptosis pathways is extremely complex and it appears to require 
a very delicate balance of E6 levels and isoform ratios.   
 
Pim et al. (1997) also demonstrated a similar scenario when studying the E6-
mediated degradation of PDZ domain-containing proteins.  They showed that 
E6*I could direct the degradation of the tumour suppressor hDlg as efficiently as 
E6 full length and that the two proteins appeared to cooperate to allow efficient 
degradation (Pim et al., 1997).  Again the ratio between the two isoforms was 
reported to be important for regulating the function of E6 (Pim et al., 1997). 
 
Finally, a recent report showed that splicing of E6 is regulated by the EGF 
pathway.  Rosenberger et al. (2010) demonstrated the requirement for EGF for 
production of full length E6 transcripts and that a reduction in EGF levels altered 
the E6 splicing pattern into producing mainly E6*I transcripts (Rosenberger et 
al., 2010).  This finding is very interesting as the authors suggested that perhaps 
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full length E6 is required initially to avoid apoptosis after infection (Rosenberger 
et al., 2010).  There is a concentration gradient of EGF in the differentiating 
epithelium and the levels of EGF are highest in the basal epithelial layer.  
Rosenberger et al propose that as the infected cell moves up through the 
epithelium the requirement for full length E6 may change and E7 production, to 
keep the infected cell cycling, becomes more important. Therefore the EGF 
levels drop, E6*I transcripts becomes more predominant and translation of E7 is 
enhanced (Rosenberger et al., 2010). This hypothesis is still controversial 
because there is conflicting evidence that E6*I allows enhanced E7 production.  
However, this study provides the first suggestion of a switch between isoform 
production being important for the virus life cycle.  It is also important to note 
that the E6*I transcript is the dominant isoform in transformed cells and the 
levels of E6*I have been reported to be indicative of severity of the clinical 
lesion (Kosel et al., 2007).  This may also fit with our current knowledge of E6 
splicing control: if lesions express higher levels of E6*I and if the original 
hypothesis of alternative splicing of E6 providing enhanced translation of E7 is 
true, and there is a proliferative advantage of expressing high E7 levels, this may 
explain why E6*I levels are high in lesions.   
 
As already mentioned there have so far been no reported functions for E6*II and 
E6*X.  In my opinion, however, due to the vast number of E6 protein-interacting 
partners already identified, I think it is entirely possible that one or more of the 
E6 isoforms may be involved in some of the functions attributed to the E6 
protein.  For example all isoforms are spliced from the same splice donor site 
therefore all proteins have the same N-terminus. Given the presence of the 
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same N-terminus in all E6 isoforms these could still carry out any functions 
mapped to this domain in the full length E6 protein, for example part of the first 
zinc finger domain is retained in the E6 isoforms however it will be unable to 
form the loop finger structure, therefore E6AP could still bind if the structure is 
not important for binding.  All isoforms lack the entire C-terminus of E6 
including the second zinc finger domain and the whole PDZ domain. Splicing in 
all isoforms occurs at splice donor 226 which is equivalent to amino acid 41 
meaning that the first CXXC motif at amino acid 30 is present in all isoforms but 
the second at amino acid 63 is absent.  This means the zinc finger structure 
cannot form; therefore it is likely that interactions dependent on this first zinc 
finger domain will also be lost.  E6*I is a small protein and after splicing only two 
additional amino acids are added after the splice junction before meeting a 
frameshift termination codon.  Therefore it is likely that only interactions 
attributed to full length E6 N-terminus (amino acids 1-41) will be able to be 
fulfilled by E6*I.  However as E6*I still conatins the L1 and S1 domains (Figure 
1.5) it could retain the capacity to bind full length E6 and block folding between 
the N-terminus and C-Terminus of E6.  This could explain why E6*I can 
antagonise full length E6 function if there is a dominant negative effect of E6*I 
binding to full length E6.  The same could be true of all isoforms as they contain 
the same portion of the N-terminus.  This however does not explain any 
transformation properties of the isoforms and at present these properties cannot 
be determined or mapped to the structures of the isoforms. E6*II has an 
additional 22 amino acids added after the splice junction before meeting a stop 
codon, however there is a frame shift meaning the amino acids are not the same 
as in full length E6 protein, therefore the structure and the interactions in this 
region will be different.  It is not possible to determine what the structure of 
E6*II may be as there is no crystal structure for the altered amino acids and the 
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presence of these different amino acids could in fact alter the folding of the N-
terminus.  E6*X is spliced into E7 therefore it is possible that functions 
attributed to the N-terminus of E6 and the C-terminus of E7 will be the same.  
Importantly E6*X is spliced in frame with the 3' end of the E7 open reading frame 
therefore these interactions may be the same as full length E7.  For example 
E6*X could still interact with E2F6 which interacts with the extreme C- terminus 
of HPV16 E7 (McLaughlin-Drubin et al., 2008).  As detailed by the crystal 
structure, the C-terminus of HPV45 E7 is a highly structured domain, whereas 
the N-terminus is not structured, therefore as E6*X is spliced in frame and 
expresses the C-terminus of E7 the function of E6*X could be the same as full 
length E7.  Similar to the full length E7 protein it is also possible that E6*X could 
form dimmers due to the highly structured C-terminus. 
Due to the lack of sensitive antibodies for the detection of endogenous E6 
protein levels, it is not known if E6*II and E6*X mRNA isoforms can produce 
functional proteins, however even if no protein is produced from the RNA, the 
RNAs themselves could still have a function.  For example, they could be 
controlling viral or cellular gene expression.  It has recently been shown that a 
class of long non coding RNAs called lncRNAs can epigenetically regulate 
expression of target genes (Kaikkonen et al., 2011).  LncRNAs have been 
proposed to recruit chromatin remodelling complexes to target genes with 
homology to the lncRNA and silence their expression.  Other ncRNAs have been 
found to associate with the enhancer and promoter elements of target genes and 
alter their expression (Kaikkonen et al., 2011).  It has also been demonstrated 
that ncRNAs can also interfere with post-transcriptional gene expression by 
inhibiting splicing by masking splice sites and preventing spliceosome binding 
(Kaikkonen et al., 2011).  It is also possible that the original hypothesis proposed 
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by Sedman et al. (1991) is true; that E6 is spliced to allow for enhanced and 
efficient translation of E7.  While this could be true for E6*I and E6*II, it seems 
unlikely for E6*X as the RNA is spliced from E6 into the middle of the E7 open 
reading frame producing a hybrid RNA which could therefore have a completely 
different function from either E6 or E7 alone. 
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3.1.1 Alternative splicing of E6 during epithelial differentiation 
HPV16 E6/E7 gene transcripts can be alternatively spliced and the putative 
splice isoforms are shown in Figure 3.2 B.   With the production of multiple RNA 
isoforms there are two hypotheses I addressed. First, E6 isoform levels may 
change during the virus replication cycle or during tumour progression if a 
function attributed to a particular isoform is only required under certain 
conditions. Second, any proteins produced by these alternatively spliced RNAs 
may have differing functions.  In the first experiment shown in Figure 3.2, I 
addressed the first hypothesis. In order to determine whether alternative 
splicing of HPV16 E6/E7 is altered during the virus life cycle, RNA was extracted 
from W12E cells which were originally isolated from a low grade cervical lesion 
and contain HPV16 episomal genomes. (Stanley et al., 1989, Jeon et al., 1995).  
These cells provide a model system for the study of the viral life cycle as they 
are capable of epithelial differentiation: they produce virus particles. As a 
control for productive viral replication I also isolated RNA from W12G cells. 
W12G cells (clone 20861) were cloned from the original W12 cell line at the 
same time as W12E cells (clone 20863) and contain multiply integrated HPV16 
genomes with no episomal genomes. These cells have more limited 
differentiation capacity and are incapable of virus production.  
 
Previous work in our laboratory has identified the optimal days for harvesting 
cells in different populations and obtaining practical concentrations of starting 
material.  McPhillips et al (2004) showed that the differentiation level of the 
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W12E and G cell populations at day 5 is low as indicated by low levels of the 
differentiation marker involucrin at day 5 while at day 10 high levels of 
involucrin were detected (McPhillips et al., 2004). Similar results were found 
using confocal microscopy. At day 5 70-85% of the cell population is 
undifferentiated while at day 10, 70-80% of the cell population is differentiated 
(Milligan et al., 2007). Markers of cellular differentiation such as involucrin, 
keratin 10 and filaggrin can be readily detected (Cheunim et al., 2008).  An 
example of the involucrin protein levels extracted from the same W12E cells at 
day 5 and day 11 are shown in Figure 3.2 D.  This experiment was carried out by 
Dr T. Klymenko using the same cell stocks I have used in my experiments.  There 
is a clear increase in involucrin protein levels in the day 11 extract compared to 
the day 5 extract. Involucrin is detected at a low level in the undifferentiated 
cell population because these are a heterogeneous cell population where a small 
percentage of the cells will have begun to differentiate. W12G cells also showed 
increased involucrin expression, although not to the same level as in W12E cells 
(data not shown). For the viral life cycle, the late viral protein E1^E4 was not 
detected after W12 cells were grown for five days in cell culture but was 
detected after ten days (McPhillips et al., 2004).  Milligan et al (2007) showed 
that after 10 days of culturing, W12E cells could be found to be expressing L1 
protein in a subset of cells (Milligan et al., 2007).  This result indicates that after 
ten days of culture the W12 cells are differentiated at least to the extent of 
allowing viral capsid protein formation.  An example of L1 protein levels at day 5 
and day 11 in the same W12E cells as used in this experiment is shown in Figure 
3.2 D.  Here there is a clear increase in L1 protein levels in the day 11 extract 
when compared to the day 5 extract.  GAPDH levels were used as an internal 
control standard.  
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The W12E and G RNAs were reverse transcribed followed by PCR amplification 
using primers that amplify the whole E6/E7 open reading frame (red arrows 
Figure 3.2 A, Table 2).  Undifferentiated W12E and W12G cells were grown in an 
identical manner on J2 3T3 fibroblast feeder layers at low density for five days 
before the feeder layers were removed and the cells harvested for RNA 
preparation.  Differentiated W12E and W12G cells were grown on the same 
feeder layer cells to high density for ten days before the feeder layer cells were 
removed and the W12 cells harvested for RNA extraction.  All cell populations 
were grown in DMEM medium containing 1.2 mM Ca++: differentiation was 
controlled by cell density alone as described previously (McPhillips et al., 2004).  
Polyadenylated RNA was extracted from total RNA.  The polyadenylated RNA was 
DNase-1 treated before being reverse transcribed and amplified by semi-
quantitative PCR using GAPDH as an internal control standard.  The PCR products 
were resolved on 6% acrylamide gels and stained with ethidium bromide and 
viewed under UV.  Figure 3.2 C shows the result of acrylamide gel 
electorphoretic separation of E6 isoforms from undifferentiated and 
differentiated W12E and G cells. Tracks 2, 4, 6, and 8 show the reaction carried 
out in the absence of reverse transcriptase. These control tracks are designed to 
demonstrate the absence of DNA in the input RNA samples in the cDNA reaction. 
No bands were observed in any of these tracks. Track 3 shows that only low 
levels of E6  
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Figure 3.2 E6 isoform expression is not altered upon epithelial 
differentiation.  A) Schematic diagram depicting the E6/E7 open reading frame.  
The position of the early promoters, P-60 and P97 is shown by the black arrows 
and the position of the E6/E7 primers used in this study is shown by red 
chevrons.  B) Schematic diagram of the E6/E7 isoforms with the splice donor 
(SD) and acceptor (SA) sites labelled and the nucleotide numbers given.  C) 
Upper panel Ethidium-bromide stained acrylamide gel electrophoresis of E6/E7 
isoforms RT-PCR amplified from polyadenylated W12 RNA during epithelial 
differentiation.  Isoforms are indicated to the right of the gel. RT, reverse 
transcriptase; “-“, RT-PCR reaction in the absence of reverse transcriptase; “+”, 
RT-PCR reaction in the presence of reverse transcriptase; “UW12E”, 
undifferentiated W12E RNA; “DW12E”, differentiated W12E RNA; “UW12G”, 
undifferentiated W12G RNA; “DW12E”, differentiated W12E RNA.  Lower Panel 
Ethidium-bromide stained acrylamide gel electrophoresis of GAPDH RNA RT-PCR 
amplified from polyadenylated W12 RNA during epithelial differentiation. RT, 
reverse transcriptase; “-“, RT-PCR reaction in the absence of reverse 
transcriptase; “+”, RT-PCR reaction in the presence of reverse transcriptase; 
“UW12E”, undifferentiated W12E RNA; “DW12E”, differentiated W12E RNA; 
“UW12G”, undifferentiated W12G RNA; “DW12E”, differentiated W12E RNA. D) 
Western Blot analysis of protein extracted from undifferentiated (U) and 
differentiated (D) W12E cells.  The protein being detected is indicated to the 
right of the gel.  Involucin is a marker for differentiation, L1 is a late viral 
protein and GAPDH is used as a loading control.  E) Quantification of the E6 
isoforms shown in Figure 3.1 (C).   The gel was scanned and band density 
estimated using Photoshop. The levels of E6 isoforms are calculated relative to 
GAPDH mRNA levels.  The results shown are from one experiment. Two 
experiments were carried out with very similar results.  
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isoforms could be detected in undifferentiated W12E cells where there is 
detectable E6*I and E6*II mRNAs.  There is no detectable E6 full length or E6*X 
RNA expression suggesting that these isoforms have very limited expression in 
those cells.  Track 5 shows the E6 isoforms detected in differentiated W12E 
cells. Similar to undifferentiated W12E cells (track 3) E6*I is the predominant 
isoform however the total levels of E6/E7 RNAs appeared to increase 
significantly upon epithelial differentiation and E6 full length and E6*II were now 
detectable.  E6*X was not detected.  Both experiments were carried out with 
similar starting concentrations of RNA therefore the increased levels of E6/E7 
RNAs are differentiation-dependent.  To test whether there might be a 
requirement for higher levels of E6 and E7 as the viral life cycle progresses I 
carried out a similar experiment in W12G cells which have only integrated HPV16 
genomes and where there is no virus life cycle completion.  Track 7 shows the E6 
isoforms detected in undifferentiated W12G cells.  Similar to W12E cells, full 
length E6, E6*I and E6*II mRNAs were all detectable in those cells.  Again E6*X 
was not detected in undifferentiated W12G cells.  Track 9 shows the E6 isoforms 
detected in differentiated W12G cells.  Again the three largest isoforms were 
detected while the smallest isoform, E6*X was not.  In contrast to the findings 
from W12E cells however, the total levels of E6 RNAs were not increased upon 
differentiation of W12G cells yet although W12G cells display a reduced 
differentiation capacity, they were higher than the levels in undifferentiated 
W12E cells.  As W12G cells contain integrated HPV16 genomes the expression 
levels of E6 and E7 RNAs and proteins may be higher than in W12E cells where E2 
is present to control the expression of E6 and E7.  Indeed, Northern blot analysis 
of E6/E7 mRNA levels comparing W12E with W12G cells indicated around five-
fold more E6/E7 mRNA in W12G cells that W12E cells (SV Graham, unpublished 
observations).  The experiment in Figure 3.2 C was carried out twice with very 
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similar results.  Figure 3.2 E shows a quantification of one of the experiments.  
The data were quantified by measuring the pixel density of each of the 
individual isoforms relative to GAPDH levels.  Combination of the data from the 
two independent experiments was not possible as the raw figures were vastly 
different and masked any difference that was visible from the raw data.  
Although the pixel density numbers were different the trend in the data was not 
and both experiments showed similar results.  Quantitative PCR experiments 
were also attempted to quantify properly the levels of each of the E6 isoforms 
during differentiation of the epithelial cells.  However Taqman probe and primer 
design proved impossible for the individual isoforms.  The only way to 
specifically amplify individual isoforms was to design either one of the primers 
or the probe to cover the splice junction as this is the only part of the RNAs that 
is unique to the individual isoforms.  Unfortunately the area surrounding the 
splice junctions was not optimal for primer design.  Initial attempts to quantify 
the isoforms did not work as the probe and primer sets were not compatible with 
the relative quantification method; the primer efficiencies were not equal or 
even similar.  Quantitative PCR is an excellent method for quantification if the 
procedure is carried out correctly, however the E6 isoforms proved unsuitable 
for this type of quantification.  The probe and primer efficiencies are shown in 
Table 6. 
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Probe and Primer Set Efficiency 
E6 Full Length 92% 
E6*I 94% 
E6*II 86% 
E6*X 85% 
Β-Actin 99% 
 
Table 6: Efficiencies of E6 isoform probe and primer sets.  The efficiencies of 
the E6 probe and primer sets were calculated using a standard curve of 
W12GPXY cDNA.  For probe and primer sets to be compatible for relative 
quantification they should have efficiencies of +/- 10% with the endogenous 
reference gene (β-Actin). 
  
Contrary to what was suggested by data in the recent report by Rosenberger et 
al (2010), I did not detect any alteration in E6 isoform RNA expression during 
differentiation of the W12E or W12G epithelial cells (Rosenberger et al., 2010).  
Rosenberger et al (2010) predicted that due to the relatively higher levels of EGF 
in the basal epithelial layer there should be higher levels of full length E6 RNAs 
than in the upper layers (Rosenberger et al., 2010). However, in my experiments 
differentiation of the epithelial cells increased the levels of all E6 transcripts 
which could suggest that differentiation of the epithelial cells promotes 
transcription from the P97 promoter.  This may or may not be in response to 
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changing EGF levels.  It should also be noted that EGF is added to the W12 cell 
media every two days therefore EGF levels may remain high throughout the 
epithelium.  Rosenberger et al (2010) did not use W12 cells but used 
immortalised keratinocytes stably transfected with either the full HPV16 genome 
or E6/E7 alone. This means they were examining E6/E7 expression under 
conditions of over expression and when carrying out experiments with “low” EGF 
this was achieved by not adding EGF to the media (Rosenberger et al., 2010).   
The increase in levels of E6 transcripts that I observed upon epithelial 
differentiation may suggest an increased requirement for E6 and E7 activities in 
differentiated cells, however the increase may also be because there is an 
increased requirement for other viral proteins and because the viral RNAs are 
polycistronic E6 and E7 are also transcribed at higher levels.  The cooperative 
and antagonistic effects of E6 and E6*I may allow this to occur without resulting 
in catastrophe for the cell as any unwanted E6 actions could be prevented by 
interaction with E6*I.  It is not surprising that the increase in E6/E7 mRNA levels 
was only identified in W12E cells and not in W12G cells.  HPV16 DNA is episomal 
in W12E cells.  This means that the virus is able to go through a productive 
replication cycle, where the demand for expression of individual viral proteins is 
altered depending on the differentiation status of the infected cell.  Whereas in 
W12G cells the viral DNA is integrated and there is no virus replication taking 
place and therefore there is no requirement for altered viral protein levels.  As 
there is no productive viral replication in W12G cells and the viral genome is 
integrated into the host cell genome, expression of E6/E7 RNAs will be 
controlled by cellular transcription factors. 
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In conclusion, this experiment indicated that E6 splicing is not changed upon 
epithelial differentiation.  However the requirement for E6 appears altered 
during epithelial differentiation.  The levels of all of the detectable E6 isoforms 
are increased upon differentiation suggesting the virus requires increased levels 
of E6 in later stages of the viral life cycle.  The increase in E6 levels is not due 
to any non-specific epithelial differentiation signals as a similar increase in E6 
levels is not seen upon differentiation of W12G cells where there is no 
productive viral replication taking place.  It is not clear however, from this 
experiment, whether any proteins are produced by the RNA isoforms and 
whether they might have different functions. 
 
3.1.2 Alternative splicing of E6 during cervical tumour 
progression 
In order to determine whether alternative splicing of HPV16 E6/E7 is altered 
during HPV-induced transformation of infected epithelial cells RNA was 
extracted from the four W12 cell lines that model HPV16-induced cellular 
transformation (Stanley et al., 1989, Jeon et al., 1995, Aasen et al., 2003).  The 
W12 cervical cancer progression model is depicted in Figure 3.2 A.  The RNA was 
reverse transcribed followed by PCR amplification using the same primers used 
in section 3.1.1 and illustrated in Figure 3.2 A.  For this experiment 
differentiated populations of W12E and W12G cells were chosen purely to 
maximise the RNA concentrations obtained from the extractions and as shown in 
Figure 3.2 C differentiation had no effect on the pattern of alternative splicing 
of the E6/E7 RNAs. W12GPX and W12GPXY cells did not require feeder cells for 
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growth so these were simply harvested directly for RNA extraction.  
Polyadenylated RNA was selected from total RNA.  All polyadenylated RNAs were 
DNase-1 treated before being reverse transcribed and amplified in a semi-
quantitative PCR reaction using GAPDH as an internal control for input of equal 
concentrations of RNA to the reactions.  The PCR products were resolved on a 6% 
acrylamide gel and stained with ethidium bromide.  Again acrylamide gels were 
used as they provide superior separation of DNA with molecular weight of less 
than 1Kb.  The amplified products are shown in Figure 3.3 B.  Tracks 2, 4, 6 and 
8 show the reactions carried out in the absence of reverse transcriptase which 
confirms the absence of DNA from the RNA starting material for the cDNA 
reaction. Similar to what was observed in Figure 3.2 C there was no apparent 
difference in E6 isoform production between W12E (track 3) and W12G (track 5) 
cells. However, several differences between the transformed cell lines, W12GPX 
(track 7) and W12GPXY (track 9), and the untransformed W12E and W12G cells 
were noted. W12GPX and W12GPXY cells expressed all four E6/E7 isoforms 
including E6*X which was not detectable in W12E (track 3) and W12G cells (track 
5). The most highly expressed isoform in all samples was E6*I, in agreement with 
the original findings Smotkin and Wettstein (Smotkin & Wettstein, 1986, Smotkin 
et al., 1989).  The appearance of E6*X only in the transformed cells could 
indicate that the smallest spliced isoform, is a tumour specific isoform and may 
be involved in the transformation of the epithelial  
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Figure 3.3 E6 isoform expression is altered upon epithelial transformation.  
A) Table listing the properties of the W12 model cell lines.  B) Upper panel 
Ethidium-bromide stained acrylamide gel electrophoresis of E6/E7 isoforms RT-
PCR amplified from polyadenylated W12 RNAs during epithelial transformation.  
Isoforms are indicated to the right of the gel. RT, reverse transcriptase; “-“, RT-
PCR reaction in the absence of reverse transcriptase; “+”, RT-PCR reaction in 
the presence of reverse transcriptase; “DW12E”, differentiated W12E RNA; 
“DW12G”, differentiated W12G RNA; “W12GPX”, W12GPX RNA; “W12GPXY”, 
W12GPXY RNA.  Lower panel Ethidium-bromide stained acrylamide gel 
electrophoresis of GAPDH RNA RT-PCR amplified from polyadenylated W12 RNAs 
during epithelial transformation.  Isoforms are indicated to the right of the gel. 
RT, reverse transcriptase; “-“, RT-PCR reaction in the absence of reverse 
transcriptase; “+”, RT-PCR reaction in the presence of reverse transcriptase; 
“DW12E”, differentiated W12E RNA; “DW12G”, differentiated W12G RNA; 
“W12GPX”, W12GPX RNA; “W12GPXY”, W12GPXY RNA. C) Quantification of the 
E6 isoforms shown in Figure 3.2 (B).   The gel was scanned and band density 
estimated using Photoshop. The levels of E6 isoforms are relative to GAPDH 
mRNA levels.  The results shown are from one experiment. Three experiments 
were carried out all with very similar results. 
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cells.  Similarly the E6*II isoform appeared to be increased upon epithelial 
transformation suggesting that there is perhaps a shift towards expression of the 
smaller isoforms.  The experiment in Figure 3.3 B was carried out three times 
with similar results.  Figure 3.3 D shows a quantification of one such experiment.  
The data were quantified by measuring the pixel density of each of the 
individual isoforms relative to GAPDH levels.  Combination of the data from the 
three independent experiments was again not possible due to the same reasons 
as described in section 3.1.1.  Although the pixel density numbers were different 
the trends in the data were very similar.  Quantitative PCR experiments were 
also attempted to quantify properly the levels of each of the E6 isoforms during 
differentiation of the epithelial cells.  However the same difficulties were 
encountered as described in section 3.1.1.  This gel also appears to show doublet 
bands for most of the isoforms however this is probably just a feature of this 
particular gel as doublet bands are not seen in every gel.  Similarly in this gel 
there is a band higher than full length E6 which could be a second full length E6 
isoform due to the promoter reported to be present upstream from the major 
early promoter (Milligan et al., 2007).  This band would have to be confirmed by 
cloning and sequenceing, which was attempted but due to the low levels of 
expression, this was never confirmed. 
 
I conclude that E6 RNA isoform expression is altered upon transformation of the 
epithelial cells.  The smaller isoforms appear to be upregulated in transformed 
epithelial cells which suggests that proteins produced by the RNA isoforms may 
have differing functions.  The upregulation of the smaller isoforms during 
transformation of the virus-infected epithelial cells suggests these isoforms may 
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have growth promoting or tumour promoting functions that are normally tightly 
regulated during a productive viral infection. 
 
Next, it was important to identify whether the increased expression of the 
smallest isoform E6*X was unique to the W12 transformed cell lines or was a 
general feature of HPV16-positive cervical cancer cell lines.  It was possible that 
as the GPX and GPXY cells were derived in a laboratory setting that this splicing 
event may not be present in other, more directly derived cervical tumour cell 
lines.  Therefore, RNA was harvested from two other HPV16 positive cervical 
cancer cell lines that were derived completely independently from the W12 cell 
lines and originated from high grade cervical tumours, CaSki and SiHa cells.  The 
RNA was DNase-1 treated before being reverse transcribed and amplified by 
semi-quantitative PCR using the E6 primers described in section 3.1.1.  GAPDH 
was used as an internal control standard.  The PCR products were resolved on 6% 
acrylamide gels and stained with ethidium bromide and viewed under UV.  
Figure 3.4 shows the result of acrylamide gel electorphoretic separation of E6 
isoforms from the cervical tumour-derived cells and from W12GPXY cells. Tracks 
2, 4 and 6 show the reactions carried out in the absence of reverse transcriptase 
confirming the absence of DNA from the RNA used in the cDNA reactions.  Track 
3 shows the E6/E7 mRNA isoforms expressed in SiHa cells. Full length E6, E6*I 
and E6*II can all be detected.  Track 5 shows the mRNA isoforms expressed in 
W12GPXY cells which, as shown in Figure 3.3 C, expressed full length E6, E6*I, 
E6*II and E6*X.  Track 7 shows the mRNA isoforms expressed in CaSki cells, which 
like GPXY cells express all four E6 isoforms, however E6*X is expressed at very 
low levels and can only be seen when the gel is over-exposed.   The experiment 
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was carried out three times with very similar results.  This experiment indicated 
that the increased levels of E6*X compared to other E6 isoforms is not unique to 
W12 cells and that the isoform is also present at increased levels in CaSki cells.  
Very similar amounts of RNA starting material were used in each sample. The 
difference in levels of E6/E7 RNAs between the different tracks (tracks 3, 5 and 
7) is likely due to the number of HPV16 genome insertions in each cell line.  
CaSki cells have many more genome insertions (more than 500)  than SiHa which 
reported has less than 10 genome insertions (Yee et al., 1985) and the lack of 
detectable E6*X in SiHa cells is likely due to the limits of detection and not due 
to a lack of isoform expression.  
For this experiment I conclude that the alteration in E6 splicing observed in 
W12GPX and W12GPXY cells is not unique to these cell lines.  E6*X is also 
detectable in epithelial tumour-derived CaSki cells.  It is not possible to say 
whether E6*II is also upregulated in these cells, as there is no non-transformed 
cells for comparison.  These findings suggest a probable tumorigenic property for 
E6*X and perhaps E6*II. 
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Figure 3.4 E6 isoforms are also expressed in other HPV16 transformed 
epithelial cells lines Upper Panel Ethidium-bromide stained acrylamide gel 
electrophoresis of E6/E7 isoforms RT-PCR amplified from SiHa, W12GPXY and 
CaSki RNA.  Isoforms are indicated to the right of the gel. RT, reverse 
transcriptase; “-“, RT-PCR reaction in the absence of reverse transcriptase; “+”, 
RT-PCR reaction in the presence of reverse transcriptase.  Lower Panel 
Ethidium-bromide stained acrylamide gel electrophoresis of GAPDH RNA RT-PCR 
amplified from SiHa, W12GPXY and CaSki RNA. RT, reverse transcriptase; “-“, 
RT-PCR reaction in the absence of reverse transcriptase; “+”, RT-PCR reaction in 
the presence of reverse transcriptase.  
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3.1.3 SR proteins levels are altered upon transformation 
Cellular transformation often results in altered gene expression.  Transformation 
often leads to genomic instability and with this, control over gene expression 
and DNA replication is lost.  For example during transformation control over 
expression of oncogenes including c-Myc can be lost resulting in increased 
proliferation and resistance to apoptosis.  Conversely tumour suppressor 
functions are often lost during transformation.  For example BRCA1 tumour 
suppressor is often mutated in breast cancers which interferes with the DNA 
damage repair pathway and allows a build up of genetic mutations leading to 
transformation. Lack of control during DNA replication can result in alteration in 
the chromosome copy numbers leading to an increase in expression of genes 
encoded on the affected chromosomes.  In particular, recently several groups 
have demonstrated alterations in SR protein expression in various tumours such 
as breast and ovarian cancers (Stickeler et al., 1999, Fischer et al., 2004). SR 
proteins are the cellular splicing factors that are involved in determining which 
RNAs are to be spliced and alternative splicing is regulated by SR proteins 
(reviewed by (Long & Caceres, 2009). The changes in SR protein expression 
noted in tumour cells likely have functional significance because Karni et al 
(2007) identified that an oncogenic isoform of S6K1 is often overexpressed in 
breast and lung cancer cells after overexpression of SRSF1 (Karni et al., 2007).  
This S6K1 isoform was then shown to be sufficient for the transformed 
phenotype of the cells.  Overexpression of S6K1 isoform 2 (the oncogenic 
isoform) was able to promote anchorage independent growth in NIH 3T3 cells 
(Karni et al., 2007).  Based on these observations I hypothesised that SR proteins 
may be overexpressed in cervical cancers resulting in changes in HPV 
Chapter 3  135 
 
oncoprotein isoform expression during cervical tumour progression, especially if 
smaller isoforms such as E6*I had antagonistic properties to E6 full length. 
 
The preceding experiments demonstrated that E6/E7 expression is altered upon 
cellular transformation due to a change in the splicing pattern of HPV16 E6/E7 
mRNAs. Therefore, the next step was to investigate any changes in the levels of 
the SR splicing regulator proteins in the transformed cells.  Total cellular protein 
was harvested from differentiated W12E and W12G cells and W12GPX and 
W12GPXY cells.  I chose to examine differentiated W12E and G cells because we 
had demonstrated previously increase expression of SR proteins upon HPV-16 
positive cervical epithelial differentiation (Mole et al., 2009b).  The proteins 
were electrophoresed on a gradient 4-12% acrylamide gel in SDS denaturing 
conditions and blotted onto a nitrocellulose membrane.  The membrane was 
then western blotted with SR protein-specific antibodies.  Figure 3.5 B-E shows 
western blot analysis of relative levels of each of the indicated SR proteins.  The 
protein being detected is indicated on the right of each membrane.  GAPDH was 
used as an internal control standard for protein loading (Figure 3.5 A). These 
experiments were carried out three times and the protein levels quantified 
relative to GAPDH (Figure 3.5 G-J). In the western blot panels, track 1 (W12E) 
shows that SRSF1 and SRSF3 are all expressed to higher levels than in track 2 
(W12G) whereas other SR proteins, for example, SRSF5 and SRSF7 are expressed 
at very similar levels. Western blot panel D was probed with Mab104. This 
antibody detects all classical SR proteins. Only the portion of the blot containing 
SRSF1, 2 and 5 is shown. Close examination of the bands corresponding to SRSF2 
also indicates an increase in expression comparing W12E to W12G cells. 
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Figure 3.5 Specific SR proteins are upregulated upon cervical epithelial 
transformation.  Western Blot analysis of SR protein levels in the various W12 
model cell lines.  The cell lines are indicated to the top of the blots. A) Blot 
probed with Mab6CS against GAPDH and used as an internal control. B) Blot 
probed with Mab98 showing SRSF7 levels in the model cell lines. C) Blot probed 
with Mab96 showing SRSF1 levels in each cell line.  D) Blot probed with Mab104 
showing SRSF1, SRSF2 and SRSF5 levels in the model cell lines.  Only the portion 
of the gel showing SRSF1, 2 and 5 is shown. E) Blot probed Mab7B4 showing 
levels of SRSF3 protein in the W12 model cell lines.  F) Blot probed with TVG261 
showing HPV16 E2 levels in the W12 model cell lines.  Quantification of three 
independent experiments showing the mean and standard deviation for three 
experiments is shown in the graphs.  In every case the levels of SR proteins are 
calculated relative to GAPDH levels. G) SRSF7 levels H) SRSF1 levels I) SRSF2 
levels and J) SRSF3 levels 
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Unfortunately, the antibodies specific for this SR protein do not work efficiently 
in western blotting so I was unable to obtain better evidence for changes in 
SRSF2 expression between these two cell lines. This suggests that SRSF 1-3 are 
upregulated either by differentiation or by full viral protein expression in W12E 
cells where the viral DNA is episomal and is able to support the virus life cycle.  
For SRSF1 and SRSF3 our laboratory has shown upregulation to be a result of 
HPV16 E2 transcriptional control of the genes encoding these proteins (Mole et 
al., 2009a, Mole et al., 2009b).  When levels of the SR proteins in tracks 2, 3 and 
4 are compared an increase in levels of the same three proteins can be 
observed, particularly between W12G (track 2) and W12GPX cells (track 3).  The 
viral genome is integrated into the host DNA in these cells and the E2 protein is 
not expressed (Figure 3.5 F). Therefore E2 cannot be responsible for the 
observed upregulation in the tumour progression cell models. The proteins are 
being upregulated by some other mechanism.  The overexpression of SRSF1, 2 
and 3 is specific to these proteins as other SR proteins, for example SRSF5 and 
SRSF7, remained relatively constant in all cell lines regardless of whether the 
cells were transformed or had a productive viral infection (Figure 3.5 G-J).    
Further experiments to determine if the SRSF protein overexpression also occurs 
in patient tissue were undertaken.  Cervical biopsy samples stored in paraffin 
were stained for the presence of SR proteins SRSF1-3.  Diagnosis of the severity 
of the cervical lesion was performed by Dr David Millan a gynaecological 
pathologist at Glasgow Royal Infirmary.  Tissues were stained by the Institute of 
Comparative Medicine’s Histopathology service at the University of Glasgow.  
Figure 3.6 Shows representative images from 10 CIN 1 and 10 CIN3 lesions.  The 
protein being detected is indicated to the right of the images.  In all cases 
expression of the SR protein in low grade (CIN1) lesions is found in the lower and 
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middle layers of the epithelium with little expression in the terminally 
differentiated cells at the top of the epithelium.  However in CIN 3 lesions SR 
proteins were detected throughout the epithelium. This is probably because the 
epithelium is now filled with basal-like cells that are no longer differentiating.  
This confirms the western blotting experiments in Figure 3.5.  The SR protein 
overexpression seen in W12GPX and W12GPXY cells is due to the presence of 
basal like cells with no differentiation taking place. 
The results indicate that some (SRSF1, SRSF2 and SRSF3) but not all, SR proteins 
are specifically upregulated upon transformation of W12 epithelial cells and in 
patient tissue.  This upregulation of SR proteins could explain the changes in 
splicing of the E6/E7 RNAs upon W12 cell transformation.  It is also clear that 
the same SR proteins, SRSF1, SRSF2 and SRSF3, are upregulated in W12E cells 
when compared to W12G cells.  This is in agreement with the recent publication 
by Mole et al (2009) which reported that HPV16 E2 could bind and 
transcriptionally activate the SRSF1 promoter resulting in an increase of SRSF1 
protein. SRSF1 has been shown to be required to process viral E4^L1 RNAs at 
least from subgenomic constructs in HeLa cells (Somberg & Schwartz, 2010).  
More recent studies from our laboratory have demonstrated E2 regulation of 
SRSF2 and 3 (Mole et al., 2009b).  The reduced levels of SRSFs 1-3 in W12G cells 
are likely due to the absence of E2 due to the viral genome being integrated into 
the cellular DNA and disrupting the E2 open reading frame.   
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Figure 3.6 Specific SR proteins are upregulated in cervical lesions.  
Immunohistochemical analysis of SR protein levels in CIN1 and CIN3 cervical 
biopsies.  The lesion severity is indicated at the top of the pictures. A) Cervical 
lesions probed with Mab96 against SRSF1. B) Cervical lesions probed with Mab 
SC-35 showing SRSF2 levels in the cervical biopsies. C) Cervical lesions probed 
with Mab7B4 showing SRSF3 levels in the cervical biopsies.   
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To conclude, epithelial transformation by HPV causes an upregulation of specific 
members of the SR protein splicing regulatory family.  This upregulation 
probably aids in the transformation process by resulting in a number of 
alterations in splicing of cellular RNAs. Changes in alternative splicing will lead 
to production of a tumour specific-proteome. 
 
3.1.4 SR protein overexpression may not be due to chromosomal 
duplication 
In the W12 transformed cells the increase in SR protein levels identified in 
section 3.1.3 cannot be due to the presence of HPV16 E2 because it is not 
expressed in these cells.  Therefore there must be a different mechanism 
involved in the upregulation of SR proteins during cellular transformation.  One 
possible reason for this upregulation could be that the SR genes become 
amplified during cellular transformation.  This has been shown to be the case in 
some breast cancers as Karni et al (2007) showed that the 17q23 chromosome 
containing SRSF1 becomes duplicated in some breast cancer cells (Karni et al., 
2007).  In order to test whether this is the case in our W12 model cell lines DNA 
was extracted from differentiated W12E and W12G cells and W12GPX and 
W12GPXY cells and qPCR carried out in order to determine the gene copy 
number of the SR gene in each case.  DNA was extracted and diluted to equal 
concentrations for each cell line.  qPCR was carried out using Stratagene 
Mastermix and Applied Biosystems commercially available predesigned Taqman 
probe and primer sets.  All qPCR experiments were carried out using the Applied 
Biosystems 7500 machine and the data analysed using the 7500 system software.  
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Standard curves of W12E DNA were generated using the Applied Biosystems user 
manual instructions.  W12E DNA was used to create the standard curve as the 
viral DNA is episomal and is unlikely to have caused significant alteration to the 
cellular chromosomes.  Similar to some breast cancers a significant difference in 
SRSF1 gene copy numbers was identified in the assay comparing SRSF1 gene copy 
number in W12E with W12GPXY cells. W12E cells gave a CT value of 29 ± 1 while 
W12GPXY gave 25 ± 1. This difference was significant because a student's T-test 
gave a p value of 0.029 (Figure 3.7, asterisk).  In CT values a difference of 1 is 
actually a two-fold difference as one CT value is a doubling of the target.  
Therefore a difference of 4 is actually a 16-fold difference in target DNA.  This 
indicates that there has been an increase in the gene copy number of the SRSF1 
gene between derivation of the W12GPXY cell line from W12GPX epithelial cells.  
Figure 3.5 C showed that there was significantly more SRSF1 protein detected in 
W12GPX cells compared to W12G cells yet I discovered no significant difference 
between the SRSF gene copy number in these cell lines. This indicates that 
increased levels of SRSF1 protein in W12GPX cells must be due to another 
mechanism. Interestingly, I was not able to detect any significant difference 
between any of the cell lines when qPCR was used to amplify the SRSF2 or SRSF3 
genes (Figure 3.7) indicating that there is transcriptional upregulation or an 
increase in protein stability of these proteins in the transformed cells. 
I conclude that transformation of the W12 epithelial cells leads to a specific 
overexpression of SRSF1, 2 and 3.  The overexpression of SRSF1 is due to an 
increase in gene copy number at least in part, similar to breast cancer cells.  
The SRSF2 and SRSF3 overexpression cannot be explained by gene amplification 
therefore the upregulation is most likely due to transcriptional upregulation of 
the SR RNAs and proteins or an increase in the stability of the proteins.  
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Figure 3.7 SRSF1 DNA is amplified during cervical epithelial cell 
transformation but SRSF2 and SRSF3 DNA is not.  qPCR analysis of DNA copy 
numbers in the W12 model cell lines.  The experiment was carried out three 
times and the graph shows the mean and standard deviation of three 
independent experiments. SRSF1 DNA is significantly amplified in W12GPXY cells 
indicated by “*”.  SRSF2 and SRSF3 DNA are not significantly different. 
 
 
* 
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3.1.5  HPV11 E2 also up-regulates SRSF3 expression 
As certain SR proteins are overexpressed in differentiated W12E cells and this 
correlate with HPV16 E2 expression (Figure 3.5) and it has previously been shown 
that HPV16 E2 activates the promoter of the genes encoding SRSF1 and 3 (Mole 
et al., 2009a, Mole et al., 2009b), I wanted to determine if this regulation is 
restricted to high risk viruses or whether low risk viruses also upregulate SR 
protein expression.  To this end I transiently transfected GFP expression 
constructs containing HPV16, HPV11 or HPV6 E2 into 293-T cells and monitored 
expression of SRSF3.  GFP HPV E2 plasmids were a gift of Dr Kevin Gaston 
(University of Bristol).  SRSF3 was chosen as 293-T cells express high levels of 
SRSF1 naturally and this may mask any differences in expression.  I did not 
examine SRSF2 because antibodies against this protein do not work well in 
western blotting. Previously we have used the Mab104 that recognises all 
classical SR proteins.  However the number of bands on the blot and the fact 
that the bands corresponding to SRSF1 and SRSF2 migrate very close to one 
another made differences in protein levels very difficult to determine.  E2 
constructs were transiently transfected in to 293-T cells using Lipofectamine 
reagent (Invitrogen) and incubated for 48 hours.  After 48 hours protein was 
extracted into NP40 lysis buffer and the protein concentration determined by 
Bradfords Assay.  Equal concentrations of protein were loaded in each well and 
fractionated on a 4-12% denaturing SDS-PAGE in SDS buffer.  The proteins were 
transferred onto a nitrocellulose membrane and western blotted for SR protein 
expression.  The results from one experiment are shown in Figure 3.8.  γ-tubulin 
is used as a loading control standard to demonstrate equal concentrations of 
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protein are being compared.  The antibodies being detected are indicated to the 
right of the gel.  Track 1 shows 293-T cells alone with no transfection.  Track 2 
contains extracts from 293-T cells treated with Lipofectamine alone, this control 
was included as Lipofectamine can be toxic to cells and I wanted to ensure that 
the Lipofectamine was not altering protein expression through cellular 
cytotoxicity.  Track 3 contains protein extracts from 293-T cells transfected with 
an empty GFP vector and is an appropriate control for this experiment.  Tracks 4 
and 5 contain HPV6 E2 transiently transfected 293-T cells with 100ng or 500ng of 
E2 respectively.  Two concentrations of E2 were tested as E2 can cause cell 
death and can also function as a repressor at high concentrations therefore two 
concentrations were used to ensure optimal activation of SRSF2.  In track 5 there 
is a small increase in SRSF3 expression with the higher concentration of E2 
suggesting HPV6 E2 may be upregulating SRSF3 expression.  Tracks 6 and 7 
contain protein extracts from 293-T cells that were transiently transfected with 
HPV11 E2 at 100ng or 500ng respectively.  In these extracts there is a clear 
increase in SRSF3 expression when compared to the empty GFP vector alone 
(track 3).  Similarly in tracks 8 and 9 where HPV16 E2 has been transiently 
transfected there is an increase in SRSF3 levels as has been reported previously 
(Mole et al., 2009a, Mole et al., 2009b).  The experiment was carried out three 
times with similar results.  HPV16 has been shown to bind to SP1 and 
transactivate the promoter of SRSF1 (Mole et al., 2009b).  Similarly, HPV11 E2 
has SP1 binding sites, which suggests that HPV11 E2 could have similar 
transactivation functions as HPV16 E2 through the interaction with SP1. These 
data suggest that low risk viruses may also regulate SR protein expression which 
suggests that these SR proteins are essential for a productive viral life cycle.
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Figure 3.8 SRSF3 is upregulated by high and low risk papillomaviruses. 
Western Blot analysis of SRSF3 protein levels in transiently transfected 293-T 
cells.  The transfected expression constructs are indicated to the top of the 
blots. A) Blot probed with GTU88 against γ-tubulin and used as an internal 
control. B) Blot probed with Mab7B4 showing SRSF3 levels in the transfected 
cells.  
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 It is not surprising that low risk viruses also require SR protein expression as SR 
proteins are expected to be required for alternative splicing and other RNA 
processing functions in the cells.   
In conclusion high risk viruses are not alone in their capacity to upregulate 
expression of SR proteins, specifically SRSF3.  Therefore treatment of both high 
risk and low risk viruses could possibly be carried out by targeting of the same SR 
protein. 
 
3.1.6 Small E6 isoforms promote cell growth 
The final aim for this chapter was to identify any function for the small HPV16 
E6/E7 isoforms that become up regulated upon transformation of the W12 
epithelial cells.  As these isoforms are upregulated upon transformation of the 
epithelial cells it is likely they will have some function that is associated with 
tumourigenesis.  To test any oncogenic function, I created constructs containing 
cDNAs encoding each E6/E7 isoform cloned into the GFP expression vector 
pEGFP-C1 (Clontech).  A full length E6 construct cloned into p3XFLAG vector 
(Sigma) was also used in this experiment (created by Dr Alasdair MacDonald).  
The constructs were transfected individually into C33a HPV-negative cervical 
epithelial cells using Lipofectamine (Invitrogen) and the transfection efficiency 
monitored by GFP expression.  The transfection efficiency seemed similar in all 
cases at around 70%.  The number of cells was counted after 24, 48 and 72 hours 
of transfection for each experiment.  Figure 3.9 A shows the result from the 
growth curve study.  Compared to cells transfected with a GFP-expression  
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Figure 3.9 Transient transfection of E6 isoforms promotes cell growth. A) 
Growth curve analysis of the total C33a cell numbers after 24, 48 and 72 hours 
of transfection with expression constructs for each of the E6 isoforms.  The 
isoform that was transfected is indicated to the right of the graph.  One 
experiment is shown in the graph.  The experiment was carried out three times. 
B)  The percentage change in total cell numbers is shown in the bar chart.  Cell 
numbers at 24 hours were set at 100%.  The results of three independent 
experiments are shown in the chart.  The data show the mean and standard 
deviation in each case.  The transfected isoforms are indicated to the right of 
the graph. C) Western blot analysis of E6 construct expression levels. Blot 
probed with Mab GTU88 against γ-tubulin and Mab 2555 against GFP.  The 
protein being detected is indicated to the right of the blot. 
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construct control, C33a cells transfected with constructs expression E6FL or E6*I 
grew faster and each grew at a similar rate. In contrast, cells transfected with 
expression constructs for E6*II and E6*X grew even faster with an almost 2-fold 
increase in cell numbers relative to control transfected cells (Figure 3.9 A) The 
graphs indicate that transfection of the cells with the smaller isoforms, E6*II and 
E6*X promotes cellular proliferation.  This finding could explain why there are 
increased levels of these isoforms in transformed epithelial cells only.  It is also 
interesting that in these experiments E6*I seems to have a negative effect on 
cell growth as the total cell numbers are decreased (Figure 3.9 B 72 hour time 
point) when compared to the cells expressing full length E6/E7.  This however 
seems to fit with other reports of E6*I having antagonistic functions to full length 
E6.  Cells expressing GFP-tagged constructs appeared to be transfected to 
similar levels, with around 70-80% of cells being transfected.  Therefore 
differences in growth are probably not due to differences in transfection 
efficiences or expression levels.  Similarly, GFP protein levels are similar. 
Anchorage independent growth assays were also performed using the same E6 
isoform constructs transfected into the HPV-negative cervical epithelial tumour 
cell line, C33a.  Cells were transfected with the E6 isoform plasmids and grown 
on soft agar for 14 days as described in section 2.2.2.8.  The top layer of media 
was removed and the colonies stained with 0.005% crystal violet for 1 hour.  The 
cells were then dried and photographed and one experiment shown in Figure 
3.10.  No reproducible, statistically significant, difference was seen between the 
control cells and any of the transfected isoforms.  The reason for this could be 
that there is a combinatorial effect of the isoforms when it comes to 
transforming the cells and no single isoform is solely responsible for the 
induction of anchorage independent growth.
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Figure 3.10 Colony formation assay after transient transfection of E6 
isoforms.  A) Colonies formed after transient transfection with empty GFP 
vector. B) Colonies formed after transient transfection with a full length E6/E7 
vector. C) Colonies formed after transient transfection with an E6*I expressing 
plasmid. D) Colonies formed after transient transfection with an E6*II expressing 
vector. E) Colonies formed after transient transfection with a plasmid expressing 
E6*X. Each picture is from a single experiment.   F) Quantification of the number 
of colonies present after each transfection from three independent experiments. 
F 
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3.2 Discussion 
HPV16 E6/7 mRNAs can be alternatively spliced, with at least four possible 
mRNA isoforms being produced.  It was originally thought that the alternative 
splicing of E6 allowed for efficient translation of E7 (Sedman et al., 1991). 
However, a number of studies over many years have demonstrated that 
translation of E7 is just as efficient from full length and spliced E6/E7 mRNAs.  
These studies were carried out by overexpression of HPV16E6E7 constructs.  
Therefore in these analyses E6 and E7 were not under the control of the viral 
promoter, but under a strong alternative promoter such as CMV.  Also the 
polyadenylation site provided in the plasmid construct is a strong SV40 
polyadenylation site and does not reflect the efficiency of any of the viral 
polyadenylation sites. Both these facts mean that splice site selection and 
translation efficiency for E6 and E7 may be altered. When proteins are 
overexpressed in cells they will not have the same biological activities as the 
protein as expressed normally because there may be saturation of protein-
protein interactions or an induction of novel interactions that do not occur with 
normal protein levels. Moreover, the translation apparatus may be overwhelmed 
with mRNAs affecting translation efficiency. Therefore it is not possible to say 
whether E7 is translated more efficiently or not from spliced E6 transcripts.  
Alternative splicing of E6/E7 mRNAs in our W12E cell line does not appear to be 
altered upon differentiation of the infected epithelial cells. Even when the total 
E6/E7 RNA levels increased in differentiated W12E cells (Figure 3.2 C, track 5) 
compared to undifferentiated W12E cells (Figure 3.2 C, track 3), the isoform 
ratios did not appear to change. That does not mean, however that the splicing 
of E6/E7 is not important for the viral life cycle.  As has been suggested by a 
number of studies it is perhaps the ratio between the different E6 isoforms that 
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is important for determining the function of E6 at any one stage in the life cycle.  
Like other studies, this work has shown that E6*I is the predominant isoform 
expressed in HPV-infected cells regardless of differentiation or transformation 
status.  Lack of any apparent change in isoform expression upon differentiation 
of W12 epithelial cells could suggest that there is tight control over expression 
levels of each isoform in relation to the levels of the other isoforms.  Again this 
would point towards the ratios of the isoforms being important for E6 function 
during the virus life cycle. Alternatively, the lack of any qRT-PCR data means 
that I cannot rule out subtle changes in E6 isoform expression not revealed by 
semi-quantitative RT-PCR. 
Transformation of the epithelial cells on the other hand seems to have a 
significant effect on E6 splicing.  Transformation seems to increase expression of 
the smallest two isoforms, E6*II and E6*X.  The smallest isoform E6*X is only 
detectable, in these assays, in fully transformed W12GPXY and CaSki cells 
(Figure 3.3 C tracks 7 and 9 and Figure 3.4 C tracks 5 and 7).  Altered isoform 
expression and altered expression levels during tumour progression could explain 
why during transformation the E6 protein interactions essential for viral 
replication become oncogenic.  If the levels of E6 protein are the key to the 
function of E6 then there is likely to be a strict control over the ratio of 
expression between the isoforms.  However when the proteins become 
overexpressed, as they are during transformation, then such strict control may 
be lost.  If control over isoform expression is lost then loss or changes in patterns 
of interactions may aid in the transformation of the cells.  It is not likely that 
the E6*X isoform is only expressed in these cells but that the expression is 
increased to detectable levels.  In fact, Milligan et al. (2007) identified at least 
one polycistronic mRNA expressing E6*X in their analysis of transcripts isolated 
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from differentiated W12E cells encoding late HPV16 RNAs.  These data could 
indicate that the smaller isoforms have functions, that when over expressed, 
have transforming effects on the infected cell.  For example, they could be 
promoting cell growth and division.  E6*II isoform also appears to be increased in 
levels upon transformation whereas E6*I is the dominant isoform in both non-
transformed and transformed cells and level of the RNA do not appear to 
increase.   It has been suggested that detection of high levels of E6*I could be 
indicative of high grade lesions and could be used as a diagnostic tool (Kosel et 
al., 2007). However my data suggests that this might not be a useful assay 
because E6*I is highly expressed even in W12E cells where there is a productive 
viral infection taking place. The data shown in Figures 3.2 and 3.3 require to be 
replicated in patient tissue to determine whether E6*II or E6*X are more readily 
detected in high grade lesions than in low grade lesions.  If so, detection of 
these isoforms might be more useful in diagnostics. 
If E6*X is in fact a tumour-specific isoform then it could also provide a possible 
therapeutic target for treatment of HPV16-positive cervical cancers.  Cervical 
cancers are considered to be one of the more accessible tumours and therefore 
topical therapies could be designed to treat the tumours.  This therapeutic 
avenue however, could only be used for HPV16-positive tumours as HPV18 does 
not produce E6*II or E6*X isoforms.  Therefore therapy would only be effective in 
40-50% of HPV-positive cervical cancers.  It is interesting that HPV18 does not 
express E6*II or E6*X isoforms, in my opinion this may explain why HPV16-
infections are more commonly linked to squamous cell carcinoma and HPV18 
infections are more commonly linked to adenocarcinomas (Bulk et al., 2006).  
This suggests that the smaller isoforms may have a role infection of the 
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squamous epithelial cells in the ectocervix but are not necessary for infection of 
the epithelial cells in the endocervix. 
Alternative splicing requires SR splicing regulatory proteins to identify exonic 
splicing enhancer elements and define exon-intron boundaries.  Due to the 
alteration in E6/E7 mRNA splicing upon transformation of the epithelial cells, 
the levels of individual SR proteins were studied.  SR proteins 1, 2 and 3 are all 
upregulated upon transformation of the cells (Figure 3.5), and in patient tissues 
(Figure 3.6) (Mole et al., 2009a).  This could be why E6/E7 RNA splicing is 
altered during transformation.  Overexpression of an individual or a combination 
of SR proteins may be changing the splice site usage and thereby disrupting the 
ratios of E6 isoforms.  If one of these upregulated SR proteins is responsible for 
enhancing the usage of the E6*X splice acceptor site at nt 742 then this SR 
protein could perhaps be targeted by small molecule inhibitors to remove the 
E6*X isoform from transformed cells thus also removing any tumour specific 
functions the isoform may have. Alternatively, siRNA targeted to the E6*X-
specific splice junction would ablate this transcript isoform. 
Papillomaviruses have a unique problem where viral replication and gene 
expression takes place in differentiating epithelial cells where SR protein 
expression is normally switched off.  Therefore in order to express their RNAs 
and proteins, HPVs must control the expression of SR proteins.  The analysis of 
SR protein levels in the W12 transformation model provides evidence that SRSF2 
may be required for the completion of the viral life cycle. Previously in our 
laboratory we discovered that SRSF1 levels are upregulated in W12E cells. This is 
particularly striking when compared to the lack of upregulation in HaCaT or 
W12G cells (McPhillips et al., 2004). Mole et al. (2009) found a similar increase 
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in SRSF2 and 3 in W12E cells but not in HaCaT cells implying that virus infection 
was responsible for the change in SR protein levels. Here I have also 
demonstrated that the level of SRSF2 and SRSF3 are upregulated in W12E cells 
when compared with W12G cells.  Preliminary evidence has suggested HPV16 E2 
transcription factor upregulation of SRSFs 2 and 3 as well as SRSF1 (Mole et al., 
2009b).  Changes in levels of these other SR proteins may be relevant for the 
virus life cycle because unpublished data from our laboratory show that knock 
down of SRSF3 leads to a significant decrease in viral late mRNAs and late 
protein expression in differentiated W12E cells and in NIKS/HPV16 cells and 
previously SRSF3 was shown to be required to process late viral RNAs in U2OS 
osteosarcoma cells, although these tumour cells overexpress SR proteins (Mole et 
al., 2009b),  and E6/E7 RNAs in CaSki cells (Jia et al., 2009). 
 
From these data it is possible to suggest that SRSF2 may also have a role in 
processing virus RNAs during the life cycle the mechanism of which has yet to be 
determined.  The viral regulation of these SR proteins underlines the importance 
of splicing to the completion of the viral life cycle and emphasises the 
complexity of the viral RNA processing regulation.   
The overexpression of SR proteins is not unique to cervical tumour cells; in fact 
several SR proteins have been shown to be overexpressed in a number of 
cancers.  However, the mechanism controlling this overexpression is not known 
in every case.  For SRSF1, in breast cancers, it appears that the gene becomes 
duplicated during transformation (Karni et al., 2007). Now I have shown that 
SRSF1 gene copy number is also increased in cervical tumour cells (Figure 3.7) 
making gene amplification a likely mechanism for SRSF1 overexpression in 
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cancers in general.  The 17q23 has been shown to be amplified in a number of 
cancers including breast, testicular, ovarian and lung tumours (Kallioniemi et 
al., 1994, Ried et al., 1994, Korn et al., 1996, Hirasawa et al., 2003). Gene 
amplification explains why there is more SRSF1 expressed in cancer cells than 
normal cells.  In contrast, SRSF2 and SRSF3, in the W12 cervical tumour cells 
(Figure 3.7), do not seem to be overexpressed due to gene amplification.  It is 
possible that their overexpression is carried out at the transcriptional level or 
through an alteration to the protein stability. These mechanisms may also 
regulate SRSF1 together with gene amplification.  These data along with other 
evidence from our laboratory are the first demonstration of SR protein 
overexpression in cervical cancer.  SRSF1 and SRSF3 have been shown to be 
oncogenic in breast and ovarian cancers as reduction in protein levels can revert 
the tumour phenotype (Karni et al., 2007, He et al., 2011).  From these data it is 
reasonable to suggest that SRSF2 may also be considered to be an oncoprotein. 
The overexpression of the SR proteins will most likely, not only effect the viral 
gene expression prolife, but the cellular gene expression profile (reviewed by 
(Ward & Cooper, 2009).  SR proteins could then provide an attractive 
therapeutic target for not only cervical but other cancers as well. 
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4.1 Introduction 
Results in Chapter 3 demonstrated alternative splicing of HPV16 E6/E7 is altered 
upon transformation of W12 cervical epithelial cells.  Cellular transformation 
also caused a change in the levels of certain SR proteins; namely SRSF1, 2 and 3.  
It is possible therefore that the increase in SR protein levels in the fully 
transformed cervical epithelial cells is responsible for the change in splicing of 
E6/E7 mRNA.  SR proteins are cellular splicing regulators and their most well 
known function is to define exon/intron boundaries and promote RNA splicing.  
Alternative splicing is a way in which one RNA molecule can encode multiple 
proteins with differing functions.  SR proteins bind to RNA and direct which 
exons and introns are to be included or excluded from the resulting mRNA.  
Control of RNA splicing is tightly regulated during development and 
differentiation with numerous proteins involved. Indeed, aberrant splicing is 
associated with many human diseases.   SR proteins recruit spliceosomal 
components to the pre-mRNA by binding to enhancer elements within the mRNA.  
SR proteins help to define exons by facilitating interactions between U1 snRNP 
bound at the 5’ splice site and the 65 kDa subunit of U2AF which is bound to the 
3’ splice site (Robberson et al., 1990).  Similarly, SR protein interactions with U1 
snRNP and U2AF35 can also bridge interactions across introns (Wu & Maniatis, 
1993).  Finally SR proteins (SRSF1 in particular) can bind at the branch point and 
facilitate spliceosome assembly (Shen et al., 2004).  All of these steps are tightly 
regulated and levels of SR proteins are known to contribute to this regulation.  
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Therefore increased expression of any SR protein may lead to the splicing 
process becoming deregulated and could be catastrophic for the cell. 
In addition to well documented roles in splicing and its regulation, SR proteins 
have other RNA-related functions in the cell.  For example, SR proteins have 
been shown to be involved in regulating RNA stability, RNA export from the 
nucleus and translation of the RNA (Huang & Steitz, 2001, Lemaire et al., 2002, 
Huang et al., 2003, Huang et al., 2004, Sanford et al., 2004, Zhang & Krainer, 
2004, Michlewski et al., 2008).  This means that there are a number of RNA 
processing steps where increased levels of SR proteins either during HPV-
infected cervical epithelial differentiation or HPV-associated cervical tumour 
progression, could be acting upon E6/E7 expression. 
SR proteins control accurate RNA processing which is essential for production of 
the normal cellular proteome. It is accepted that altered SR protein expression 
could lead to cell transformation.  Overexpression could cause novel RNA splice 
isoforms to be produced. These could encode an oncogenic isoform of the wild 
type protein or a dominant-negative isoform that abrogated function of for 
example, a wild type tumour suppressor. Such possibilities have already been 
demonstrated by Karni et al. (2007).  In this study SRSF1 overexpression was 
shown to be sufficient to induce anchorage independent growth and to 
immortalise rodent fibroblasts and NIH 3T3 cells.  Injection of NIH 3T3 cells 
stably overexpressing SRSF1 subcutaneously into nude mice formed large 
sarcomas (Karni et al., 2007).  Overexpression of SRSF1 protected the 
transfected cells from serum starvation-induced apoptosis and when co-
transfected with H-Ras enhanced cellular proliferation (Karni et al., 2007). The 
study also showed that knockdown of SRSF1 overexpression, to levels that are 
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normally present in human lung cancer cells, was sufficient to reverse the 
transformed phenotype by reversing the cell’s ability to form colonies in soft 
agar (Karni et al., 2007).   
Significantly, while knockdown of SRSF1 altered the isoform expression of some 
of the cancer-related genes studied, it did not seem to affect expression of 
several endogenous genes that were also analysed (Karni et al., 2007).  The 
study focused on several proto-oncogenes and tumour suppressors which are 
known to be alternatively spliced.  Some targets, for example BIN1 which 
normally acts as a tumour suppressor, suppressing c-Myc activity, were found to 
have an increased level of one isoform upon SRSF1 overexpression that prevents 
the suppression of Myc activity (Karni et al., 2007).  In contrast other targets 
such as Caspase 9 were not affected by SRSF1 overexpression.  This is probably 
due to the functionally redundant nature of the SR proteins.   SR proteins are 
structurally related proteins and bind to loose consensus sequences in the 
elongating mRNA strand.  In a couple of studies knockdown of a single SR protein 
was not lethal to the cells and this is thought to be because other SR proteins 
can carry out the functions that would normally be carried out by the knocked 
down SR protein (Bakkour et al., 2007, Keriel et al., 2009).  
Very recently SRSF3 was identified as being oncogenic in ovarian epithelial cells 
(He et al., 2011).  Knockdown of SRSF3 resulted in reduced cell growth and 
reduced the cells' ability to form colonies in soft agar by around 90%. Knockdown 
of SRSF3 also induced apoptosis in ovarian tumour cells.  SRSF3 was knocked 
down using a doxycycline inducible siRNA for 5 days and the apoptotic cells 
detected by Hoechst 33342 staining.  Hoechst 33342 stain binds to AT base pairs 
in DNA, however it stains condensed chromatin brighter than normal chromatin 
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giving an indication of apoptosis by counting the cells with condensed 
chromatin.  There was a 40% increase in the number of cells positive for bright 
Hoechst stain when SRSF3 was knocked down compared to control.  The authors 
then went on to implicate the intrinsic apoptosis pathway as being activated in 
response to SRSF3 knockdown.  Cleaved caspase-9 was upregulated in the siRNA 
knockdown cells indicating that the intrinsic apoptosis pathway is active.  From 
these data it could be concluded that SRSF3 knockdown reduces cell growth and 
colony formation and also results in apoptosis, which suggests that SRSF3 in 
these A2780 ovarian cancer cells may be oncogenic (He et al., 2011). 
As these splicing factors, SRSF1 and SRSF3, have been implicated in enhancing 
tumour properties and I have shown them to be overexpressed in transformed 
cervical epithelial cells (Chapter 3 section 3.1.3), it is possible that they may be 
having a similar tumour promoting effect in cervical tumours.  Similarly the 
reported altered splicing effects on a number of targets after SRSF1 
overexpression prompted me to investigate whether the alteration to E6 splicing 
observed in the transformed cervical epithelial cells (Chapter 3 section 3.1.2) 
may be due to the overexpression of an SR protein.  With this in mind there were 
two hypotheses I addressed in this chapter.  Firstly, that the overexpression of 
one of the SR proteins is responsible for the upregulation of the small E6 
isoforms in transformed cervical epithelial cells.  Secondly, that the 
overexpression of an SR protein is contributing to the transformed phenotype of 
the epithelial cells. 
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4.1.1 SRSF2 controls HPV16 E6/E7 RNA expression in 
transformed cervical epithelial cells 
As shown in Chapter 3, section 1.1.3 a subset of SR proteins are overexpressed in 
transformed cervical epithelial cells.  In the same cells, E6/E7 RNA splicing 
pattern is altered. So I hypothesise that one or all of the overexpressed SR 
proteins is responsible for the change in viral RNA splicing.  More specifically, 
the overexpression of an SR protein is responsible for the upregulation of E6*X 
expression.  In order to determine whether any of the classical SR proteins could 
theoretically bind to the HPV16 E6/E7 mRNAs a bioinformatic analysis of the 
E6/E7 open reading frame was carried out.  The full E6/E7 open reading frame 
sequence was entered into the Reg RNA sequence prediction website 
(http://regrna.mbc.nctu.edu.tw/index.php ).  The program analyses input 
sequences for consensus SR protein binding sequences.  The resulting output is 
shown in Figure 4.1.  Binding sequences are indicated by the presence of a 
vertical green bar, a green bar within 100 nucleotides of an exon junction is 
normally considered to be specific and functional.  Therefore SRSF1, SRSF2 and 
SRSF7 could all be involved in processing of the E6/E7 mRNAs.  SRSF3 and SRSF5 
binding is not specific therefore they are unlikely to be involved in E6/E7 mRNA 
processing. 
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SRSF2 binding sequence: GRYcSYR  (R, purine; Y, pyrimidine; S, G or C) 
Possible HPV16 E6 binding sequence: GTATATAG or GCTCAGAG 
Figure 4.1 Computer prediction of SR protein binding sites in the HPV16 
E6/E7 open reading frame. Online program into which the target sequence is 
entered and algorithm identifies possible binding sites for RNA binding proteins.  
Any binding sites within 100 nucleotides of a splice junction could be significant.  
Proteins with multiple binding sites such as SRSF3 are unlikely to be significant.  
http://regrna.mbc.nctu.edu.tw/index.php.  Red circles identify those SR 
proteins which are predicted to specifically bind the target mRNA close to splice 
donor or acceptor sites. 
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In order to determine which, if any, SR protein contributed to E6/E7  RNA 
processing, the SR proteins SRSF 1-3 were individually knocked down using siRNA 
transfection in W12GPXY cells, the most transformed cell line displaying the 
highest levels of SR protein expression.  SRSFs1-3 were chosen as they are 
overexpressed in transformed cervical epithelial cells and SRSF1 and 2 have been 
predicted to bind the E6/E7 RNAs.  Although SRSF6 binding appears to be 
specific and unique the expression of the protein is not changed upon 
transformation, therefore I thought it unlikey to be involved in the alteration of 
E6 splicing upon epithelial transformation.  All siRNA reactions were carried out 
using Lipofectamine RNAiMAX (Invitrogen).  This reagent is formulated to 
specifically deliver siRNA molecules into cells with minimal toxicity.  Total RNA 
was prepared followed by reverse transcription before being PCR-amplified using 
the same E6/E7 primers used in section 3.1.1 and listed in Table 1.  All RNAs 
were DNase-1 treated before being reverse transcribed and amplified in a semi-
quantitative PCR reaction using GAPDH primers as an internal control standard.  
The PCR products were resolved on a 6% acrylamide gel and stained with 
ethidium bromide. The results of this experiment are shown in Figure 4.2.  
Protein was also extracted from siRNA-treated cells and western blotted as 
described in section 2.2.3.2 to check for efficiency of knockdown of the various 
SR proteins.  Knockdown of all three SR proteins was consistently achieved 
(Figures 4.2 A and C).  Moreover, siRNA knockdown was specific because for 
example, SRSF2 knock down did not alter levels of SRSF3 and vice versa and 
SRSF5 was not altered by either knock down (Figure 4.2 C).  However, 
knockdown was only around 50%. I considered that this was sufficient for the 
experiments, especially since SR proteins are essential cellular proteins required 
for splicing of cellular mRNAs and a higher percentage knockdown could 
compromise cellular functions.  Figure 4.2 B shows the pattern of E6/E7 mRNA 
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expression after SRSF1 knockdown.  Tracks 2, 4 and 6 show the reactions carried 
out in the absence of reverse transcriptase.  No bands were detected confirming 
the absence of DNA from the initial RNA starting material.  Track 3 shows the E6 
isoforms expressed in W12GPXY cells without any treatment. Track 5 shows the 
E6 isoforms expressed after transfection with a fluorescent non-targeting siRNA 
called siGlo that was used to monitor transfection efficiency.  The transfection 
efficiencies are detailed in Table 4.  Track 7 shows the E6 isoforms expressed 
after SRSF1 knockdown.  In all cases the E6 isoform pattern remained constant, 
with all isoforms being expressed. This result showed that SRSF1 is not required 
for E6/E7 isoform expression in W12GPXY cells.  Figure 4.2 D shows the E6/E7 
mRNAs expressed after SRSF2 and SRSF3 knockdown.  Again tracks 2, 4, 6 and 8 
all confirm the absence of DNA from the RNA starting material as the reactions 
have been carried out in the absence of reverse transcriptase.  Tracks 3 and 5 
show control experiments similar to those shown in tracks 3 and 5 of Figure 4.2 
B.  Track 7 shows the E6/E7 RNA isoform pattern expressed after SRSF3 
knockdown.  SRSF3 knockdown (Figure 4.2 C track 7) did not have any effect on 
E6/E7 mRNA expression as the isoform pattern and RNA levels are similar to 
those seen in tracks 3 and 5. Track 9 shows the E6/E7 RNA isoforms expressed 
after SRSF2 knockdown.    Surprisingly, SRSF2 knockdown appeared to decrease 
total levels of all E6/E7 RNA isoforms.  Although the levels of E6/E7 isoforms 
were very low it appeared that SRSF2 knockdown had no detectable effect on 
isoform pattern expression; isoforms E6 full length, E6*I and E6*II could still be 
observed with E6*I still being the most abundant isoform. These experiments 
were carried out three times with very similar results.  Again quantification of 
the isoforms by qRT-PCR was not possible due to the difficulties in probe and 
primer design described in section 3.1.1.  For each case in Figure 4.2 B and D  
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Figure 4.2 E6 RNA expression is reduced upon SRSF2 knockdown in W12GPXY 
cells.  A) Western blot showing knockdown efficiency of SRSF1 compared to 
control cells.  Mab96 is used to detect SRSF1 levels and Mab6CS is used to detect 
GAPDH.  The protein being detected is indicated to the right of the blot.  GAPDH 
is used as a loading control.   B) Upper panel Ethidium-bromide stained 
acrylamide gel electrophoresis of E6/E7 isoforms RT-PCR amplified from control 
and siRNA treated RNA from W12GPXY cells.  Isoforms are indicated to the right 
of the gel. RT, reverse transcriptase; “-“, RT-PCR reaction in the absence of 
reverse transcriptase; “+”, RT-PCR reaction in the presence of reverse 
transcriptase; “mock”, untransfected RNA; “control”, siGlo treated RNA; 
“siSRSF1”, siSRSF1 treated RNA; Lower Panel Ethidium-bromide stained 
acrylamide gel electrophoresis of GAPDH RNA RT-PCR amplified from control and 
siRNA treated RNA from W12GPXY cells. RT, reverse transcriptase; “-“, RT-PCR 
reaction in the absence of reverse transcriptase; “+”, RT-PCR reaction in the 
presence of reverse transcriptase; “mock”, untransfected RNA; “control”, siGlo 
treated RNA; “siSRSF1”, siSRSF1 treated RNA; . C) Western blot showing 
knockdown efficiency of SRSF2 and SRSF3 compared to control cells. Mab7B4 is 
used to detect SRSF3 levels, Mab104 is used to detect SRSF2 levels and Mab6CS is 
used to detect GAPDH. The protein being detected is indicated to the right of 
the blot.  GAPDH is used as a loading control. D) Upper panel Ethidium-bromide 
stained acrylamide gel electrophoresis of E6/E7 isoforms RT-PCR amplified from 
control and siRNA treated RNA from W12GPXY cells.  Isoforms are indicated to 
the right of the gel. RT, reverse transcriptase; “-“, RT-PCR reaction in the 
absence of reverse transcriptase; “+”, RT-PCR reaction in the presence of 
reverse transcriptase; “mock”, untransfected RNA; “control”, siGlo treated RNA; 
“siSRSF3”, siSRSF3 treated RNA; “siSRSF2”, siSRSF2 treated RNA; Lower Panel 
Ethidium-bromide stained acrylamide gel electrophoresis of GAPDH RNA RT-PCR 
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amplified from control and siRNA treated RNA from W12GPXY cells. RT, reverse 
transcriptase; “-“, RT-PCR reaction in the absence of reverse transcriptase; “+”, 
RT-PCR reaction in the presence of reverse transcriptase; “mock”, untransfected 
RNA; “control”, siGlo treated RNA; “siSRSF3”, siSRSF3 treated RNA; “siSRSF2”, 
siSRSF2 treated RNA.  
Chapter 4  171 
 
GAPDH was used as a loading control and this control panel is shown beneath 
each RT-PCR gel. Similar to the isoform expression experiments in the previous 
chapter, it was important to test whether the effect of SRSF2 knockdown on 
E6/E7 RNA processing was unique to W12GPXY cells.  Therefore a similar SRSF2 
knockdown experiment was carried out in CaSki cells.  Commercially available 
siRNA designed against SRSF2 (Dharmacon) was transfected into CaSki cells using 
Liopfectamine RNAiMAX (Invitrogen).  RNA was extracted after transfection of 
the SRSF2 siRNA for 48 hours.  All RNAs were DNase-1 treated before being 
reverse transcribed.  cDNA was amplified using the same E6/E7 primers 
described in section 3.1.1.  The cDNAs were amplified by semi-quantitative PCR 
using GAPDH primers as an internal control standard (Figure 4.3 A).  The 
amplified products were resolved on a 6% acrylamide gel and post stained with 
ethidium bromide.  Figure 4.3 A shows the amplified PCR products.  Tracks 2, 4 
and 6 show the reactions carried out in the absence of reverse transcriptase, 
thereby confirming the absence of DNA from the RNA starting material.  Track 3 
shows the E6/E7 isoforms expressed in untransfected CaSki cells.  Track 5 shows 
the E6/E7 isoforms expressed after transfection of CaSki cells with a fluorescent 
non-targeting siRNA, siGLO.  The transfection efficiency is listed in Table 4.  
Track 7 shows the E6/E7 isoforms expressed after SRSF2 knockdown.  
Significantly, SRSF2 knockdown in CaSki cells had a similar effect in reducing 
E6/E7 RNA levels, but not E6/E7 mRNA isoform expression pattern, as in 
W12GPXY cells (Figure 4.2 D, track 9).  This suggests that SRSF2 may be 
responsible for processing of HPV16 E6/E7 RNAs in virus-infected transformed 
cells.  As there is no SRSF2 commercially available that works well in Western 
blots, Mab104 was used to determine knockdown.  However, as this antibody 
detects phosphorylated proteins it may also be true that it is the loss of 
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Figure 4.3 E6 RNA expression is also reduced upon SRSF2 knockdown in CaSki 
cells. A) Upper panel Ethidium-bromide stained acrylamide gel electrophoresis 
of E6/E7 isoforms RT-PCR amplified from control and siRNA treated RNA from 
CaSki cells.  Isoforms are indicated to the right of the gel. RT, reverse 
transcriptase; “-“, RT-PCR reaction in the absence of reverse transcriptase; “+”, 
RT-PCR reaction in the presence of reverse transcriptase; “mock”, untransfected 
RNA; “control”, siGlo treated RNA; “siSRSF2”, siSRSF2 treated RNA; Lower Panel 
Ethidium-bromide stained acrylamide gel electrophoresis of GAPDH RNA RT-PCR 
amplified from control and siRNA treated RNA from CaSki cells. RT, reverse 
transcriptase; “-“, RT-PCR reaction in the absence of reverse transcriptase; “+”, 
RT-PCR reaction in the presence of reverse transcriptase; “mock”, untransfected 
RNA; “control”, siGlo treated RNA; “siSRSF2”, siSRSF2 treated RNA. B) Western 
blot showing knockdown efficiency of SRSF2 and SRSF3 compared to control 
cells.  Mab104 is used to detect SRSF2, Mab 7B4 is used to detect SRSF3 and 
Mab6CS is used to detect GAPDH.  The protein being detected is indicated to the 
right of the blot.  GAPDH is used as a loading control. 
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phosphorylation of SRSF2, and not a reduction in protein levels, that is reducing 
the E6/E7 RNA levels. 
 
4.1.2 SRSF3 not SRSF1 or SRSF2 is required for E6/E7 RNA 
expression during the virus life cycle 
My novel data suggests that SRSF2 but not SRSF1 or SRSF3 may be required for 
E6/E7 RNA processing in transformed cervical epithelial cells. In contrast with 
my results in W12GPXY cells, SRSF3 has previously been shown to be required for 
HPV16 E6/E7 expression in CaSki cells (Jia et al., 2009). I did not test knock 
down of SRSF3 in CaSki cells. However, I decided to investigate whether SRSF2 
and/or SRSF3 could also control E6/E7 RNA expression during the viral life cycle. 
Compared to cervical cancer cells, there are only low levels of SRSF2 in W12E 
cells (Figure 3.4).  W12E cells were grown on feeder layers for 4 days before 
being re-plated without feeder cells in keratinocyte growth medium (Lonza) 
without antibiotics.  The cells were siRNA treated with siSRSF2 or siSRSF3 on day 
five and incubated for 72 hours before RNA was extracted.  All RNA was DNase-1 
treated before being reverse transcribed.  The cDNA was amplified using the 
E6/E7 primers described in section 3.1.1.  The amplified PCR products were 
resolved on a 6% acrylamide gel and stained with ethidium bromide.  The PCR 
products are shown in Figure 4.4 A.  In W12E cells SRSF2 knockdown had some 
effect on the levels of E6/E7 RNAs or mRNA isoforms. However in contrast to the 
results with W12GPXY and CaSki cells, SRSF3 knockdown resulted in very 
significantly reduced levels of E6/E7 RNAs. In summary, SRSF3 had no effect on 
expression of integrated E6/E7 open reading frames in W12GPXY cells but had a  
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Figure 4.4 E6 RNA expression is reduced upon SRSF3 knockdown in W12E 
cells. A) Upper panel Ethidium-bromide stained acrylamide gel electrophoresis 
of E6/E7 isoforms RT-PCR amplified from control and siRNA treated RNA from 
W12E cells.  Isoforms are indicated to the right of the gel. RT, reverse 
transcriptase; “-“, RT-PCR reaction in the absence of reverse transcriptase; “+”, 
RT-PCR reaction in the presence of reverse transcriptase; “mock”, untransfected 
RNA; “control”, siGlo treated RNA; “siSRSF2”, siSRSF2 treated RNA; “siSRSF3”, 
siSRSF3 treated RNA; Lower Panel Ethidium-bromide stained acrylamide gel 
electrophoresis of GAPDH RNA RT-PCR amplified from control and siRNA treated 
RNA from W12E cells. RT, reverse transcriptase; “-“, RT-PCR reaction in the 
absence of reverse transcriptase; “+”, RT-PCR reaction in the presence of 
reverse transcriptase; “mock”, untransfected RNA; “control”, siGlo treated RNA; 
“siSRSF2”, siSRSF2 treated RNA; “siSRSF3”, siSRSF3 treated RNA. B) Western blot 
showing knockdown efficiency of SRSF2 and SRSF3 compared to control cells.  
Mab104 is used to detect SRSF2 protein, Mab7B4 is used to detect SRSF3 protein 
and GTU88 is used to detect γ-tubulin protein. The protein being detected is 
indicated to the right of the blot. γ-tubulin is used as a loading control. 
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very significant effect on episomal E6/E7 expression in W12E cells. These 
differences are probably due to the fact that E6/E7 is expressed from a very 
different mRNA population in W12E cells (Milligan et al., 2007). This result also 
highlights the potential role in splicing regulation of the key differences I 
observed in SRSF protein levels in W12E and in the W12 transformed cell lines. 
Even subtle changes in SR protein levels in cells can result in quite different 
patterns of gene expression. It remains to be seen what other effects SRSF3 has 
on episomal HPV16 gene expression.   
 
4.1.3 SRSF2 knockdown in transformed cells functionally impairs 
E6 protein 
As has been shown in Figure 4.2 and 4.3, SRSF2 knockdown decreases E6/E7 
mRNA levels in cervical cancer cells.  However, changes in RNA expression may 
not always be reflected in an effect at the protein level due to regulation of RNA 
stability and translation efficiency.    It is very difficult to study E6 protein levels 
due to low levels of expression, even in HPV-positive cervical cancer cells and 
due to a lack of suitable antibodies. E7 antibodies are better at detecting E7 
protein in such cells. However, I decided to use surrogate markers of E6/E7 
expression to examine the role of SRSF2 in the cervical tumour phenotype. I 
examined E6 and E7 separately and then concentrated on E6 function because 
three out of four of the E6/E7 mRNA isoforms are predicted to encode E6 
isoforms and not E7.  p53 is often used as an indication of E6 presence and 
function and pRb as an indication of E7 presence and function.  Therefore SRSF2 
was knocked down for 48 hours in W12GPXY cells using commercially available 
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siRNAs (Dharmacon).  Protein was then extracted into NP40 lysis buffer 
containing protease and phosphatase inhibitors.  The proteins were quantified by 
Bradfords protein assay and equal concentrations of proteins were denatured 
and resolved on a denaturing SDS-PAGE gradient gel in SDS running buffer.  The 
proteins were then western blotted by transferring onto a nitrocellulose 
membrane and incubating with protein-specific antibodies.  Detection of the 
protein was done using horseradish peroxidise tagged secondary antibodies 
followed by ECL detection.  The results of the experiment are shown in Figure 
4.5.  Figure 4.5 A track 1 shows the protein levels in untransfected cells.  Track 
2 shows the protein levels in the cells after transfection with a non-E6/E7 
targeting fluorescent siRNA (Dharmacon).  Track 3 shows p53 protein levels after 
SRSF2 knockdown.  The proteins being detected are indicated to the right of the 
membrane.  In track 3 the p53 protein levels are increased when SRSF2 is 
knocked down corresponding to the observation that E6/E7 RNA levels decrease 
upon SRSF2 knock down (Figure 4.2 D).  Figure 4.5 B shows the result of a 
quantification of three independent experiments.  The increase in p53 levels was 
found to be significantly different, with a p value of 0.021, between control 
siRNA and SRSF2 knockdown samples after carrying out a student’s T-test.  This 
indicates that not only is the E6/E7 RNA reduced but oncoprotein levels are 
either correspondingly reduced or E6 protein is functionally impaired because 
increased p53 levels implies a reduction in E6-mediated p53 degradation.    
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Figure 4.5 SRSF2 knockdown results in increased p53 levels. A) Western blot 
showing p53 levels in W12GPXY cells after SRSF2 knockdown.  MabDO-7 is used to 
detect p53 protein and Mab6CS is used to detect GAPDH protein levels.  The 
protein being detected is indicated to the right of the blot.  GAPDH is used as a 
loading control.   B) Graph showing the mean and standard deviation from the 
mean from three independent experiments.  Pixel density was measured using 
Adobe photoshop.  The increase in p53 levels after SRSF2 knockdown is 
statistically significant as indicated by “*”. 
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A similar experiment was carried out using pRb as a surrogate marker to 
investigate levels of E7 protein. Figure 4.6 shows the protein levels of pRb with 
and without SRSF2 knockdown.  The same protein extracts that were used in 
experiment 4.5 were western blotted for pRb levels.  Track 1 shows the pRb 
levels in W12GPXY cells transfected with siGlo for 48 hours.  Track 2 shows the 
pRb levels after SRSF2 knockdown for 48 hours.  GAPDH is used as an internal 
loading control.  The protein being detected is indicated to the right of the blot.  
Whereas in the previous experiment p53 levels increased upon SRSF2, pRb levels 
dropped (Track 2).  This reduction in pRb protein levels was not highly 
significant as after a student’s T-Test the p value was 0.08.  It has been reported 
that pRb is phosphorylated however the antibody used detects total pRb levels 
and does not recognise phosphorylated pRb forms. This seemingly paradoxical 
finding is at first confusing as the expectation would be that if E6/E7 mRNAs are 
reduced upon SRSF2 knockdown and E6 protein is functionally impaired, then 
one would expect E7 to be likewise impaired.  If E7 protein was reduced or 
impaired, according to the literature, pRb levels should increase.  A possible 
explanation for this finding could be that the increase in p53 levels is causing 
the cell to switch off expression of cell cycle associated proteins and prepare to 
enter apoptosis.  Due to the unexpected pRb finding further experiments were 
designed around the E6 impairment and the subsequent increase in p53.  
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Figure 4.6 SRSF2 knockdown results in decreased pRb levels. A) Western blot 
showing Rb levels in W12GPXY cells after SRSF2 knockdown. Mab 4H1 is used to 
detect pRb and Mab6CS is used to detect GAPDH levels. The protein being 
detected is indicated to the right of the blot.  GAPDH is used as a loading 
control.   B) Graph showing the mean value and the standard deviation from the 
mean from three independent experiments. The pixel density was measured 
using Adobe photoshop.  
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4.1.4 SRSF2 contributes to the transformed phenotype of the 
cells 
4.1.4.1 SRSF2 knockdown decreases cellular growth rate, alters cell 
morphology and interferes with the cell cycle 
As E6 and E7 both cooperate to promote cell growth, the consequences of SRSF2 
knockdown, and the subsequent reduction in E6/E7 RNA and by implication, E6 
protein levels, on cell growth was investigated.  W12G or W12GPXY cells were 
reverse transfected with commercially available SRSF2 siRNA (Dharmacon) and 
plated.  W12G cells were grown on J2 3T3 feeder layer cells until day 5 when the 
feeder layer was removed and the cells counted, transfected and plated out.   A 
reverse transfection was used in this instance instead of the usual forward 
transfection as I wanted to ensure that cell numbers were equal and to prevent 
the control cells from becoming confluent at the last time point.  At 24, 48 and 
72 hours of transfection, cells were harvested and counted.  Figure 4.7 A and B 
show the growth curves of W12G and W12GPXY over the course of the 
experiment. Compared to mock-transfected cells, SRSF2 knockdown had no 
significant effect on cell growth rate in W12G cells (Figure 4.7 A). This result is 
as expected because these cells are not transformed and do not have high levels 
of SRSF2 protein (Figure 3.4).  Importantly, this result also demonstrates that 
SRSF2 knock down does not significantly compromise cervical epithelial cell 
growth. The black line with black squares represents the total cell numbers after 
the specified time of transfection with a non-E6/E7-targeting fluorescent siRNA  
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Figure 4.7 SRSF2 knockdown results in decreased cell growth in W12GPXY 
cells. A) Growth curve analysis of W12G cells treated with siSRSF2 and the total 
cell numbers counted every 24 hours post transfection.  The siSRSF2 cells are 
shown by the gray line and the control cells indicated by the black line.  Graph 
shows the mean and standard deviation from the mean number of cells. B) 
Growth curve analysis of W12GPXY cells treated with siSRSF2 and the total cell 
numbers counted every 24 hours post transfection.  The siSRSF2 cells are shown 
by the gray line and the control cells indicated by the black line. Graph shows 
the mean and standard deviation from the mean number of cells. C) Table 
displaying the actual cell numbers at 24 hours and 72 hours for each treatment. 
D) Western blot showing the knockdown efficiency in W12G cells after SRSF2 
knockdown.  Mab104 is used to detect SRSF2 levels and Mab6CS is used to detect 
GAPDH levels.  The protein being detected is indicated to the right of the blot.  
GAPDH is used as a loading control. E) Western blot showing the knockdown 
efficiency in W12GPXY cells after SRSF2 knockdown. Mab104 is used to detect 
SRSF2 levels and Mab6CS is used to detect GAPDH levels. The protein being 
detected is indicated to the right of the blot.  GAPDH is used as a loading 
control.  
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(Dharmacon).  The gray line with gray triangles represents the total cell numbers 
after the specific times of transfection with SRSF2 siRNA.  In contrast to the 
results with W12G cells, there was a dramatic effect on cell growth rate in the 
W12GPXY cells upon SRSF2 knockdown (Figure 4.7 B).  After 72 hours there was 
an almost 50% reduction in total cell numbers in the SRSF2 knockdown cells (gray 
line) compared to the non-targeting fluorescent siRNA treated cells (black line).  
The experiments were not carried out for longer time periods due to a reduction 
in effectiveness of the siRNA after this period of time in the transient 
transfection experiment.  72 hours is the longest recommended time point for 
transfection, after which the siRNA effect may be lost as the siRNA does not 
divide with the cells. Moreover, Lipofectamine can be relatively toxic to the 
cells.  This means that any cells remaining after 72 hours may in fact not be 
transfected and may outgrow the transfected cells.  The finding of a slowing of 
cell growth in W12GPXY cells contributes to the evidence that E6/E7 RNAs and 
proteins are reduced upon SRSF2 knockdown. These data suggest that SRSF2 is 
required to maintain growth rate of W12GPXY cells. 
 
When SRSF2 was knocked down in W12GPXY I noticed an alteration in the 
appearance of the cells. In order to investigate this further, W12GPXY cells were 
transfected using commercially available SRSF2 siRNA (Dharmacon) and a 
fluorescent non-targeting siRNA (Dharmacon).  Pictures were taken using a Leica 
light microscope and the 10X objective.   Figure 4.8 shows an example of the 
phenotype of the cells after transfection.  Normal untransfected GPXY cells are 
elongated and grow both in small colonies and in isolation.  Lipofectamine 
RNAiMAX treatment with a non-targeting fluorescent siRNA altered the  
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Figure 4.8 SRSF2 knockdown alters the morphology of the transfected cells. 
A) W12GPXY cells transfected with siGlo for 48 hours.  Picture was taken with 
the 10X objective   B) W12GPXY cells transfected with siSRSF2 for 48 hours.  
Picture was taken with the 10X objective C) Western blot showing knockdown 
efficiency of SRSF2 compared to control cells.  Mab104 is used to detect SRSF2 
protein and Mab6CS is used to detect GAPDH protein levels. The protein being 
detected is indicated to the right of the blot. GAPDH is used as a loading 
control. 
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phenotype to some extent with some cells showing a more rounded phenotype. 
However the cells were still able to grow in large colonies (Figure 4.8 A).  When 
SRSF2 was knocked down however, the cells became more rounded and more 
individual cells were present (Figure 4.8 B).  The pictures were taken 48 hours 
after transfection.  Some of the transfected cells also appeared smaller in size 
and more refractile than the control-transfected cells. These data suggested 
that the cells treated with siRNA against SRSF2 were entering senescence or 
beginning apoptosis. 
The observation that W12GPXY cells grow more slowly and alter their cellular 
phenotype in the presence of reduced SRSF2 levels prompted me to examine cell 
growth in terms of the cell cycle. As SRSF2 may have oncogenic properties it was 
possible that cells were growth-arrested in its absence. To examine this I used 
propidium iodide to stain cellular DNA and examined DNA content in cell 
populations either untreated, treated with control siRNA or treated with siRNA 
against SRSF2. W12GPXY cells were mock transfected, transfected with siGLO or 
with SRSF2 siRNA (Dharmacon) and harvested after 48 hours of transfection.  The 
cells were then fixed in 70% ethanol for 30 minutes on ice before being stained 
with propidium iodide overnight at 4°C to visualise the DNA content.  RNase A 
was added to digest RNA that could interfere with the DNA profiles.  The DNA 
content was analysed using the EXPO32ADCXL4 Colour program on a Beckman 
Coulter Epics XL-MCL machine.  Figure 4.9 shows the results of one experiment. 
Two experiments were carried out with very similar results in each case. All 
three W12GPXY DNA profiles looked similar and each population of cells appear 
to be cycling normally because distinct G1, S and G2-phase peaks could be 
observed.  There was little difference between the percentage of cells in G1 and 
S-phase of the cell cycle in the cells mock transfected (Figure 4.9 A) or  
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Figure 4.9 SRSF2 knockdown affects the cell cycle. A) DNA content of 
W12GPXY cells that were not transfected. B) DNA content of W12GPXY cells 
transfected with siGlo for 48 hours.  C) DNA content of W12GPXY cell 
transfected with siSRSF2 for 48 hours. D) Table displaying the mean number of 
cells in each stage of the cell cycle in two independent experiments. E) Western 
blot showing knockdown efficiency of SRSF2 compared to control cells.  Mab104 
is used to detect SRSF2 protein and Mab6CS is used to detect GAPDH protein 
levels. The protein being detected is indicated to the right of the blot. GAPDH is 
used as a loading control. 
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transfected with a fluorescent non-targeting siRNA (Figure 4.9 B) except that a 
reduction in G2 phase was noted in the latter.  However, after SRSF2 knockdown 
there was around a 7% decrease in the percentage of cells in the G2 stage of the 
cell cycle with a corresponding increase of cells in the G1 stage compared to 
mock transfected cells (Figure 4.9 C).  Figure 4.9 D summarises the 
quantification of the mean percentage of cells in each stage of the cell cycle in 
two independent experiments.  These data suggest that SRSF2 knock down might 
arrest the cells in G1 or at least could slow the cycling time of the cells. 
 
4.1.4.2 SRSF2 knockdown results in apoptosis 
As SRSF2 knockdown affects the morphology and growth of the cells and may 
affect the cell cycle, the next feature to investigate was whether SRSF2 
knockdown caused the cells to enter senescence or apoptosis.  One observation 
that suggested that this may be the case, was that knockdown of SRSF2 resulted 
in visibly more cells detaching from the cell culture dish and floating in the 
growth medium.  Cell detachment could suggest cell senescence or cell death. 
To examine senescence, Senescence-Associated β-Galactosidase Assays (SA β-
Gal) (New England Biolabs) were carried out.  SA- β gal staining only occurs at 
pH 6 therefore only cells that are senescent and have a reduced pH will stain 
positive for β- galactosidase.  W12GPXY cells were treated with siSRSF2 
(Dharmacon) or siGlo (Dharmacon) for 24-72 hours and fixed before being 
stained for expression of SA-β-gal.  However, regardless of the length of time of 
SRSF2 knockdown no β-gal staining was observed (data not shown). One problem 
with this assay, however is that there was no appropriate standard positive 
control suggested by the kit, therefore lack of staining could indicate there is no 
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senescence taking place or that the kit was not working efficiently.  Tumour 
cells do not senesce and I did not have access to any primary cell lines. It has 
previously been suggested that expressing E2 in HPV16 positive transformed cells 
will induce senescence in the transfected cells however these experiments have 
been done with overexpression vectors for E6, E7 and E2 (DeFilippis et al., 
2003).  Although W12GPXY cells express E6 and E7 they are not highly expressed 
compared to overexpression constructs.  The study also used BPV E2 to repress 
HPV16 E6 an E7 expression and a recent publication by Ottinger et al (2009) has 
suggested that different PV LCRS and E2 proteins behave differently depending 
on the cell type and the combination of LCR and E2.  However, I did include an 
HPV16 E2 transfected control in one experiment and I still observed no staining.  
Therefore it is possible that my cells do not undergo senescence or that the kit 
was not working.  I therefore moved on to studying apoptosis as there were 
positive controls available for these assays.   
To examine apoptosis, TUNEL assays were carried out.  TUNEL (Terminal 
deoxynucleotidyl transferase mediated dUTP nick end labelling) assays detect 
DNA fragmentation that occurs during apoptosis.  When the DNA is fragmented 
the fluorescently labelled dUTP nucleotide can be incorporate into the DNA 
during end-labelling and can be detected by fluorescent microscopy.  W12GPXY 
cells were plated onto 4 well chamber slides and either mock transfected or 
transfected with control siGLO siRNA or with SRSF2 siRNA (Dharmacon) for 24, 48 
and 72 hours.  After transfection cells were fixed in 4% formaldehyde at 4°C and 
permeablised with 0.2% Triton X-100.  The cells were stained for 1 hour at 37°C 
in a humidified chamber before the reaction was stopped.  As a staining control,  
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Figure 4.10 Cells with treated with siSRSF2 do not stain positive for TUNEL. 
A) W12GPXY cells without siRNA transfection. B) W12GPXY transfected with 
siGlo for 48 hours.  C) W12GPXY cells transfected with siSRSF2 for 48 hours. D) 
W12GPXY cells without TUNEL stain added to act as a negative control. E) 
W12GPXY treated with DNase-1 to act as a positive staining control. F) Western 
blot showing knockdown efficiency of SRSF2 compared to control cells.  Mab104 
is used to detect SRSF2 protein and Mab6CS is used to detect GAPDH protein 
levels. The protein being detected is indicated to the right of the blot. GAPDH is 
used as a loading control. 
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mounting media containing DAPI was used to stain nuclei.  A positive control was 
created by adding DNase-1 to the control cells before staining.  A negative 
staining control with no labelled dUTP added to the staining solution was also 
included.  Figure 4.10 shows an example of the staining achieved after 48 hours 
of transfection.  DAPI staining was detected in all samples showing the number 
of cells that were present in the assay. Although TUNEL staining could be 
observed in the positive control W12GPXY cells and no staining was detected in 
the negative control cells, no TUNEL staining was evident in any of the test 
W12GPXY cell populations at any time post-transfection.  This result indicated 
that SRSF2 knockdown in W12GPXY cells did not cause apoptosis, which also 
concurs with the small sub-G1 peak in the Flow Cytometry data in Figure 4.9.  
However as TUNEL staining detects nicks in the DNA it is only detecting the late 
stage of apoptosis and will not detect cells that are entering into early 
apoptosis.  
An alternative method of detecting cells undergoing apoptosis uses Annexin V 
detection.  Annexin-FITC conjugate can detect the presence of 
phosphatidylserine on the surface of cells which is a marker of early apoptosis.  
Phosphatidylserine is normally present on the inside of the plasma membrane 
however once the cell enters apoptosis the caspase signalling cascade is 
activated and the phosphatidylserine is relocated to the external membrane.  
This allows the apoptotic cell to be identified and cleared in a controlled 
manner.  Therefore Annexin V apoptosis detection often gives a better indication 
of cells undergoing apoptosis.  I designed an apoptosis assay to determine the 
effect of SRSF2 knockdown that regulates E6/E7 mRNA abundance in W12GPXY 
cells relative to direct knockdown of E6/E7 RNA. W12GPXY cells were either 
transfected with control siRNA or transfected with SRSF2 siRNA (Dharmacon) or 
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with E6 siRNA for 48 hours before being harvested.  The E6 siRNA is situated in 
the first exon and will therefore knockdown all E6 isoforms.  The cells were 
resuspended in Annexin binding buffer and stained with Annexin V 488nm and 
propidium iodide for 15 minutes at room temperature.  A positive apoptosis 
control was included by treating untransfected W12GPXY cells with 500 J/m2 of 
UVB 24 hours prior to harvesting. The cells were then analysed on a BD 
Biosciences FACSCalibur machine and the results analysed using FlowJo 
software. Figure 4.11 shows the result of one such experiment. Three 
experiments were carried out with similar results in each case. For the plots, the 
lower left quadrant contains cells which are negative for both annexin V and 
propidium iodide and are therefore live cells.  The lower right quadrant contains 
cells that are positive for annexin V and negative for propidium iodide and are 
therefore in apoptosis.  The upper right quadrant contains cells positive for both 
annexin V and propidium iodide and are considered to be dead through either 
apoptosis or necrosis.  The upper left quadrant is cells that are positive only for 
propidium iodide.  Anything in this quadrant is most likely cellular debris. Figure 
4.11 A shows the cell profile after treatment with a non-targeting fluorescent 
siRNA. The majority of cells were in the lower left hand side quadrant of the 
plot representative of live cells. UVB treatment was used as a positive control 
for cell death and resulted in the majority of the cells entering the upper and 
lower right hand side of the plot representing dead cells and cells undergoing 
apoptosis respectively (Figure 4.11 D).  Following SRSF2 knockdown the majority 
of cells entered the lower right hand quadrant indicating that apoptosis was 
indeed taking place (Figure 4.11 B).  Interestingly, the cell population profile 
after E6 siRNA treatment displayed a similar pattern, although more cells 
occupied the upper right hand quadrant compared to cells with reduced SRSF2 
levels (Figure 4.11 C).   
Chapter 4  196 
 
  
 
Average percentage of cells in each quadrant
0%
20%
40%
60%
80%
100%
Mock siSRSF2 siE6 UVB
Cell Treatment
A
v
er
ag
e 
Pe
rc
en
ta
ge
 
o
f C
el
ls
Other
Dead
Apoptotic
Live
 
E 
Chapter 4  197 
 
 
Figure 4.11 Cells with treated with siSRSF2 stain positive for annexin V. A) 
W12GPXY cells transfected with siGlo for 48 hours and stained with annexin V 
and propidium iodide. B) W12GPXY transfected with siSRSF2 for 48 hours and 
stained with annexin V and propidium iodide.  C) W12GPXY cells transfected 
with siE6 for 48 hours and stained with annexin V and propidium iodide. D) 
W12GPXY cells treated with 500J/cm2 for 24 hours and stained with annexin V 
and propidium iodide. E) Graph displaying the mean percentage of cells in each 
quadrant after each treatment.  Graph shows the results from three 
independent experiments. F) Western blot showing knockdown efficiency of 
SRSF2 compared to control cells.  Mab104 is used to detect SRSF2 protein and 
Mab6CS is used to detect GAPDH protein levels. The protein being detected is 
indicated to the right of the blot. GAPDH is used as a loading control. 
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Figure 4.11 E shows the combined results of three experiments. The graph shows 
the mean percentage of cells in each quadrant from the three independent 
experiments.   There is one error in this experiment. The control siRNA in the 
transfection control was fluorescently labelled.  This may explain why in the 
control experiment a high percentage of cells appear positive for propidium 
iodide staining.  The siRNA fluorescence is detected in the red channel as is 
propidium iodide. This experiment suggests that SRSF2 knockdown cells are 
entering into early apoptosis however as later time points were not used I 
cannot definitively say that the cells are dying through apoptosis. 
 
I conclude that knocking down SRSF2 in HPV16 transformed epithelial cells may 
cause the cells to enter early apoptosis.  The annexin V data indicates that the 
SRSF2 knockdown cells may be entering into early apoptosis, however as the 
TUNEL data is negative and there is an absence of a sub-G1 peak in the Flow 
Cytometery analysis late stage apoptosis cannot be confirmed.  Therefore it is 
possible that SRSF2 knockdown cells are becoming positive for Annexin V staining 
via another route.  For example ER stress can result in the release of calcium 
followed by the plasma memebrane becoming permeabilised and could result in 
the redistribution of phosphatidylserine and Propidium iodide could then enter 
to stain the DNA.  Apoptosis was suggested due to the altered morphology with 
the cells rounding up and detaching from the culture dish.  However in order to 
definitively confirm apoptosis further experiments including extending the time 
points studied in the Annexin V experiment and determination of cell viability by 
methods such as an MTT assay or Hoescht 33342 staining. 
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4.1.4.3 SRF2 knockdown inhibits anchorage independent growth 
I have shown that knockdown of SRSF2 slows cell growth rate, changes the 
phenotype of the cells and causes the cells to enter early apoptosis.  These 
observations indicate that SRSF2 is required for maintenance of the tumour 
phenotype of W12GPXY cells. One final phenotype commonly attributed to 
tumour cells is the ability to form colonies in soft agar.  Knockdown of SRSF3 in 
A2780 ovarian cancer cells has already been shown to result in a reduced ability 
to form colonies in soft agar (He et al., 2011) . To discover whether SRSF2 
knockdown also resulted in a reversal of anchorage-independent growth  
W12GPXY cells were transfected with siRNA designed against SRSF2 (Dharmacon) 
for 24 hours before being harvested and plated out on soft agar.  A 24 hour 
transfection was used as I did not want to loose any of the knockdown cells that 
may have detached from the cell culture dish when harvesting the cells to plate 
out onto soft agar. The base layer contained 0.75% agar and the top layer 
contained 0.4% agar.  This provided a concentration gradient of agar.  The base 
layer was added and allowed to set before the cells were added to the top layer 
and the cell-containing top layer plated out onto the base layer.  The cells were 
allowed to grow for 14 days before the medium was removed and the colonies 
stained with 0.005% crystal violet for 1 hour before being dried and 
photographed.  Figure 4.12 A shows an example of the appearance of colonies of 
W12GPXY cells transfected with control siRNA present after staining.  A number 
of colonies can be clearly seen, especially on the periphery of the plate. Figure 
4.12 B shows a plate of colonies following transfection with SRSF2 siRNA 
(Dharmacon).  The reduction in SRSF2 levels resulted in a reduced number of 
colonies:  fewer colonies were stained and the size of the colonies that were 
present was smaller, on average, to that of the control siRNA-transfected cells.  
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Figure 4.12 D shows a quantification of three independent experiments.  
Colonies larger than a defined square were counted.  The pictures were 
imported into Powerpoint and adjusted to equal sizes.  I zoomed in to 300% and 
drew the smallest square possible from the Powerpoint tool.  The same square 
was used to count the colonies in all pictures.  The experiment was carried out 
three times and the graph shows the mean number of colonies larger than the 
square. I conclude from this experiment that SRSF2 knockdown can reverse the 
transformed phenotype of W12GPXY cells.   
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Figure 4.12 Cells with treated with siSRSF2 have a reduced ability to form 
colonies in soft agar. A) W12GPXY cells transfected with siGlo for 48 hours 
grown in soft agar for 14 days and stained with 0.005% crystal violet. B) 
W12GPXY transfected with siSRSF2 for 48 hours and grown in soft agar for 14 
days and stained with 0.005% crystal violet.  C) Western blot showing knockdown 
efficiency of SRSF2 compared to control cells.  Mab104 is used to detect SRSF2 
protein and Mab6CS is used to detect GAPDH protein levels. The protein being 
detected is indicated to the right of the blot. GAPDH is used as a loading 
control. D) Graph displaying the mean number of colonies and the standard 
deviation from the mean of colonies larger than a defined square after each 
treatment.  Graph shows the results from three independent experiments. 
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Another important feature of tumour cells is their ability to invade a collagen 
matrix.  An invasive phenotype is indicative of a malignantly transformed cell.  
Therefore to determine if SRSF2 knockdown would also reverse the invasive 
phenotype of the W12GPXY cells, I performed Matrigel invasion assays.  Before 
starting with transfections, W12GPXY cells were assayed for their ability to 
invade without any treatment.  Matrigel (BD biosciences) was diluted 1:1.5 in 
serum free DMEM and added to the appropriate number of transwells before 
being left to set.  2x104 cells were added to the bottom of the transwell and 
incubated at 37°C for 3 hours to allow the cells to attach.  The transwells were 
washed twice in serum free medium before being placed into 600µl serum free 
medium.  150µl of DMEM containing 10% FBS was added to the centre of the 
transwell creating a concentration gradient of medium that will attract any 
invasive cells to move up through the matrigel towards the serum containing 
medium.  The cells were incubated at 37°C for 3 days before the cells were 
stained with 4µM Calcein-A for 1 hour at 37°C.  Cells were analysed using the 
Leica Confocal microscope.  Unfortunately, W12GPXY cells did not invade into 
the matrigel matrix even after further dilution of the matrigel matrix and 
increasing the cell attachment time and cell invasion time.  Equine sarcoid 
control cells that were capable of invading the matrigel gel were used to ensure 
the protocol was carried out correctly, however W12GPXY cells were unable to 
invade the matrigel matrix.  W12GPXY cells alone are not invasive in a matrigel 
system therefore it would have been impossible to determine whether knocking 
down SRSF2 would have any effect on invasivness of the cells.  Perhaps another 
method of determining migration would have been to carry out a similar 
experiment using a different matrix for example a collagen matrix. 
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4.1.5 The mechanism of action of SRSF2 on E6/E7 expression: 
SRSF2 does not trans-activate the P97 promoter.  
The reduction in E6/E7 RNA after SRSF2 knockdown could be accounted for by a 
number of different mechanisms.  As SRSF2 is thought not to traffic between the 
nucleus and cytoplasm, it is unlikely to be as a result of changes to SRSF2-
mediated trafficking of the RNAs.  Moreover, as evidence suggests that SRSF2 is 
confined to the nucleus it is unlikely to control E6/E7 expression through a 
cytoplasmic event, for example translational control.  Therefore I reasoned that 
either SRSF2 might exert a transcriptional effect on the P97 promoter from which 
E6/E7 mRNA is transcribed or SRSF2 might alter nuclear stability of the E6/E7 
RNA.   SRSF2 has previously been shown to promote transcriptional elongation 
(Lin et al., 2008).  SRSF2 was found to be associated with the Pol II C-terminal 
domain (CTD) subunit and P-TEFb which phosphorylates serine 2 of Pol II CTD to 
allow for transcription elongation.  When SRSF2 was depleted the 
phosphorylation at serine 2 was reduced and the total mRNA levels were reduced 
(Lin et al., 2008). SRSF2 has also recently been shown to stabilise a target mRNA 
containing a SRSF2 binding site.  SRSF2 was shown to bind to tau mRNAs 
containing exon 10 and stabilise the RNAs (Qian et al., 2011).  The authors 
demonstrated that the increase in mRNAs was not due to increased transcription 
but by direct binding and stabilisation of the mRNAs (Qian et al., 2011).  Either 
of these scenarios could be occurring with regards to the E6/E7 mRNAs.   
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Figure 4.13 SRSF2 knockdown does not reduce transcription from the 
P97 promoter. A) Schematic diagram of the HPV16 LCR construct cloned 
into pGL3-Basic.  The start and end nucleotide of the LCR fragment is 
indicated as is the approximate position of the major early promoter P97. 
B) Graph showing the results from three independent experiments where 
293-T cells were transfected with siGlo or siSRSF2 and HPV16 LCR vector 
in the absence of E2 for 48 hours.  Cells were harvested and the 
expression of the luciferase reporter measured. The mean and standard 
deviation from the mean are plotted on the graph.  C) Graph showing the 
results from two independent experiments where 293-T cells were 
transfected with siGlo or siSRSF2 and HPV16 LCR vector in the presence of 
E2 for 48 hours.  Cells were harvested and the expression of the luciferase 
reporter measured. The mean and standard deviation from the mean are 
plotted on the graph. 
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To test the first hypothesis, an HPV16 LCR transcription assay construct (a gift 
from Prof Iain Morgan) was transfected into HEK 293-T cells. The construct 
contained the HPV16 LCR from nucleotide 7101 to +137 and was cloned into 
pGL3-basic (Promega). The HPV16LCR construct was transfected into 293-T cells 
with increasing concentrations of an HPV16 E2 expressing construct (a gift from 
Prof Peter Howley) with or without SRSF2 knockdown.  A schematic diagram of 
the LCR construct is shown in Figure 4.13 A. The HPV16LCR construct contains a 
luciferase reporter plasmid, therefore transcription from the P97 promoter can 
be quantified by levels of luciferase produced after transfection.  The cells were 
transiently transfected using Lipofectamine (Invitrogen) and incubated for 48 
hours before harvesting.  The transfected cells were lysed in Reporter lysis 
buffer (Promega) and the levels of luciferase determined by spectrophotometer.  
pGL3-B is a control plasmid which does not have a promoter therefore it is used 
as a background luciferase control and any expression above the pGL3-B levels is 
an activation of luciferase transcription.  pGL3-C is another control plasmid 
which acts as a positive control.  In this plasmid luciferase is under the control 
of a strong CMV promoter therefore luciferase should be highly expressed, this 
provides a control for the detection of the luciferase by the spectrophotometer. 
In Figure 4.13 B, I first carried out transcription assays using only the HPV16 LCR 
construct without the addition of E2 as I thought perhaps any action by E2 would 
mask any effects on the LCR activity after SRSF2 knockdown.  From this 
experiment there is no significant difference between the siGlo and siSRSF2 
treated samples; the luciferase production is almost equal.  However it is clear 
from this experiment that the HPV16 LCR is not active in these cells as the levels 
of luciferase expression is below that of the pGL3-B negative control.  I then 
went on to carry out the same experiment with the addition of E2.  A titration of 
E2 concentration was used as E2 has been reported to have activation and 
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repression activities depending on the concentration.  Therefore a titration was 
used to ensure optimal activation of the HPV16 LCR.  Again pGL3-B and pGL3-C 
are used as controls and shown in Figure 4.13 C.  From this experiment it does 
not seem like SRSF2 knockdown is having any effect on LCR activity.  When 10ng 
of E2 is added to the cells the levels of transcription in both the siSRSF2 and 
siGlo treated cells are very low and there is no significant difference between 
the luciferase expression levels.  Similarly when 100ng of E2 is added the levels 
of transcription are again very low with no difference between the siGlo and 
siSRSF2 samples.  This suggests that at these concentrations of E2, E2 does not 
activate transcription of the HPV16 LCR and may in fact repress the LCR as the 
levels of transcription are below that of the negative control pGL3-B construct.  
However, when 1000ng of E2 is added there is a little activation from the HPV16 
LCR.  Although there is activation there is once again no significant difference 
between the siSRSF2 and siGlo knockdown cells.  The results from the 
transcription assay are difficult to draw any conclusions from.  Knockdown of 
SRSF2 does not seem to have a detrimental effect on transcription factors as the 
levels of transcription after SRSF2 knockdown are similar to those without 
knockdown.  If anything transcription could be being activated although this is 
far from convincing.  Therefore unfortunately it is not possible to say what 
effect SRSF2 has on transcriptional control from these experiments.  These 
results are similar to a recent publication by Ottinger et al (2009).  They 
reported that HPV16 LCR activity is very weak in human cells when compared to 
other high and low risk papillomaviruses (Ottinger et al., 2009).  The authors 
also reported that LCR activity for all of the different LCRs investigated were 
slightly different depending on the cell type used (Ottinger et al., 2009).  
Perhaps 293-T cells do not provide the HPV16 LCR with the required environment 
for activity.  A previous study also reported that high levels of E2 could repress 
Chapter 4  209 
 
the HPV16 LCR only when the HPV genome is integrated and not in the episomal 
form (Bechtold et al., 2003).  This may be why I do not see repression of the 
HPV16 LCR with very high concentrations of E2. 
 
4.1.6 The mechanism of action of SRSF2 on E6/E7 expression: 
SRSF2 stabilises E6/E7 RNAs 
The alternative hypothesis that I addressed is that SRSF2 is required for stability 
of the E6/E7 RNAs. To test this hypothesis, W12GPXY cells were transfected with 
control siRNA or with siRNA (Dharmacon) against SRSF2 for 24 hours. Following 
this 10µg/ml Actinomycin D was added to inhibit de novo RNA synthesis.  A time 
course of Actinomycin D treatment was carried out to determine whether the 
stability of the E6/E7 RNA was altered upon SRSF2 knockdown.  RNA was 
harvested at 0, 1, 2, 4 and 8 hours following addition of actinomycin D and 
DNase-1 treated.  RNAs were reverse transcribed and amplified using E6/E7 
primers described in section 3.1.1. Semi-quantitative PCRs were carried out and 
GAPDH amplification was used as an internal control standard.  The PCR 
products were separated on a 6% acrylamide gel.  The gel was stained with 
ethidium bromide to visualise the DNA.  The band intensity of the E6*I isoform 
was measured and the results of two independent experiments shown in the 
graph (Figure 4.14). E6*I was measured as after the later time points this was 
the only visible isoform as it is the most highly expressed isoform. There was 
little change in E6 RNA levels between 1-8 hours of actinomycin D treatment 
indicating that E6/E7 mRNA is quite stable in the W12GPXY cells with little fall-
off in levels over the 8 hours time course. This finding corresponds to a report 
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that integration of HPV16 E6/E7 gene region into host chromosomes results in a 
longer mRNA half life (Jeon & Lambert, 1995). The lower starting level is 
probably due to an error in loading the acrylamide gel. After knockdown of 
SRSF2 a clear difference was observed. After 1 hour incubation in the presence 
of actinomycin D the levels of E6/E7 RNA decrease significantly and remain low 
until the end of the time course period at 8 hours indicating that the half life of 
the E6*I RNA is significantly reduced.  These data suggest that SRSF2 controls the 
stability of the E6/E7 transcripts and is required for high levels of oncoprotein 
RNA. 
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Figure 4.14 SRSF2 knockdown alters the stability of the E6 isoform RNAs. A) 
Upper panel Ethidium-bromide stained acrylamide gel electrophoresis of E6/E7 
isoforms RT-PCR amplified from Actinomycin D treated siSRSF2 knockdown RNA 
from W12GPXY cells.  Isoforms are indicated to the right of the gel. RT, reverse 
transcriptase; “-“, RT-PCR reaction in the absence of reverse transcriptase; “+”, 
RT-PCR reaction in the presence of reverse transcriptase; “O hours”, no 
Actinomycin D added RNA; “1 hour”, RNA treated for 1 hour with Actinomycin D; 
“4h”, RNA treated for 4 hours with Actinomycin D; “8h”, RNA treated for 8 hours 
with Actinomycin D;  Lower Panel Ethidium-bromide stained acrylamide gel 
electrophoresis of GAPDH RNA RT-PCR amplified from Actinomycin D treated 
siSRSF2 knockdown RNA from W12GPXY cells. RT, reverse transcriptase; “-“, RT-
PCR reaction in the absence of reverse transcriptase; “+”, RT-PCR reaction in 
the presence of reverse transcriptase; “O hours”, no Actinomycin D added RNA; 
“1 hour”, RNA treated for 1 hour with Actinomycin D; “4h”, RNA treated for 4 
hours with Actinomycin D; “8h”, RNA treated for 8 hours with Actinomycin D. B) 
Graph showing the results from two independent experiments where W12GPXY 
cells were transfected with siGlo or siSRSF2 and 10µg/ml actinomycin D was 
added for varying lengths of time. E6*I RNA levels were measured by pixel 
density and plotted on the graph.  The gray line represents the W12GPXY cells 
treated with siSRS2 and the black line represents W12GPXY cells transfected 
with siGlo.  The mean and standard deviation from the mean are plotted on the 
graph. 
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4.2 Discussion 
Results from Chapter 3 allowed me to formulated the hypothesis that the higher 
levels of the small isoforms E6*II and E6*X in transformed cells and their 
apparent growth-promoting activity indicated that they may be transformation 
associated isoforms. Moreover, overexpression of SR proteins in cervical tumour 
cells could potentially lead to changes in E6/E7 isoform splicing pattern. To 
address these hypotheses, individual SR proteins were knocked down and the 
splicing pattern of E6/E7 analysed.  However, knocking down the overexpressed 
SR proteins did not result in an obvious change in E6/E7 isoform production. This 
was surprising because bioinformatic analysis of the E6/E7 coding region 
indicated possible high affinity binding sites for these SR proteins that might 
indicate control of alternative splicing of E6/E7 mRNAs by these proteins due to 
their close proximity to splice junctions (Figure 4.1). The major finding from 
these experiments was that knocking down SRSF2 resulted in a reduction of total 
levels of E6 RNAs (Figure 4.2 D). Importantly, this reduction in E6/E7 RNAs was 
not restricted to W12GPXY cells, which were derived in the laboratory, but also 
occurred in CaSki cells which were isolated directly from a cervical cancer 
patient.  Significantly, the reduction in E6/E7 RNA in both these cell lines could 
indicate that the SRSF2 control over E6/E7 RNA expression may be common in 
tumours initiated by HPV16 E6/E7 overexpression. 
My results suggest that SRSF2 is involved in processing of the E6 RNAs at some 
stage in the nuclear RNA biogenesis pathway because loss of the protein caused 
destabilisation of the E6/E7 RNAs.  SR proteins are involved in almost every 
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stage of the RNA maturation process and interference with any stage may induce 
nuclear degradation of RNA. Therefore the mechanism of action of SFSF2 could 
be at any number of stages. However, it is clear that the destabilised E6/E7 
RNAs are spliced and polyadenylated as several RNA isoforms are amplified after 
reverse transcription using an Oligo dT primer, so one possibility is that SRSF2 is 
acting to protect mRNAs from nonsense-mediated decay. The E6/E7 bicistronic 
mRNA is unusual in that it does not possess a 5' untranslated region and there 
are several splice acceptor sites close to stop codons (Figure 4.15).  How 
substrates are targeted to the nonsense mediated decay pathway remains 
somewhat controversial.  The original hypothesis was that it was the exon-
junction complex positioned at an exon-exon junction close to a termination 
codon that triggered decay of the RNA, however some recent reports have 
suggested that it is the distance between the termination codon and the 
polyadenylation site that triggers decay (reviewed by Brogna & Wen., 2009).  
The sometimes contrasting findings surrounding nonsense-mediated decay 
research has led Brogna and Wen to offer their own model which suggests that 
that it may be early release of the ribosome at a premature termination codon 
that results in reduced mRNA stability.  Under normal circumstances the mRNA 
would be translated in a closed loop structure and the ribosome would complete 
several rounds of translation.  A premature termination codon would prevent 
this.  This model was proposed to explain why some studies found that the 
distance between the stop codon and the poly A tail to be the determiner for 
NMD and others found the presence of an intron downstream from the stop 
codon to be important for directing NMD (Brogna & Wen, 2009).  As during 
transformation the HPV genome is inserted into the host genome E6 and E7 are 
no longer processed from the viral polyadenylation site, but from a genomic 
polyadenylation site downstream from the point of insertion.  Therefore either  
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Figure 4.15 Amino acid sequences of the E6 isoforms and small schematic 
diagrams of the possible proteins. A) Amino acid sequence of full length HPV16 
E6 and E7 with the splice donor site highlighted in red.  Zinc finger domains are 
shown in green and the PDZ domain highlighted in blue.  B) Amino acid sequence 
of E6*I and diagram of putative protein. C) Amino acid sequence of E6*II and 
diagram of putative protein. D) Amino acid sequence of E6*X and diagram of 
putative protein. 
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of these NMD mechanisms could be true for E6/E7 RNAs.  The E6/E7 open 
reading frame may be inserted into an open reading frame containing 
downstream introns or be inserted a long distance from the first genomic 
polyadenylation site.  SRSF2 could perhaps then be recruiting factors to the 
E6/E7 mRNAs in the nucleus that protect them from NMD in the cytoplasm due 
to the presence of premature stop codons.   
 
SRSF2 does not however, have a similar effect on E6/E7 mRNA abundance in 
W12E cells that support the virus life cycle as it does in tumour cells where the 
life cycle is aborted.  When SRSF2 is knocked down in W12E cells, where the 
HPV16 genome is episomal and virus particles can be produced, there is only a 
small effect on E6/E7 RNA levels.  However when SRSF3 is knocked down in 
these cells there is a reduction in E6/E7 RNA levels similar to the SRSF2 effect in 
transformed cells.  This is likely due to the polycistronic nature of the viral RNAs 
during the life cycle.  In transformed cells the only viral RNAs normally 
expressed are E6, E7 with little or no other viral RNA being produced, whereas in 
W12E cells E6 and E7 are expressed as part of RNAs that also contain sequences 
for some other viral RNAs including the late RNAs L1 and L2 (Milligan et al., 
2007). Therefore other RNAs may require other SR proteins for their processing 
and those SR proteins may have stronger affinities for the viral RNAs.   
SRSF3 has already been shown to be required for E6/E7 RNA production in 
transfected U2OS cells (Jia et al., 2009).  However this study was carried out in 
an osteosarcoma cell line (U2OS) using constructs created from the late HPV16 
promoter p670 to the late polyadenylation site under control of a CMV promoter.  
The use of alternative promoters and polyadenylation sites will alter the 
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processing of the resulting RNAs and will affect the splicing activity.  My 
experiments were all carried out in cervical epithelial cells with naturally 
occurring viral genomes which are under control of the viral promoters and 
polyadenylation sites.  
 
Not only does reducing SRSF2 protein levels in HPV16 transformed cells reduce 
E6/E7 RNA levels, but E6 protein levels are also reduced as indicated by the 
increase in p53 levels in Figure 4.5.  This is significant because if p53 levels are 
increased the cells can then activate Bax and caspase 9 to enter apoptosis.  p53 
inactivation or mutation is a common feature of a number tumours therefore 
restoring p53 signalling could reverse the transformed phenotype of the cells. 
Overexpression of SRSF2 in these cells at least seems to contribute towards the 
transformed phenotype of the cells.  FACS analysis of apoptosis in W12GPXY cells 
treated with siRNA against SRSF2 showed that these cells were in early apoptosis 
suggesting that SRSF2 contributes towards the tumourigenic phenotype. In 
contrast, siRNA knockdown of E6/E7 mRNA caused a high percentage of the cells 
to fully apoptose. SRSF2 may contribute to the tumourigenic phenotype by 
maintaining high levels of E6/E7 expression or it may have other growth-
promoting, anti-apoptotic activities through alterations it makes in splice 
isoform production of oncogene or tumour suppressor RNAs.  siRNA knockdown 
studies indicated SRSF2 overexpression  was promoting cellular proliferation and 
anchorage independent growth.  All of these features are hallmarks of tumour 
cells and knockdown of SRSF2 also appeared to affect the cell cycle progression 
of the transfected cells.  Knockdown of SR proteins SRSF1 and SRSF2 have 
already been shown to arrest the cell cycle in tumour cells.  However the 
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reported arrest occurred at the G2/M checkpoint (Li et al., 2005, Xiao et al., 
2007) whereas my data suggested an accumulation in G1 (Figure 4.9) .  It has 
also recently been shown that SRSF1 and SRSF3 bind to chromatin in interphase, 
dissociate during mitosis and reattach after completion of mitosis (Loomis et al., 
2009).  It is thought that these SR proteins could be directing the dissociation of 
the HP1 from the chromatin and therefore allowing proper condensation and 
chromosome segregation to occur during mitosis (Loomis et al., 2009).  HP1 is 
part of the Heterochromatin protein family and can bind to chromatin and 
repress the expression of genes.  The finding of a different cell cycle arrest point 
in my study does not fit the above pattern. However, if depletion of SRSF2 
causes a subsequent increase in p53 levels then this could cause arrest of the 
cell cycle in G1/S phase (reviewed by (Vogelstein et al., 2000) as well as in G2. 
One cannot distinguish whether it is the overexpression of SRSF2 itself that has 
the transforming effects on the cell, or whether it is the overexpression of 
SRSF2, and the resulting increase in E6/E7 RNA stability and the likely increase 
in E6 and E7 protein that is causing the transformation.  One can assume that it 
may in fact be a combination of the two.  SR proteins have already been shown 
to have the capacity to transform cells by altering cellular gene expression and 
of course E6 and E7 have well documented transforming abilities.  Therefore in 
my view it is likely that SRSF2 overexpression is altering cellular gene expression 
and stabilising E6/E7 RNAs and that both of these effects are having an 
oncogenic effect on the cell.   
Another aspect of my study and similar studies by others is that the mechanism 
by which SR proteins become overexpressed in cancer cells is not understood.  
From the gene copy number experiments in section 3.1.4 of Chapter 3, I can 
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conclude that the SRSF2 gene is not amplified in the W12GPXY cervical cancer 
cells. This means that it is likely that there is transcriptional upregulation of 
expression of this gene.  How this happens is not understood.  Perhaps viral 
proteins, for example E6, are activating the transcription factors that activate 
the SRSF2 promoter.  For example bioinformatic analysis of the SRSF2 promoter 
has identified that E2F among other transcription factors can bind to the SRSF2 
promoter and activate or repress transcription of SRSF2.  E7 interaction with pRb 
releases the negative control over E2F transcriptional activity and could be 
activating SRSF2 expression.  Alternatively, perhaps the insertion of the viral 
DNA into the host cell genome has disrupted either a negative regulator of SRSF2 
expression or the viral DNA has inserted into genomic DNA upstream of the SRSF2 
gene and caused an activation of transcription of the gene.  The second 
possibility seems less likely as the SRSF2 effect on E6/E7 RNA levels is seen in 
two completely independent cell lines where insertion sites are different.  It 
may also be the case that as E6 and E7 initiate cell proliferation and DNA 
synthesis, SR proteins are upregulated by normal mitogenic signalling cascades 
because they are required at increased levels to carry out a higher volume of 
RNA processing.  I believe that the last point seems the most likely.  During 
transformation the cervical epithelium becomes filled with basal-like 
proliferating epithelial cells and differentiation is switched off. Mole et al. 
(2009) already illustrated this in staining of cervical sections.  SRSF1 staining in 
low grade CIN1 cervical sections displayed high levels of SRSF1 in the basal and 
spinous layer of the epithelium (Mole et al., 2009a).  However in high grade CIN 
3 lesions the entire epithelium stained positive for SRSF1 (Mole et al., 2009a).  
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5 Discussion 
5.1 General Perspectives 
There is emerging evidence that RNA processing factors can have tumour 
promoting properties. Previously, two SR proteins, SRSF1 and SRSF3 have been 
shown to be oncogenic, in breast and ovarian cancers respectively (Karni et al., 
2007, He et al., 2011).  The work in this thesis comprises the first demonstration 
of oncogenic activities for a third SR protein, SRSF2 and the first demonstration 
of SR protein oncogenicity in cervical cancer cells. My data suggest that SRSF2 
overexpression in cervical epithelial cells is in fact oncogenic and contributes to 
the transformed phenotype.  Reducing SRSF2 overexpression in cervical 
epithelial cells reverses the transformed phenotype and leads to a resulting 
decrease in HPV16 E6/E7 RNAs.  HPV16 E6 and E7 have well documented tumour 
promoting properties and stabilisation of the E6/E7 RNAs by SRSF2 may be 
responsible for promoting the transformation of the cells.  However, it is equally 
possible that transformation of the epithelial cells may be due to the 
overexpression of SRSF2 itself and the resulting likely alterations in alterative 
splicing, such as those previously observed for SRSF1, that are responsible for 
the tumourigenic properties of the cell.  Expression of E6 and E7 may be additive 
to this effect or vice versa: a combination of both possibilities is likely driving 
transformation.   
I have shown that knockdown of SRSF2 reduces the proliferative capacity of the 
transformed cervical epithelial cell, inhibits anchorage independent growth and 
sensitises the cells to apoptosis.  All of these features are the hallmark of cancer 
cells. The identification of a single protein being responsible for promoting the 
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transformed phenotype is surely beneficial for treatment considerations as there 
are already known drugs that inhibit SR protein function.   
My demonstration that the smaller E6 isoforms, E6*II and E6*X, are capable of 
promoting cell growth is an important result as these are the isoforms that are 
increased in expression in the transformed cervical epithelial cells, where SRSF2 
is overexpressed.  The variation in the ability of the isoforms to promote 
anchorage independent growth is however perhaps unsurprising. It is likely that 
there is a combinatorial effect of isoform expression that acts to promote colony 
formation in soft agar.  In fact, E7 is surely partly responsible for this phenotype 
due to its interaction with p600 and subsequent avoidance of anoikis (Huh et al., 
2005).  Therefore the probability is that E7-expressing isoforms in combination 
with other E6 isoforms are required for anchorage independent growth. 
My data indicating that HPV11 E2 as well as HPV16 E2 upregulates expression of 
SRSF3 suggests that SRSF3 may in fact be generally required for completion of 
the HPV life cycle and is not type-specific. Whether it is the alternative splicing 
functions or other RNA processing functions of SRSF3 that HPV requires has still 
to be determined.  Interestingly, data from our laboratory suggests that 
expression of SRSF3 is required for expression of HPV16 L1 (T. Klymenko and SV. 
Graham unpublished information).  This may be why HPV16 E2 promotes the 
expression of SRSF3.  If SRSF3 is required for capsid mRNA processing this could 
also be why low risk viruses also upregulate SRSF3.  The fact that HPV11 E2 
promotes higher expression of SRSF3 than HPV6 E2 cannot be explained at 
present unless HPV6 requires a different SR protein for viral RNA processing.  
This however seems unlikely as HPV6 and HPV11 are closely related viruses as 
indicated by Figure 1.1.   
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My finding that SRSF3, but not SRSF1, is required for E6/E7 RNA processing 
during viral infection contrasts with the report of Somberg and Schwartz (2010) 
who showed a requirement for high levels of SRSF1 for E6/E7 mRNA production.  
However their studies were carried out using a subgenomic construct containing 
the early region of the HPV16 viral genome under control of a strong CMV 
promoter transiently transfected into HeLa cells along with a plasmid that 
allowed expression of SRSF1 lacking an RS domain.  When the SRSF1 plasmid was 
co-transfected with the HPV16 early region construct, E6 RNA levels appeared to 
drop (Somberg & Schwartz, 2010).  There are a number of problems with these 
experiments. Firstly, the overexpression of two plasmids under strong promoters 
simultaneously could be saturating the transcription machinery and could 
explain the decrease in mRNA levels.  Secondly, the nature of the promoter used 
can greatly influence the choice of splice site in the RNA leading to production 
of alternative isoforms that may be unstable. Thirdly, HeLa cells express an 
increased level of SRSF1 protein as they are fully transformed cells.  Finally as 
HeLa cells are transformed they do not differentiate, therefore even if SRSF1 is 
in fact acting on the E6/E7 RNAs expressed from the virus early region- 
containing construct one cannot assume that this would occur during a natural 
infection of differentiating epithelial cells.  The studies carried out during the 
course of this PhD have been carried out in naturally infected, untransformed 
cervical epithelial cells which can undergo epithelial differentiation and 
therefore allow completion of the full viral life cycle.  While overexpression 
studies can be useful for investigating protein-protein interaction, care must be 
taken when equating the findings to the natural system.   
Similarly, contrary to my results, Jia et al. (2009) reported that high levels of 
SRSF3 are required for E6/E7 RNA processing in transformed epithelial cells.  
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Their studies were performed in HeLa and CaSki cells. HeLa cells are HPV18-
positive and CaSki cells are HPV16-positive.  As both cell lines have been 
culture-adapted for many decades they have likely accumulated many genetic 
mutations and changes that make them very different from the original tumours 
from which they were derived.  The presence of HPV E6 and E7 expression will 
aid in the genetic instability and allow the accumulation of mutations.  Our 
W12GPXY cells have not been in culture for long: those that I used were passage 
1-6 since being isolated from a squamous cell carcinoma upon injection of the 
originally-derived W12GPXY cell line into nude mice (Aasen et al, 2003). It is 
likely that these cells are more similar to the transformed cells of a cervical 
lesion as they have not undergone extensive culturing and have not had as long 
to accumulate mutations.  Jia et al. (2009) investigated knockdown of SRSF3 in 
the HPV16 and 18 transformed cells and found a decrease in E6/E7 RNA levels in 
northern blotting after SRSF3 knockdown.  They did not however analyse isoform 
production or relate their findings to RNA processing.  Their northern blot 
analysis shows multiple bands using an E6/E7 spanning probe for HPV16 and an 
E7 probe for HPV18.  The HPV16 probe sits from 442-816 meaning only full length 
E6 and E6*I isoforms will be detected by the probe.  The northern blot shows the 
presence of two bands. While there is a reduction in both E6/E7 RNA bands upon 
SRSF3 knockdown, the authors estimated this to be around 54% reduction.  I 
estimate my E6/E7 total RNA (all isoforms) reduction to be around 70% after 
SRSF2 knockdown in W12GPXY cells.  In CaSki cells I would estimate the 
reduction in total E6/E7 RNAs after SRSF2 knockdown to be similar to that 
observed by Jia et al. (2009).  Additionally, the SRSF3 knockdown achieved by 
Jia et al. (2009) was around 95-100%. Perhaps a complete SRSF3 knockdown is 
not tolerated well by CaSki cells and RNA processing in general is reduced.  In 
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my experiments I ensured that I examined effects of SRSF2 knockdown at around 
50% to reduce any catastrophic effects on global cellular splicing. 
Over expression of SR proteins is common to a number of cancers and could 
perhaps be considered as a possible therapeutic treatment target.  While 
reducing SR protein overexpression has been shown to reverse the tumour 
phenotype, the SR protein that is upregulated seems to be different depending 
on the tumour type.  Therefore, some patient-specific and/or tumour specific 
studies would have to be carried out in order to identify the upregulated SR 
protein(s).  The problem with targeting essential cellular proteins such as SR 
proteins using new drugs is how does one specifically target only tumour cells?  
Some strategies have been discussed that might prove useful in the future. For 
example research has been going into investigating the efficacy and safety of 
viral vectors for treatment of diseases including cancers.  Viruses could be 
engineered to infect only cells expressing tumour specific cell surface markers 
which would allow targeting of tumour cells specifically.  Cervical cancers have 
a unique possibility in that if therapies could be formulated to be applied and 
taken up across the plasma membrane of the surface cells then this could 
theoretically be used to treat cervical cancers.  On the other hand the possible 
benefit of targeting SR proteins is that some of their functions appear 
redundant, where loss of one protein can be compensated for by another SR 
protein and in addition as demonstrated by my studies and the investigation by 
Karni et al. (2007) a complete knockdown in SR protein levels is not necessary to 
reverse the phenotype.   
Recently, there has been some very interesting research into the possibilities of 
targeting SR proteins as a treatment for some diseases.  In my view SR proteins 
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would provide an excellent target for therapy in for example, cancers where 
particular SR proteins have been demonstrated to be overexpressed, and other 
diseases such as HPV and other viral infections where alternative splicing, and 
therefore SR proteins, is essential for completion of the infectious life cycle.  As 
has been suggested by Karni et al. (2007), complete removal of an SR protein, in 
the case of cancers, may not be necessary, merely the reduction in expression of 
the SR protein to near normal levels could be sufficient to reverse the 
transformed phenotype (Karni et al., 2007). Recent studies by the Tazi group 
have focused on the use of Indole Derivative Compounds (IDCs) against SR 
proteins in the treatment of HIV infection.  IDCs bind to the RS domain of the 
target SR protein and prevent the phosphorylation of the RS domain by SR 
kinases (Bakkour et al., 2007).  It is not known exactly what effect this inhibition 
of phosphorylation is having on the action of the SR proteins.  It could be 
preventing their recognition of ESEs or inhibiting their export functions among 
others and this will need to be investigated before IDCs could be considered for 
drug therapies (Keriel et al., 2009). 
HIV-1 is another virus, along with HPV, which requires extensive alternative 
splicing in order to express all viral RNAs and complete its life cycle.  Bakkour et 
al. (2007) have shown that inhibiting SRSF1, which is essential for HIV-1 RNA 
splicing, prevents progeny virion assembly and release, thereby preventing the 
spread of virus to other cells in the surrounding area and also the spread of virus 
between individuals (Bakkour et al., 2007).  Bakkour et al. (2007) reported that 
introduction of IDC16 into cell lines, including primary cell lines, had no negative 
effects on cellular growth and of 96 cellular targets analysed only 15 displayed 
any alteration in alterative splicing upon introduction of IDC16 (Bakkour et al., 
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2007).  This suggests that IDC16 inhibition of SRSF1 activity is not catastrophic 
for the cell.    
Similarly IDC13 and IDC78 have both been shown to both inhibit Murine Leukemia 
Virus replication, this time in mice (Keriel et al., 2009).  Keriel et al. (2009) 
showed that in Murine Leukaemia Virus infection in vitro targeting of an SR 
protein also prevented virus release and spread (Keriel et al., 2009).  
Importantly these studies have also suggested that using IDCs does not appear to 
have overly deleterious effects on the cell, the cell seems able to survive 
without SRSF1 as does the whole animal after systemic introduction of IDCs by 
intra-peritoneal injection (Keriel et al., 2009).  An exon array showed that out of 
6000 murine transcripts only 52 transcripts displayed any significant fold change 
of between 1.5 and 3 fold difference (Keriel et al., 2009) which equates to 
roughly 2% of transcripts were affected by SRSF1 loss. This is probably due to the 
functional redundancy exhibited by the SR protein family; however the virus 
does not seem able to overcome this loss of SRSF1.  Another reason for the 
seemingly specific effect on viral RNAs is probably due to the fact that during a 
viral infection the cell is overwhelmed with viral RNAs and the cellular RNA 
production is either reduced or prevented.  Therefore the loss of the splicing 
factor is not of great consequence for the small number of cellular RNAs still 
being expressed.  Finally the authors hypothesised that as cellular RNAs seem to 
be able to continue to be expressed, the action of the IDCs is probably not due 
to any constitutive functions of the SR proteins such as RNA export or initiation 
of translation, but is likely due to the recognition of exonic splicing enhancers 
and therefore alternative splicing functions (Keriel et al., 2009).  Cellular RNAs 
may have constitutive exons where the ESEs contain binding sequences for other 
SR proteins enhancing the functional redundancy if SR proteins in splicing 
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events.  This means that if one SR protein is altered or functionally impaired 
another SR protein can also bind, although probably with a lower affinity, and 
still activate splicing of the RNA. 
Therefore if these compounds prove to be specific and effective in the clinical 
setting, and could be formulated to be topically delivered to the cervix, they 
could prove to be ideal for treating HPV16 induced cervical cancers.  The cervix 
is accessible through methods similar to those used during cervical smear tests 
and while they are uncomfortable they are far less invasive than surgical 
procedures and could be more specifically targeted than by systemic methods.  
If IDCs could be formulated in a way that would allow them to be topically 
applied and taken up by the actively dividing tumour cells as opposed to the 
non-dividing granular layer cells in the surrounding epithelium then a tumour 
specific therapy could be used.  For example if they could be delivered by viral 
vectors that specifically recognise tumour cells or by lipid based mechanisms 
then topical therapies could be considered. 
The targeting of SR proteins for therapy could not only help treat cervical 
cancers but could also potentially be used as antiviral therapy against both high 
and low risk mucosal HPV viruses.  High risk HPV16 E2 has previously been shown 
to upregulate a subset of SR proteins, which suggests these proteins are required 
for completion of the viral life cycle (Mole et al., 2009a, Mole et al., 2009b).  
Figure 3.7 indicates that low risk viruses may also upregulate certain SR 
proteins.  This suggests low risk viruses also require SR protein functions, 
whether it is their alternative splicing functions or other functions, in order to 
complete their life cycle.  The targeting of SR proteins could then, theoretically, 
be applied to all stages of CIN lesion and also genital warts.  Therefore for 
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treatment considerations, targeting SRSF2 should be beneficial for treating 
HPV16 transformed cells; however one would need to target SRSF3 to treat 
productive infections.  My data has shown that targeting SRSF2 in HPV16-positive 
tumour cells reverses the transformed phenotype by inducing apoptosis and 
reducing proliferation, therefore targeting SRSF2 in cancer cells could inhibit 
tumour growth.  However if a productive viral infection is being targeted then 
SRSF2 is not the best target for therapy.  As shown in Figure 4.4, SRSF3 is 
required to greater extent than SRSF2 for viral RNA processing.  Unpublished 
information from our laboratory indicates that SRSF3 is required for late RNA 
processing and L1 protein expression (T. Klymenko and SV. Graham, unpublished 
information).  Therefore if viral infections are to be inhibited then SRSF3 is a 
better therapeutic target than SRSF2.  The method of delivery and ease of 
access to the lesion is the same in both cases. 
 
5.2 Future Directions 
In order to fully complete this work and before any therapeutic considerations 
could be made, the global cellular effects of knocking down SRSF2 would have to 
be investigated.  For example an exon microarray analysis or deep sequencing 
should be performed to find out which host RNAs are affected by SRSF2 
reduction.  For example RNA expression in control and SRSF2 knockdown 
W12GPXY cells should be analysed to determine whether SRSF2 knockdown 
results in a specific down-regulation of E6/E7 mRNAs and other SRSF2 controlled 
mRNAs or whether there is a general RNA processing effect after SRSF2 
knockdown leading to catastrophic events in the transfected cells.  Similar 
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experiments should be carried out after control and SRSF3 knockdown in W12E 
cells and both viral and cellular mRNA expression analysed.  Unfortunately this 
experiment was outside the cost and time restraints of this PhD project.   
This would be particularly important for developing new avenues to therapy for 
treating other types of cancer; however one might argue that catastrophic 
consequences are not as important when targeting cervical tumour cells where 
the tumour is relatively easy to access.  Cervical tumours are one of the more 
accessible tumours so extremely invasive techniques would not be required to 
specifically target the tumour.  Therefore if topical therapies could be 
developed as opposed to systemic treatments then perhaps any global cellular 
effects of targeting SR proteins would not be as important a consideration for 
cervical cancers as it is for other cancers.  
We have been able to demonstrate increased SR protein levels upon 
transformation in patient tissue, however, the splicing pattern of E6/E7 RNAs 
would also have to be investigated in high grade lesions from patients.  For 
example FISH assays could be performed in patient tissue to continue these 
observations.  Fluorescently labelled cross splice-junction probes could be used 
to detect the presence of individual E6 isoforms in patient tissue.  If any 
increases in small isoform production with cervical cancer progression could be 
replicated in patient tissue it could perhaps lead to new treatment targets for 
HPV induced cervical cancer.  For example if the small isoforms are increased in 
expression upon transformation of real patient cervical epithelial cells, then 
perhaps targeting of the individual small isoforms using cross-splice junction 
siRNAs could potentially inhibit transformation of the cervical epithelial cells.  
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In addition, siRNA knockdown of individual E6 isoforms would aid our attempts to 
determine function for the isoforms.  Such experiments were initially planned to 
be carried out, however the struggle to design isoform specific probe and primer 
sets postponed these experiments as the splice junctions within E6/E7 gene 
region do not provide good sequences for primer and siRNA design and so even if 
individual isoforms were knocked down by siRNA targeting, there would be no 
easy means of quantifying changes in RNA isoform production.  In addition, the 
lack of isoform specific detection at the protein level also hampered these 
experiments as analysis of knockdown by protein levels would not be possible. 
SRSF2 is an RNA-binding protein and could be expected to bind E6/E7 RNAs to 
protect them from decay. To test this, further experiments should also be 
completed to confirm the hypothesis that SRSF2 binds the E6/E7 RNAs.  I have 
cloned fragments of the E6/E7 open reading frame ready to carry out EMSAs 
protein/RNA binding assays however I could not do the experiment due to time 
constraints. 
The transcription assays do not give a clear picture of any effect on transcription 
initiation from the HPV16 LCR in the presence and absence of SRSF2. However, 
SRSF2 has been shown previously to regulate transcription elongation. Perhaps a 
better approach to these experiments would have been to perform nuclear run-
on studies. Nuclear run on assays can be used to quantify the transcriptional 
activity of a gene of interest.  Cells would be transfected with siSRSF2 and their 
nucleus harvested.  The nuclei would then be incubated with radioactively 
labelled UTP and other nucleoside triphosphates.  The labelled UTP would then 
be incorporated into elongating mRNAs.  The labelled mRNAs would then be 
hybridised to gene specific single stranded DNA on a membrane and the 
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frequency of transcription indicated by the strength of the radioactive label. 
These assays are more specific and can give a quantification of the frequency of 
transcription without RNA stability issues being a problem.  Transcription assays 
like the ones carried out in this thesis only give a measure of the total number of 
transcripts not how frequently they are transcribed. These experiments should 
be attempted in future work.  
 
While the colony formation assays clearly revealed a difference in anchorage 
independent growth capability after SRSF2 knockdown the experiment that I 
carried out is not perfect because, despite transfection efficiencies of around 
80% I cannot rule out the possibility that the colonies seen in the SRSF2 
knockdown plates could have arisen from cells that were not initially 
transfected.  The assay itself must be carried out over a period of time past the 
normal effectiveness of transient siRNA experiments or in cells where levels of 
SRSF2 are permanently reduced through stable shRNA knockdown in every cell.  
An alternative way to carry out this experiment would have been to use an 
inducible shRNA-stably transfected cell line where treatment with, for example 
doxycycline, would switch on expression of the shRNA, so that carrying out the 
experiment over an extended period of time would not cause any problems.  
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5.3 Conclusions 
 
The main findings from this PhD thesis are that alternative splicing of HPV16 E6 
and E7 RNAs is altered during transformation of cervical epithelial cells.  
Transformation results in a shift towards the expression of small E6/E7 mRNA 
isoforms and these isoforms have been shown to have growth promoting effects 
on cervical epithelial cells.  In the transformed cervical epithelial cells SR 
proteins SRSFs 1-3 are overexpressed.  This upregulation was also observed in 
patient tissue.  Overexpression of SRSF2 in cervical epithelial cells is oncogenic 
and is responsible for stabilising E6/E7 mRNAs in HPV16-positive transformed 
cervical epithelial cells.  Knockdown of SRSF2 in transformed cervical epithelial 
cells results in a reduced proliferation rate, reduced anchorage independent 
growth ability, altered cell cycle and an increase in apoptosis in the transfected 
cells.  Knockdown of SRSF2 also results in a decrease in E6/E7 oncoprotein mRNA 
expression.  If topically applied therapies could be formulated that would allow 
specific targeting of SRSF2 in transformed cervical epithelial cells, then these 
therapies could inhibit tumour growth.  My data suggests that SRSF2 should be 
considered to be a proto-oncogene.  Therefore SRSF2 could prove to be an 
excellent novel therapy for treatment of HPV16-positive cervical cancers.   
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